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Abstract 
Sepsis is one of the most prevalent diseases in the world. The development of cardiac 
dysfunction in sepsis results in an increase of mortality from 20% to 70% and new treatments 
are urgently needed. In this thesis I have investigated novel therapeutic approaches to attenuate 
sepsis-induced cardiac dysfunction. 
I have developed two models of cardiac dysfunction. Firstly, the endotoxemia model: co-
administration of lipopolysaccharide (LPS)/peptidoglycan (PepG) and secondly the 
polymicrobial sepsis model: cecal ligation and puncture (CLP). It is known that Bruton’s 
tyrosine kinase (BTK) plays a role in toll-like receptor signalling and NLRP3 inflammasome 
activation, two key components in the pathophysiology of sepsis and sepsis-associated cardiac 
dysfunction. Delayed treatment of BTK inhibitors (ibrutinib 30 mg/kg or acalabrutinib 3 
mg/kg) attenuates sepsis associated cardiac dysfunction in mice by inhibiting BTK, reducing 
NF-kB activation and the activation of the NLRP3 inflammasome. Cytokines associated with
sepsis were significantly reduced by both BTK inhibitors.  
BTK-inhibitors have many off-target effects (which may account for their beneficial effects in 
sepsis), by conducting polymicrobial sepsis on X-linked immunodeficient (Xid) mice (which 
have a single point mutation in the BTK gene leading to inactivation of BTK), I have found 
that Xid mice are protected from sepsis induced cardiac dysfunction. In Xid-CLP mice, there 
was a reduction in the activation of BTK, NF-kB and NLRP3 inflammasome and a decrease in
sepsis associated cytokines and chemokines. The peritoneal bacterial count was lower in Xid-
CLP mice and this was associated with enhanced phagocytosis and reduced number of 
infiltrating macrophages and neutrophils. 
Ribonuclease 1 belongs to a group of host-defence peptides that specifically cleave 
extracellular RNA. The activity of RNase 1 is inhibited by ribonuclease-inhibitor 1. The 
treatment of septic mice with RNase 1 resulted in a reduction in cardiac apoptosis, TNF 
expression, and septic cardiomyopathy.  
In this thesis I have found that inhibition of BTK or RNase 1 attenuates sepsis-induced cardiac 
dysfunction and Xid mice are protected from developing sepsis-induced multiple organ failure. 
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Chapter 1 General 
Introduction   
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1.1  History of sepsis 
 
The concept of sepsis has been around since 460-370 BC and is derived from the Greek word 
σήψις, meaning “decomposition of animal- or plant-derived organic materials by bacteria”. In 
medical literature sepsis was first mentioned in poems of Homer as ‘sepo’ meaning ‘I rotted’. 
The physician Hippocrates wrote about sepsis in the Hippocratic corpus using the term 
‘sepidon’ to represent sepsis. Hippocrates viewed sepsis as a dangerous biological decay that 
could occur in the body releasing ‘dangerous principles’ leading to ‘auto-intoxication’ (1).  
 
It wasn’t until the 1800s that basic hygiene was introduced into the medical field and that germ 
theory was discovered. Ignaz Semmelweiss observed that medical students delivering babies 
caused more cases of puerperal sepsis (16%) than midwives (2%). He noticed that medical 
students would perform autopsies and deliver babies without washing their hands leading to 
increased infection rates. After introducing a policy to ensure hand washing between patients, 
the rates of puerperal sepsis dropped to 3% (2).  
 
After Semmelweiss, Louis Pasteur formally proposed “Germ Theory”, thus leading to Joseph 
Lister’s theory that infectious agents entered the body through breaks in the skin. He developed 
the technique of dressing wounds with carbolic acid, which led to a decline in wound infections 
and sepsis (3). 
 
Overall, the term sepsis has been in use for over 2700 years with little change in its meaning. 
It is the primary cause of death from infection and even today there are no specific and effective 
treatments for sepsis.  
 
1.2  Evolution of the definitions/diagnosis of sepsis  
 
1.2.1  Sepsis 1  
 
In 1991, the American College of Chest Physicians (ACCP) and the Society of Critical Care 
Medicine (SCCM) held a consensus conference to internationally define sepsis, these included 
sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (Table 1.1) (4).  
They proposed that sepsis was the result of a systemic inflammatory response syndrome 
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(SIRS). The definitions have contributed to an increase in the diagnosis of sepsis and, thus, 
resulted in an improvement of care.  
 
Table 1.1 Definitions for SIRS, sepsis, severe sepsis, septic shock and multiple organ dysfunction 
syndrome based on 1991 ACCP/SCCM consensus conference. Adapted from (4). 
 
1.2.2 Sepsis 2  
 
In 2001, the Society of Critical Care Medicine, the American College of Chest Physicians, 
European Society of Intensive Care Medicine (ESICM), American Thoracic Society (ATS) 
and Surgical Infection Society (SIS) held a second consensus conference to redefine sepsis. 
They provided a more comprehensive list of diagnostic criteria (Table 1.2), yet due to a lack 
of evidence failed to offer any alternatives, resulting in definitions to remain approximately the 
same for 15 years (5). Additionally, the PIRO concept was also proposed, which is the 
predisposition, infection (or insult), response and organ dysfunction (PIRO). It is a staging 
system used to assess risk and predict prognosis of sepsis, by incorporating the patient’s 
baseline assessment, factors that contribute to sepsis and their response to infection and therapy 






SIRS • Core body temperature >38oC or <36oC 
• Heart rate ³ 90bpm 
• Respiration ³20/min (or PaCO2 <32 mmHg) 
• White blood cell ³12000/µl or £4000/µl or 10% immature forms 
Sepsis At least two SIRS criteria caused by known or suspected infection 
Severe sepsis Sepsis with acute organ dysfunction (including hypoperfusion and hypotension) caused 
by sepsis 




The presence of organ dysfunction in an acutely ill patient such that homeostasis cannot 
be maintained without intervention 
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Table 1.2 Diagnostic criteria for sepsis based on 2001 ACCP/SCCM/ATS/ESICM/SIS conference. 
It serves as a supplement for diagnostic definitions of sepsis from 1991. Adapted from (5). 
Diagnostic criteria for sepsis 
General Parameter 
• Fever (core temperature >38.3°C) 
• Hypothermia (core temperature <36°C) 
• Heart rate >90 bpm or >2 SD above the normal value for age 
• Tachypnoea: >30 breaths per min 
• Altered mental status 
• Significant oedema or positive fluid balance (>20 ml/kg over 24 h) 
• Hyperglycaemia (plasma glucose >110 mg/dL or 7.7 mmol/L) in the absence of diabetes  
Inflammatory parameter 
• Leukocytosis (white blood cell count >12,000/μL)  
• Leukopenia (white blood cell count <4,000/μL) 
• Normal white blood cell count with >10% immature forms  
• Plasma C reactive protein >2 SD above the normal value  
• Plasma procalcitonin >2 SD above the normal value  
Haemodynamic parameters 
• Arterial blood pressure <90 mmHg, mean arterial pressure <70, or a systolic blood pressure decrease 
>40 mmHg in adults or <2 SD below normal for age)  
• Mixed venous oxygen saturation >70% 
• Cardiac index >3
 
 
• Organ dysfunction parameters 
• Arterial hypoxaemia (PaO2/FIO2 <300) 
• Acute oliguria (urine output <0.5 ml/kg/h or 45 mM/l for at least 2 h)  
• Creatinine increase ≥0.5 mg/dL 
• Coagulation abnormalities (international normalized ratio >1.5 or activated partial thromboplastin 
time >60 s)  
• Ileus (absent bowel sounds) 
• Thrombocytopenia (platelet count <100,000/μL)  
• Hyperbilirubinaemia (plasma total bilirubin >4 mg/dl or 70 mmol/L)  
Tissue perfusion parameters 
• Hyperlactatemia (>3 mmol/L)  
• Decreased capillary refill or mottling  
 
 31 
Table 1.3 PIRO concept from the 2001 SCCM/ACCP/ATS/ESCIM/SIS consensus conference 
 Clinical aspects Other tests 
P (predisposing conditions) Age, alcohol abuse, steroid or 
immunosuppressive therapy 
Immunologic monitoring, genetic 
factors 
I (insult) Site specific e.g. pneumonia, 
peritonitis 
X-rays, CT scan, bacteriology 
R (response) Malaise, temperature, heart rate, 
respiratory rate 
White blood cell count, C-
reactive protein, procalcitonin, 
modified activated partial 
thromboplastin time 
O (organ dysfunction) Arterial pressure, urine output, 
Glasgow coma score 
PaO2/FIO2, creatinine, bilirubin, 
platelets 
CT = computed tomography. Adapted from (6). 
 
1.2.3 Sepsis 3 
 
Advances have been made in our understanding of the pathophysiology, management and 
epidemiology of sepsis resulting in the definitions for sepsis to be re-examined in 2016 (Table 
1.4) (7). As outlined by the 2016-consortium, sepsis is now defined as a “life-threatening organ 
dysfunction caused by a dysregulated host response to an infection” and septic shock is 
regarded as a “subset of sepsis in which underlying circulatory and cellular metabolic 
abnormalities are profound enough to substantially increase mortality”. The concept of severe 








Table 1.4 New revised criteria for diagnosing sepsis based on the 2016 consensus conference. 
Table adapted from (8). 
Category Definition 
Sepsis Suspected/documented infection 
+ 
2 or 3 on qSOFA (HAT): 
Hypotension (SBP < 100 mmHg) 
AMS (GCS < 13) 
Tachypnea (> 22/min) 
or 
Rise in SOFA score by 2 or more 
Severe Sepsis Category removed 
Septic Shock Sepsis 
+ 
Vasopressors needed for MAP > 65 mmHg 
+ 
Lactate > 2 mmol/L (after adequate fluid resuscitation 
 
In addition to changing definitions, the scoring system has also been re-evaluated. The SIRS 
criteria have for many years been regarded as “overly sensitive” and “not specific” for sepsis, 
as SIRS is present in many hospitalised patients without infection (9,10). The revised criteria 
resulted in the introduction of a new scoring system, the Sequential [Sepsis-related] Organ 
Failure Assessment (SOFA) (Table 1.5) (11). An increase of SOFA score of  ³ 2 approximately 
represents a risk of 10 % mortality in hospitalised patients with suspected infection. In a general 
hospital setting, a quick SOFA is used as a mortality indicator at the bedside of patients with 
suspected infection to rapidly identify sepsis if the patient has two of the following signs: 
change in the level of consciousness, low blood pressure and/or a respiratory rate of greater 
than 22/min (Table 1.6) (8). This is a better mortality predictor than the previously used SIRS 
scoring system in patients with suspected infection who are not in the intensive care unit (ICU) 




Table 1.5 Sequential [Sepsis-related] Organ Failure Assessment Score based on 2016 consortium. 
Table adapted from (8). 
 Score 















































































































Table 1.6 qSOFA (Quick SOFA) criteria. A qSOFA score of ≥2 points indicate organ dysfunction. 
Table adapted from (8). 
qSOFA (quick SOFA) 
criteria 
Points 
Respiratory rate ³22/min 1 
Change in mental status 1 




The revised scoring system still has limitations as our understanding of the pathology of sepsis 
is incomplete and remains a work in progress. The consensus also provides easily measurable, 
clinical criteria that can be translated and recorded objectively (Figure 1.1). It is essential to 
note that if a patient fails to meet the criteria, this should not automatically lead to dismissal of 
the diagnosis of sepsis and care should not be postponed if a clinician feels that it is required, 










Sepsis has been recognised as one of the leading causes of morbidity and mortality. Globally 
there are 50 million cases of sepsis resulting in the death of 11 million people every year and 
representing 20% of all deaths worldwide (13). In the U.K., 48,000 lives are lost annually due 
to sepsis. A third of all admissions to the ICU are septic patients. Sepsis is an economic 
healthcare burden, costing the NHS approximately £2 billion every year. (14–16).  
 
Over the past several decades multiple epidemiological studies have reported an increase in the 
incidence of sepsis, but a decrease in mortality (17–24). Even though mortality has decreased, 
these reports indicate that the annual number of sepsis-associated mortality has increased due 
to the rise in incidence. The increase in incidence could be due to advances in 
diagnosis/awareness, the development of antibiotic resistance and/or an increase in the number 
of patients with other diseases/conditions known to carry a higher risk of infection including 
type-II diabetes, the ageing population and cancer, to name but a few (25,26). Improvement in 
sepsis outcome is often attributed to an increase in sepsis awareness, faster treatment and 
improvement in care for the critically ill (27–29). 
 
In general the incidence of sepsis reported worldwide is highly variable due to its complex 
condition, the changing definitions, difficulty in diagnosis and the majority of the studies 
identifying sepsis only in the ICU, for example in the US mortality rate ranged from 15% - 
29% and 35% - 54% within Europe (30–33). Sepsis is often underreported as a cause of death 
due to the lack of a sepsis-specific International Classification of Diseases, 10th Revision (ICD-
10) code and is, therefore, recorded as other infectious deaths such as pneumonia, kidney 
infection or influenza (34). Additionally, sepsis is not tracked in the Global Burden of Disease 
and taxonomy, but infections are reported separately, with only neonatal sepsis being reported 
(35). Historically, sepsis is often underreported in low and middle income countries, despite 
the fact that these countries have the highest incidence and mortality of sepsis, specifically the 
highest health-burden occurring in sub-Saharan Africa, Oceania, south Asia, east Asia, and 
southeast Asia (13,36). It is essential that global strategies are put in place in the future to 
measure the morbidity and mortality in these countries (37). 
 
 36 
1.4 Therapy of sepsis and septic shock 
 
1.4.1 Surviving sepsis campaign 
 
In 2002, the European Society of Intensive Care Medicine, the Society of Critical Care 
Medicine and the International Sepsis Forum initiated and developed the Surviving Sepsis 
Campaign. The Surviving Sepsis Campaign brings together experts in the diagnosis and 
treatment of sepsis and infectious disease from 11 professional societies to produce 
internationally recognised guidelines. The evidence-based guidelines provide the best 
therapeutic approach in reducing mortality, with the first edition being published in 2004. The 
7-point agenda proposed by the Society of Critical Care Medicine aims to reduce the relative 
mortality of sepsis by 25% over the next 5 years (Table 1.7) (38). 
 
Table 1.7 7-point agenda proposed by SCC to reduce the relative mortality of sepsis by 25% over 
the next 5 years. Table adapted from (38). 
7-point agenda plan proposed by SCC  
1. Building awareness of sepsis 
2. Improving diagnosis 
3. Increasing the use of appropriate treatment 
4. Educating healthcare professionals 
5. Improving post-ICU care 
6. Developing guidelines of care 
7. Implementing a performance improvement program 
 
 
The experts, with the addition of another 7 international organisations, updated the guidelines 
in 2008 by using a new grading system to determine the quality of the evidence and, thus, the 
strength of recommendations (39). A committee of 68 international experts from 30 
professional organisations convened to update the guidelines in 2012 (published in 2013). It 
was recommended that care for patients with sepsis or septic shock become standardised 
including control of infection, initial resuscitation or other supportive therapy (40). In 2016, 
the guidelines were once again updated by a committee of 55 international experts from 25 
professional societies, which recommend standardised care of a patient including procedures 
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of initial resuscitation, antimicrobial therapy and control of infection, to name but a few 
(Appendix 1). However, a significant proportion of aspects proposed on the early management 
and resuscitation of patients held weak support, with only 18/93 statements being regarded as 
“best practice”. The surviving sepsis campaign have recently developed specific guidelines for 
neonates and children with sepsis and septic shock out of 77 statements only 9 were identified 
as best practice (41). 
 
1.4.2 Care bundles 
 
The committee proposed care bundles in 2008, which are known to provide greater benefit 
when implemented as a group rather than individually. They first introduced “the 6-h 
resuscitation bundle” and “the 24-h management bundle”, which contain all therapeutic goals 
to be completed respectively within 6 and 24 h of the onset of sepsis (39). The bundles were 
updated in 2012, which resulted in the 24-h management bundle no longer being recommended 
and the resuscitation bundle to be split into two sections: “the severe sepsis 3 h resuscitation 
bundle” and “the 6 h septic shock bundle” (Table 1.8) (42). It has been shown that patients 
whose care consists of compliance with the 3 h bundle had a 40% reduction in mortality and a 
36% reduction with the 6-h bundle. However, compliance was only reported at 19% for the 3 
h bundle and in 36% for the 6 h bundle (43).  
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Table 1.8 2012 Surviving sepsis campaign care bundles. Table adapted from (44). 
 
 These sections were updated again in 2018, when the 3 and 6 h care bundles have been 
combined into a single 1 h bundle (Table 1.9) (45). In patients with septic shock, any delay in 
the initiation of antimicrobial therapy leads to a significant increase in the risk of dying, with 
the mortality risk increasing hourly by 10% (46).  
 
Table 1.9 2018 Surviving sepsis campaign 1 h bundle. Table adapted from (45). 
 
 
To be completed within 3 h of time of presentation*:  
1. Measure lactate level  
2. Obtain blood cultures prior to administration of antibiotics  
3. Administer broad spectrum antibiotics  
4. Administer 30 ml/kg crystalloid for hypotension or lactate ≥4 mmol/L  
* “Time of presentation” is defined as the time of triage in the emergency department or, if presenting 
from another care venue, from the earliest chart annotation consistent with all elements of severe sepsis 
or septic shock ascertained through chart review.  
To be completed within 6 h of time of presentation:   
5. Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to 
maintain a mean arterial pressure (MAP) ≥ 65 mmHg  
6. In the event of persistent hypotension after initial fluid administration (MAP < 65 mmHg) or if 
initial lactate was ≥ 4 mmol/L, re-assess volume status and tissue perfusion and document 
findings according to Table 1.  
7.  Re-measure lactate if initial lactate elevated.  
1-hour bundle: initial resuscitation for sepsis and septic shock 
1. Measure lactate level 
2. Obtain blood cultures prior to administration of antibiotics 
3. Administer broad spectrum antibiotics 
4. Administer 30 ml/kg crystalloid for hypotension or lactate ≥4 mmol/L 
5. Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to 
maintain a mean arterial pressure (MAP) ≥ 65 mmHg  
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1.4.3 Initial resuscitation  
 
In sepsis, there is a release of vasodilatory mediators, resulting in increased membrane 
permeability and a dramatic decrease in intravascular fluids, leading to hypotension, low 
cardiac output and multiple organ injury. Therefore, early aggressive fluid resuscitation with 
crystalloids have been recommended to achieve a minimum of 30 mL/kg of fluids to counteract 




If hypotension persists even after fluid resuscitation, vasopressors are the next line of treatment. 
The surviving sepsis campaign recommends norepinephrine as first choice in the treatment of 
septic shock patients and adding epinephrine or vasopressin in patients who respond poorly 
(44). Dopamine is recommended as an alternative to norepinephrine in patients with low risk 
of tachyarrhythmias and absolute or relative bradycardia. Studies have shown that dopamine is 
associated with increased cardiac arrhythmias (47) and De Backer et al. found that dopamine 
was associated with increased mortality in comparison to norepinephrine (48).  
 
The recommendation to target the use of vasopressor to maintain a mean arterial pressure 
(MAP) value of 65 mmHg is based on studies by Asfar et al. and Lamontagne et al.. Asfar et 
al. found that there was no difference in mortality at 28 and 90 days when either maintaining a 
high MAP of 80-85 mmHg or a lower MAP of 65 -70 mmHg (49). Lamontagne et al. found 
that in patients 75 years or older a lower, MAP of 60-65 mmHg resulted in reduced mortality 
when compared to MAP of 75 – 80 mmHg (50).  
 
1.4.5 Lactate clearance 
 
Historically it is believed that elevated levels of lactate in the blood are due to an increase in 
anaerobic respiration as there is an inadequate supply of oxygen. Multiple studies have shown 
that serum lactate above 1 mmol/L is independently associated with mortality and as lactate 
increases further the risk of death also increases (51–54). The Surviving Sepsis Campaign 
confirmed that lactate guided resuscitation resulted in a decrease in mortality (than without 
lactate monitoring). However, recently Marick et al. proposed that raised lactate levels are due 
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to increased aerobic glycolysis as part of the stress response and that altering therapy in 




Sepsis is a complex syndrome caused by an invading pathogen, which leads to 
activation/dysfunction of the innate immune response and suppression of the adaptive immune 
response. Early mortality is due to an overwhelming immune response e.g. the cytokine storm, 
while late mortality is due to persistent immunosuppression, leading to secondary opportunistic 
infections (Figure 1.2) (56).   
 
 
Figure 1.2 Immune responses in sepsis. Activation of both the adaptive and innate immune response 
is involved in the pathogenesis of sepsis. The peak of the red line represents early mortality due to 
excessive innate inflammation e.g. the cytokine storm, whereas late mortality results from prolonged 
immunosuppression and opportunistic secondary infections leading to organ injury/failure. Years after 
“surviving sepsis” patients can still present with prolonged immunosuppression, chronic catabolism 
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Shock and multiple organ failure can develop from inflammatory conditions, such as trauma, 
burns, drug reactions, pancreatitis, tissue ischaemia, thromboembolism etc. However, the three 
most common causes of infection are bacterial, viral and fungal (Table 1.10). They result in 
similar symptoms and as well as acting on similar mechanisms, but their differences lead to 
complications (Figure 1.3) (57). 
 
 
Figure 1.3 Representation of the differences and similarities between the three major types of 
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Table 1.10 Major microbiologic isolates and types of organisms in septic patients from the 
Extended Prevalence of Infection in Intensive Care (EPIC II) study.  
Percentages may not add up to 100 due to patients having more than one type of infection. ESBL = extended 




Bacteria are the most common cause of the infection that underlies sepsis and both Gram-
positive and Gram-negative bacteria play a major role. The prevalence of Gram-negative 
bacteria remains at 62%, with the predominant species being Pseudomonas aeruginosa (20%) 
and Escherichia coli (16%) (57). However, the incidence of Gram-positive has increased to 
47% worldwide according to the Extended Prevalence of Infection in Intensive Care (EPIC II) 
study (Table 1.3.1) (36) and was the most reported in North America at 55% (Gram-negative 
reported at 50%) (17). The rise of Gram-positive bacteria is attributed to the excessive use of 
antibiotics leading to methicillin-resistant Staphylococcus aureus (MRSA) (57). The diagnosis 
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S. epidermidis 10.8 Klebsiella 
species 
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Recently, the incidence of fungal sepsis has increased to 19% (25). This rise could represent 
effective treatment strategies for targeting bacteria, leading to fungi having a more influential 
role. Fungal sepsis differs drastically from bacterial in the fact that it is rarely found outside of 
the hospital, specifically 93% of bloodstream candidiasis is hospital-acquired, whereas 
bacterial sepsis is primarily found in patients being admitted to hospital (59,60). Additionally, 
there has been an increase in the number of nosocomial infections shifting away from Candida 
albicans to other fungi including, Candida glabrata and Candida krusei (61,62).  
 
Therapy is primarily directed at treating bacterial sepsis (since it is most common) and often 
board spectrum antibiotics are administered before blood cultures are performed. Antibiotics 
have no effect on fungal or viral sepsis and are associated with increased mortality in fungal 




Viral sepsis is the most uncommon out of the three with cases occurring in 1% of documented 
patients (64). A normal antiviral immune response results in phagocytosis of the virus by 
macrophages, neutrophils or dendritic cells and the virus antigens are presented resulting in the 
production of IFN α/β, IFN-γ. T helper 1 cells and cytotoxic T cells are generated leading to 
apoptosis of virus cells. The virus is cleared, and memory T cells are produced to rapidly 
respond to any future infections. However, in viral sepsis there is downregulation of IFN’s and 
increased production of TNF-α, IL-6, leading to the production of inappropriate T helper 2 and 
17 which result in excessive inflammation and an inability to clear the virus. In the end, T cells 
become exhausted and the virus continues to replicate (65). 
 
Viral sepsis can occur from almost any virus. Commonly viral sepsis is caused by dengue virus 
(in topical countries) (66), influenza (in young/old, pregnant women and 
immunocompromised) (67), herpes simplex virus and enterovirus (in neonatal) (68,69). 
Recently, the newly discovered coronavirus (identified as SARS-Cov-2) has been associated 
with clinical manifestations of septic shock and multiple organ failure in approximately 2-5% 
of COVID-19 patients (70). In the lung epithelial cells, the S protein on coronavirus binds to 
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ACE2, resulting in the release of viral RNA, which is detected by TLR 3, 7, 8 and 9 in the 
endosome (71). In severe cases the activation of the TLR signalling pathway leads to 
uncontrolled inflammation (cytokine storm), which in turn damages the endothelial cells 
leading to infiltration of fluid into the alveoli, resulting in acute respiratory distress syndrome 




Figure 1.4 Schematic diagram of coronavirus infection in the lungs. In the lung epithelial cells, the 
S protein on coronavirus binds to angiotensin converting enzyme II (ACE2), releasing viral RNA. Viral 
RNA is detected by TLR3/7, leading to the downstream activation of NF-kB and interferon regulatory 
factors producing pro-inflammatory cytokines and type 1 interferons. Dendritic cells migrate to the 
lymph nodes and activate CD8 T cell (adaptive immunity) by presenting virus antigen to CD8 T cells. 
CD8 T cells then induces apoptosis. Excessive inflammation (from the cytokine storm) damages the 
lung epithelium through formation of fibrin and gap junctions appear in the blood vessels, allowing for 





1.5.1.4 Site of infection 
 
The most common source of infection is the respiratory tract accounting for 64% of all sepsis 
cases (often community-acquired pneumonia). Other sources are the abdomen, genitourinary 
system, skin, catheter-related and the central nervous system (Table 1.11) (36).  
 
Table 1.11 Site of infection for sepsis culture positive infected patients based on the Extended 













1.5.2 Pattern recognition receptors and signalling 
 
The innate immune system has evolved to detect conserved molecular structures on bacteria 
known as pathogen-associated molecular patterns (PAMPs) and host-derived damage-
associated molecular patterns (DAMPs) from injured cells such as ATP and mitochondrial 
DNA. PAMPs and DAMPs are not found in healthy vertebrate cells and activate the innate 
immune system, leading to the production of multiple pro-inflammatory and anti-inflammatory 
molecules secondary to the activation of NF-kB and interferon regulatory factors (IRFs) (75). 
PAMPs and DAMPs are recognised by highly conserved pattern recognition receptors (PRR), 
which are expressed on innate immune cells such as macrophages, NK cells, mast cells, 
dendritic cells, fibroblasts, neutrophils, monocytes and non-professional immune cells such as 
epithelia. There are four families of PRRs including, toll-like receptors (TLRs) and C-type 
lectin receptors (CLRs) that reside on the cell surface, as well as nucleotide-binding 
Site of infection Frequency (%) 
Respiratory 63.5 
Abdominal 19.3 
Blood stream 15.1 
Renal/urinary tract 14 
Skin 6.6 
Catheter-related 4.7 
Central nervous system 3.2 
Others 7.7 
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oligomerisation domain (NOD)-like receptors (NLRs) and retinoic acid-inducible gene I-like 
receptors (RLRs), which are located inside the cytoplasm (76). PRR subfamilies differ in their 
structure and detect specific PAMPs (Table 1.12) leading to activation of distinct intracellular 
signalling cascades (77). PRRs activation is crucial in resolving the infection by eliminating 
invading pathogens, however, over-activation can cause a systemic inflammatory response 
damaging the host (78).  
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Table 1.12 Pattern recognition receptors and their corresponding pathogen-associated molecular 
pattern (PAMP) and origin of PAMP. Table adapted from (77). 
 
  
Pattern recognition receptor Microbial component Origin 























Gram-positive and gram-negative bacteria 
Mycobacteria 
Neisseria 





















TLR5 Flagellin Flagellated bacteria 
TLR7/8 ssRNA RNA viruses 
TLR9 CpG DNA Viruses, bacteria, protozoa 
TLR10 Unknown  Unknown 
RLRs RIG-I Short dsRNA Viruses (influenza A, HCV, RSV) 
MDA5 Long dsRNA Viruses (picorna and noroviruses) 
NLRs NOD1 Diaminopimelic acid Gram-negative bacteria 
NOD2 MDP Gram-positive and gram-negative bacteria 
NALP1 MDP Gram-positive and gram-negative bacteria 
NALP3 ATP, uric acid crystals, RNA, 
DNA, MDP 
Viruses, bacteria and host 
CLRs Mannose receptor Fungal mannans Candida 
Dectin-1 Beta-1,3-glucans Fungi 
Dectin-2-FcR g Mannans Candida hyphae 
MINCLE – RcR g Mannans 
Mycobacterial cord factor 
Candida 
Mycobacteria 
Mannose binding lectin Repetitive oligosaccharides Bacteria and fungi 
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1.5.3 Toll-like receptors 
 
TLRs are the most extensively researched family of PRR with 10 different TLRs being known 
in humans and 13 in mice. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 reside on the cell 
surface and detect lipids primarily from bacteria and fungi, whereas TLR3, TLR7, TLR8 and 
TLR9 are located intracellularly in the membrane of the endosome, where they recognise 
nucleic acids from viruses and bacteria that have been taken into the cell by phagocytosis, 
receptor-mediated endocytosis or micropinocytosis (79). Structurally, TLRs are single-pass 
transmembrane proteins characterised by an extracellular domain consisting of 18-25 copies of 
leucine-rich repeat (LRR) motifs and a cytoplasmic Toll-IL-1 receptor (TIR) domain. LRRs 
create a horseshoe shape that adapts for ligand binding. When PAMPs bind, TLRs form dimers 
or oligomers subsequently triggering MyD88-dependent pathways and/or TRIF-dependent 
pathways. Heterodimers are also formed from TLR2 and TLR1, or TLR2 and TLR6 (80).  
 
Cell walls and membranes of bacteria contain components not found in animal cells, which are 
detected by TLRs. Generally, TLR4 recognises a wall fragment located in the outer cell wall 
of Gram-negative bacteria called lipopolysaccharide (LPS) by binding to the lipid A domain 
of LPS (81). The structure of LPS consists of three regions: a hydrophobic lipid A domain, a 
core oligosaccharide and a highly variable O-antigen (82). In contrast, TLR2 detects 
components of the cell wall of Gram-positive bacteria including peptidoglycan (PepG) and 
lipoteichoic acid. PepG activates the innate immune system to a lesser extent than LPS (83,84). 
LPS and PepG can act synergistically to activate the inflammatory cascade, leading to cytokine 
production (85). Systemic injection of LPS leads to an overwhelming secretion of cytokines 
resulting in septic shock. During an infection, LPS is shed from the cell wall and binds to LPS-
binding protein, this complex then binds to soluble CD14 or CD14 on the cell surface of 
macrophages, dendritic cells and neutrophils (86). The CD14/LPS complex binds to TLR4 with 
the help of another accessory protein called myeloid differentiation protein-2 (MD-2), leading 
to homodimerisation of TLR4 (87). The two TIR domains are now close enough to initiate 
signalling by interacting with their adaptor molecules. There are four adaptor molecules 
MyD88 (myeloid differentiation factor 88), MAL (MyD88 adaptor-like), TRIF (TIR domain-
containing adaptor-inducing IFN-β) and TRAM (TRIF-related adaptor molecule). TLR4 
signals using both MyD88/MAL and TRIF/TRAM (88).  
 49 
1.5.3.1 MyD88 signalling 
 
Activation of the MyD88-dependent pathway results in recruitment to MyD88 of the serine-
threonine kinase interleukin-1 receptor-associated kinase (IRAK)4, which phosphorylates 
IRAK1 and IRAK2, allowing the complex to recruit TRAF6 (tumour-necrosis-factor-receptor-
associated factor 6), an E3 ubiquitin ligase (89). TRAF6 ubiquitinates TAK1 (90). TAK1 
activates the NF-kB pathway, which phosphorylates and activates the IkB kinase (IKK) 
complex. IKK complex consists of two catalytic subunits IKKα/IKK1 and IKKβ/IKK2 and a 
regulatory subunit IKKγ/NEMO (91). Normally, NF-kB is inactive within the cytoplasm by 
IkB (inhibitor of kB) molecules masking their nuclear localisation signals (92). Activated IKK 
phosphorylates IkB molecule on two serine residues leading to the dissociation of NF-kB (93). 
NF-kB then enters the nucleus and activates the transcription of genes for pro-inflammatory 
cytokines such as: tumour necrosis factor (TNF)-α, IL-1β and IL-6 (92). TAK1 also activates 
mitogen-activated protein kinases (MAPKs) such as c-Jun terminal kinase (JNK) and MAPK14 
(p38 MAPK), which activate AP-1 transcription factors (94).  
 
1.5.3.2 TRIF signalling 
 
TLR4 signals via the TRIF-dependent pathway with additional adaptor molecule TRAM to 
recruit TRIF to TLR4 (95,96). Upon ligand binding, TRAF3 activates IKKs, TBK1 and IKKε, 
which leads to phosphorylation of transcription factor IRF3, which induces IFN-β expression, 
required for the production of type 1 interferon and inflammatory mediators (97,98). TRAF6 
is also activated, leading to the activation of NF-kB through TAK1 ubiquitination (99). Overall, 
the two pathways allow TLRs to respond to both antiviral and antibacterial response by 





Figure 1.5 TLR4 and TLR2 signalling pathway. 
 
1.5.4 NLR Proteins 
 
NLRs are divided into 3 subfamilies based on their phylogenetic relationship: NODs, NLRPs 
and IPAF, which consists of 22 members. All members have a tripartite domain structure 
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consisting of centrally located conserved nucleotide-binding oligomerisation domain 
(NACHT), which facilitates self-oligomerisation by ATPase (100). A leucine rich repeat 
(LRR) domain to detect ligands and an N-terminal interaction domain consisting of either: 
caspase-recruitment domains (CARDs), pyrin domain, baculovirus inhibitor repeats, or acidic 
transactivating domain (101).  
 
The subfamily NLRP is involved in the formation of the inflammasome in response to stress. 
NLRP3 senses PAMPs and DAMPs such as ATP derived from dead cells as well as potassium 
ions (K+) which are released from stressed cells, resulting in activation of the NLRP3. The 
pyrin domain can interact with another pyrin domain on apoptosis-associated speck-like 
protein containing a CARD (ASC), which results in the ASC binding to pro-caspase-1 by 
CARD-CARD interactions and allowing the proteolytic cleavage to form active caspases 
(80,102). Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to active IL-Iβ, IL-18 and also 
initiates programmed cell death, pyroptosis (Figure 1.6) (103). It has been found in 
endotoxemia models that the NLRP3 inflammasome is activated (104) and that a deficiency in 




Figure 1.6 Formation and signalling pathway of the NLRP3 inflammasome. NACHT = nucleotide-
binding oligomerisation domain, PYD = pyrin domain, CARD = caspase-recruitment domain, LRR = 
leucine rich region, PAMPs = pathogen associated molecular patterns, DAMPs = damage associated 
molecular patterns, ASC = apoptosis-associated speck-like protein containing a CARD. 
 
1.6 Cardiac dysfunction in sepsis 
 
Cardiovascular dysfunction is characterised as impaired biventricular myocardial contractility, 
reduced cardiac index, diastolic dysfunction and reduced left ventricular ejection fraction (EF) 
(106). The development of cardiovascular dysfunction in sepsis is associated with an increased 
mortality rate of 70-90% in comparison to 20% mortality in patients who do not present with 
cardiac dysfunction (107). However, the mechanisms that underlie cardiac dysfunction are not 
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well known. Evidence suggests that multiple factors contribute to the pathophysiology of the 
cardiac dysfunction associated with sepsis. These include the excessive formation of IL-1β, 
TNF-α (108) and nitric oxide (NO) (109), altered calcium homeostasis (110), myocardial 
ischaemia and mitochondrial dysfunction, to name but a few (111).  
 
1.6.1 Myocardial depressing factors  
 
Myocardial depressing factor(s) were first identified in 1947 in an animal model of  
haemorrhagic shock (112)  and was later linked to sepsis in 1985, where Parrillo et al. exposed 
rat cardiomyocytes to the serum of septic shock patients resulting in a reduction in contractility; 
whereas the serum from healthy volunteers had no effect (113). Several factors, such as TNF-
α and IL-1β, have been reported to reduce cardiac contractility (108). Both of these cytokines 
induce NO production secondary to the expression of inducible NO synthase (iNOS), and 
excessive formation of NO reduces myocardial contractility (114).  
 
1.6.1.1 Cytokines  
 
TNF-α is essential in controlling and removing an infection, however, in sepsis an excessive 
amount of TNF-α is released by activated macrophages from the spleen and liver. TNF-α 
causes expression of iNOS in blood vessels, resulting in excessive vasodilation and increased 
permeability. This leads to a loss of plasma volume. Both excessive vasodilation and plasma 
leakage contribute to the development of hypotension (115). TNF-α also leads to disseminated 
intravascular coagulation, a pathological condition in which the clotting cascade becomes 
activated resulting in blood clots being formed in small vessels. The tissue no longer receives 
adequate blood supply and together with an excessive local inflammation leads to the failure 
of multiple organs including the heart, liver, kidneys and lungs (116). Mice deficient in TNF-
α receptors are resistant to septic shock but are unable to control a local infection (117). Also, 
other inflammatory cytokines such as IL-6, and IL-8 are amplified by TNF-α, as TNF-α 
activates macrophages in a paracrine and autocrine manner (118). IL-6 has a longer half-life 
than TNF-α and remains elevated in the blood of diseases, therefore excessive levels of IL-6 
is a good marker of localised TNF-α activity (119). 
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1.6.1.2 Nitric oxide production 
 
NO is produced from the oxidation of L-arginine to L-citrulline by a group of isoenzymes 
termed NO synthase (NOS) (120).  Three isoforms of NOS have been identified so far: iNOS, 
endothelial NOS (eNOS) and neuronal NOS (nNOS). The production of NO from eNOS and 
nNOS is tightly regulated by intracellular calcium and small amounts of NO are continuously 
released, important in maintaining cardiovascular homoeostasis (121). In contrast, iNOS is 
independent of calcium and induced by pro-inflammatory stimuli, such as LPS, TNF-α, IL-1β 
and IFN-γ, resulting in the formation of excessive amounts of NO (122). Evidence shows that 
NO can have beneficial and detrimental effects, specifically when eNOS produces small 
amounts of NO it improves LV function. However, in sepsis, the hyperproduction of NO by 
iNOS contributes to cardiodepression, hypotension and vascular hyporeactivity (123,124). 
Non-specific NOS inhibition has been shown to attenuate LPS-induced left ventricular 
dysfunction, however, high doses of non-specific NOS inhibitors have been detrimental (125).  
 
1.6.2 Mitochondrial dysfunction 
 
Mitochondrial dysfunction is present in septic patients (126) and animal models of sepsis (127). 
The mitochondrial dysfunction seen in skeletal muscle biopsies obtained from septic patients 
is characterised by a reduced respiratory chain complex I activity and low ATP levels, resulting 
from an increase in NO production and a decrease in antioxidants e.g. glutathione. NO causes 
oedema of the mitochondria, thus suppressing its function. The severity of the disease and 
multiple organ failure correlated with the level of mitochondrial dysfunction (128).  It has been 
proposed that the decrease of ATP supply is a ‘last resort’ response to inflammation, similar 
to hibernation of the myocardium during ischaemia, where organ function is restored. 
Depression of the myocardium may, thus, be a protective response to conserve energy (129).  
 
1.6.3 Calcium trafficking 
 
Changes in calcium trafficking are often involved in cardiac dysfunction, for example, 
exposure to endotoxins and cytokines suppress the L-type calcium channels, decreasing 
intracellular calcium, as well as opening ATP-dependent potassium channels (130). This 
shortens the action potential and reduces calcium influx, thus suppressing cardiac contractility 
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(131). Calcium-calcium release from the sarcoplasmic reticulum (SR) in sepsis is thought to 
be decreased by a reduction of the density of ryanodine receptors (a sarcoplasmic reticulum-
associated Ca2+-sensitive release channel that together forms with LTCC structures called 
‘dyads’ (132). The release of Ca2+ binds to troponin, resulting in the cross-linkage of 
actin/myosin. The entry of Ca2+ is determined by LTCC, but the amount of Ca2+ available for 
release is regulated by SR Ca2+-ATP-ase (SERCA2) (133). The inhibition of SECRA2 leads to 
impaired diastolic relaxation due to the reuptake of Ca2+ into the SR being blocked (134). 
 
1.6.4 Ischaemia and circulation 
 
Sepsis is characterised by circulatory abnormalities due to vasodilation and intravascular 
volume depletion, potentially causing an imbalance in oxygen supply and demand. Originally 
it was thought that cardiac dysfunction in sepsis was the result of myocardial ischaemia (103). 
Cunnion et al. disproved this theory by using thermodilution catheters to measure coronary 
blood flow. They found that coronary blood flow was the same or greater in septic patients and 
healthy individuals, while the levels of lactate were not elevated in septic patients (100). This 
study was further supported by autopsies of septic patients showing no signs of cardiac necrosis 
(101). Even though coronary blood flow is increased in septic patients, the microcirculatory 
system undergoes major alterations, including endothelial disruption and maldistribution of 
blood flow secondary to the development of shunts (111). The disruption of the endothelium 





1.6.5 Cardiac apoptosis 
 
Apoptosis is a form of programmed cell death which plays a role in cardiac failure. In 1999 it 
was found that activation of the intrinsic apoptosis pathway occurred in the spleen of septic 
patients (135). The intrinsic apoptosis pathway is where a cell receives a signal to destroy itself 
from one of its own genes or proteins due to detection of DNA damage, whereas the extrinsic 
pathway is in response to an external stimuli by ligands binding to ‘death’ receptors (tumour 
necrosis factor receptor) on the cell surface (136). DNA damage activates BCL-2 homology 3 
proteins which lead to activation of BCL-2-associated X (BAX) and BCL-2-antagonist killer 
(BAK). BAX and BAK form channels on the membrane of the mitochondria leading to the 
release of cytochrome C (proapoptotic factors) which then leads to the formation of the 
apoptosome by cytochrome C binding to the apoptotic protease activating factor 1 (APAF1) 
(137). The formation of the apoptosome activates caspase 9, which then activates caspase 3 
and 7. Caspase 3 leads to the activation of caspase 6 and 2 and caspase 6 leads to the activation 
of caspase 8 and 10. Activation of the caspases leads to cell death (Figure 1.7) (136). 
 
 
Figure 1.7 Extrinsic and intrinsic apoptosis signalling pathway. 
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1.7 Sepsis-induced lung injury 
 
The most common cause of sepsis is respiratory infections such as community-acquired 
pneumonia, which in extreme cases can lead to acute respiratory distress syndrome (36). 
Pulmonary pathogens initiate the recruitment of innate immune cells, neutrophils and 
macrophages, leading to the production of pro-inflammatory cytokines: TNF-a, IL-6 and IL-
1b. These cytokines lead to a disruption of the alveolar-endothelial barrier, resulting in the 
interstitial lung space and alveoli to be filled with fluid. Excessive fluid in the lungs is known 
as lung oedema and causes a decrease in respiration and oxygen intake, leading to hypoxia and 
a build-up of lactic acid due to anaerobic respiration (Figure 1.8) (138).  
 
 






1.8 Cognitive impairment in sepsis 
 
An altered mental state is an underlying feature of sepsis, resulting from disruption of the 
blood-brain barrier, which is normally tightly regulated. Changes in the blood-brain barrier 
result in toxins, inflammatory cells and cytokines to cross into the brain, this causes oxidative 
stress, changes in cerebral oedema and disruption in neurotransmission, leading to septic 
encephalopathy (139). Septic encephalopathy can range from mild confusion to coma and is 
measured by the Glasgow coma scale, which assesses the patients: motor response, verbal 
response and eye-opening response (Table 1.13) (140). 
 
Table 1.13 Glasgow coma scale. 
Feature Response Score 
Eye response Open spontaneously 
Open to verbal command 
Open to pain 















Motor response Obeys commands 
Localising pain  
Withdrawal from pain 
Flexion to pain 
Extension to pain 









1.9 Sepsis-induced renal dysfunction 
 
Acute kidney injury (AKI) is defined as “an abrupt and persistent decline in renal function” 
and clinical diagnosis is based on a rise in serum creatinine and decreased urinary output. AKI 
is a common result of sepsis occurring in 19% of patients with moderate sepsis, 23% with 
severe sepsis and 51% with septic shock (when blood cultures are positive) (141). AKI from 
sepsis independently increases mortality from 45.2% (patients with renal failure not from 
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sepsis) to 74.5% (patients with septic renal failure) (142). AKI is commonly thought to arise 
from impairment of renal blood flow; however, recent evidence suggests that septic AKI can 
result from preserved or increased renal blood flow. No single mechanism is responsible for 
septic AKI, but it arises from multiple mechanisms such as endothelial dysfunction, 
inflammation, changes intrarenal hemodynamic and tubular injury (143). 
 
1.10 Sepsis-induced hepatocellular injury 
 
The liver is the largest organ in the body and is responsible for maintaining normal systemic 
homeostasis. In sepsis, toxins and bacteria injure the liver within 1.5 h leading to hepatocellular 
injury/dysfunction, which increases mortality. Hepatocellular dysfunction is defined as subtle 
alterations in function such as decreased synthesis and clearance function (144). Ongoing 
inflammation and hypoperfusion result in irreversible injury of the hepatocytes, eventually 
leading to liver failure, which is defined as a loss of function in 80-90% of hepatocytes (145). 
 
The liver has two main roles in sepsis: 1) it is responsible for clearing bacteria and toxins and 
2) it also plays a role in inflammation, immunosuppression and organ damage. In patients with 
sepsis, bacterial clearance is essential for the survival with immune response and liver injury 
all correlate to bacterial levels. Within 10 minutes of intravenous bacterial injection, 60% of 
the bacteria from the bloodstream can be removed from and trapped in the liver, at 6 h this 
increases to 80% (146).  
 
There are multiple types of cells in the liver that contribute to bacterial phagocytosis and 
clearance. The first line of defence involves Kupffer cells, liver sinusoidal endothelial cells and 
stellate cells (147). The Kupffer cells constitute 80-90% of the tissue macrophages in the body 
and reside in the lumen of the liver sinusoids, thus are constantly exposed to gut-derived 
bacteria and endotoxins (148). The pathogens are recognised by PRR, Deng et al. showed that 
TLR4 KO mice resulted in impaired phagocytosis and bacterial clearance by Kupffer cells post 
CLP (149). Chemokines are also secreted by the Kupffer cells during sepsis, resulting in 
neutrophils to migrate and accumulate in the liver sinusoids. This leads to the release of 
neutrophil extracellular traps to capture and remove the pathogen (150).  
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In the early phase of sepsis Kupffer cells are responsible for producing pro-inflammatory 
cytokines: TNF-a, IL-1, IL-6, IFN-g, IL-8, MCP-1 as well as NO and ROS (secondary 
mediators of tissue injury) (151). An injured liver can induce detrimental inflammatory 
responses in other organs during sepsis e.g. the excessive production of cytokines and NO-
induced acute lung injury, which leads to respiratory failure in patients with severe sepsis (152). 
Depleting Kupffer cells by administering gadolinium chloride before CLP results in a reduction 
of pro-inflammatory cytokines, prevents hepatocellular injury/dysfunction during early sepsis 
(5 h post CLP) as well as protecting distant organs from inflammation-induced injury. 
However, reduced numbers of Kupffer cells results in impaired bacterial clearance and 




1.11 Bruton’s tyrosine kinase  
 
Bruton’s tyrosine kinase (BTK) was first identified in X-linked agammaglobulinemia as a non-
receptor protein tyrosine kinase belonging to the Tec family of kinases (153). BTK is most well 
known as a critical component of the B-cell antigen receptor (BCR) signalling pathway and is 
involved in B-cell development in normal and malignant B cells (153,154).  However, BTK 
expression is not just restricted to B cell it is also expressed in all cell lineages of the 




BTK is a member of the Tec family of protein tyrosine kinases. It compromises of five 
domains, N-terminal pleckstrin homology domain, responsible for membrane localisation and 
interaction of BTK with PIP3, a proline-rich Tec homology region, essential for autoregulation 
of Tec kinases and the binding site for protein kinase C (PKC)-B, Src-homology 3 domain 
(SH3), Scr-homology 2 domain (SH2) and tyrosine kinase or Src-homology 1 (Figure 1.9). 
Transphosphorylation takes place on tyrosine kinase resulting in autophosphorylation of SH2 




Figure 1.9 Schematic representation of the five BTK domains. PH = pleckstrin homology domain, 
TH = Tec homology region, SH3 = Src-homology 3 domain, SH2 = Scr-homology 2 domain, TK = 
tyrosine kinase, SH1 = Scr-homology 1. Adapted from (156). 
 
 
1.11.2 Function  
 
BTK is normally found in the cytosol, but upon stimulation of the BCR phosphatidylinositol 
3-kinase (PI3K) is activated, resulting in phosphorylation of phatidylinositol-4,5-bisphosphate 
(PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) (157). PIP3 binds to the pleckstrin 
homology domain and recruits BTK to the plasma membrane, where upstream Src-family 
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kinases; Lyn and Syk, phosphorylate BTK at the Try551 residue (158). BTK becomes active by 
autophosphorylation at the Tyr223 residue (159). Once active, BLINK/SLP65 (an adaptor 
protein) binds at the SH2 domain, where the complex activates phospholipase C (PLC)-γ2 
(160). BTK contains a PIP3 binding site, which signals through to PLC-γ2 resulting in the 
hydrolysis of PIP3 into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the 
release of Ca2+ from intracellular stores and DAG leads to the activation of PKC isoenzymes 
including PKCβ. PKCβ activates the IKK complex, which phosphorylates IkBα at Ser32 and 
Ser36, marking IkBα for ubiquitination and, hence, degradation to release NF-kB (161). NF-
kB migrates to the nucleus initiating transcription factor that controls numerous fast-acting 
primary transcription factors utilised in cell survival, cytokine production and transcription of 
DNA e.g. TNF-α, IL-1β, IL-6 and iNOS (Figure 1.10) (162,163).  
 
 




BTK is also involved in TLR signalling pathways and regulates the activation of the NLRP3 
inflammasome. BTK interacts with the TIR domain of TLR4 at MyD88, MAL, IRAK1 and 
TRIF, resulting in downstream activation of NF-kB and the generation of proinflammatory 
cytokines (Figure 1.11) (164,165). BTK is an essential component in specifically regulating 
the assembly and, hence, activation of the NLRP3 inflammasome. BTK directly 
phosphorylates ASC through its tyrosine kinase domain. In addition, overexpression of BTK 





Figure 1.11 Schematic diagram of the role of BTK in the pathophysiology of sepsis. LPS is released 
from Gram-negative bacteria, which results in the activation of the TLR4 signalling pathway. The 
release of PepG from Gram-positive bacteria results in the activation the TLR2 signalling pathway. 
BTK is involved in the activation of TLR4 and TLR2 by binding to MyD88 and TRIF, thus activating 
their representative signalling cascades. The activation of the MyD88 signalling pathway, leads to the 
activation of NF-kB and the production of pro-inflammatory cytokines. Additionally, BTK activates 
the NLRP3 inflammasome by binding to the ASC component of the inflammasome. Once active the 
NLRP3 inflammasome cleaves pro-IL-1b to active IL-1b. The production of chemokines from NF-kB 
activation results in the recruitment of neutrophils and macrophages. Excessive inflammation from the 
cytokine storm and innate immune cells results in multiple organ failure/injury.  
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1.11.3 BTK inhibitors 
 
Inhibition of BTK by BTK inhibitors reduces NF-kB activation and the formation of NF-kB-
dependent cytokines in murine models of arthritis (168). Multiple irreversible and reversible 
BTK inhibitors have been developed, however, only two have been approved for use by the 
food and drug administration (FDA) and the European medicines agency (EMA).  The FDA 
has approved the use of the irreversible BTK inhibitors ibrutinib (first generation) in chronic 
lymphatic leukaemia, mantle cell lymphoma, Waldenstrom macroglobulinemia and graft vs. 
host (169) and acalabrutinib (more selective, second-generation) in mantle cell lymphoma 
(170). Ibrutinib is also approved by the EMA for the treatment of chronic lymphatic leukaemia, 
mantle cell lymphoma and Waldenstrom macroglobulinemia (171), whereas acalabrutinib has 
an orphan status for chronic lymphatic leukaemia, mantle cell lymphoma and 
lymphoplasmacytic lymphoma (172–174).  
 
1.11.3.1 BTK inhibitor – Ibrutinib 
 
Ibrutinib is an irreversible, small-molecule inhibitor of BTK, approved for use as an anti-cancer 
drug in chronic lymphatic leukaemia, which targets B-cell malignancies (175). Ibrutinib forms 
a covalent bond with Cys481 of BTK resulting in inhibition of BTK tyrosine phosphorylation, 
thus, abrogating downstream BCR and TLR4 signalling pathways such as MAPK, AKT, NF-
kB and the inflammasome. I propose here (hypothesis) that inhibition of these pathways by 
ibrutinib may reduce the cardiac dysfunction of septic patients. Mice deficient in BTK have a 
blunted response to LPS and produce significantly lower amounts of TNF-α, IL-1β and NO. 
In both animal models of sepsis and septic patients, activation of NF-kB is increased in every 
organ and the degree of activation of NF-kB correlates positively with mortality. Mice deficient 
in NF-kB dependent genes are resistant to developing sepsis (176). It has previously been 
reported that interventions that inhibit NF-kB and the inflammasome reduce sepsis-associated 
cardiac dysfunction, such as an IKK inhibitor (167,177,178). This beneficial effect of the IKK-
inhibitor IKK-16 was still observed in models with both sepsis and chronic kidney disease, in 
which the cardiac dysfunction is more severe (179). Overall, NF-kB inhibition improves 
survival in septic murine models and prevents multiple organ injury.  
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1.11.3.2 BTK inhibitor – Acalabrutinib 
 
Acalabrutinib is a second-generation BTK inhibitor, which is more selective than ibrutinib and 
does not inhibit other kinases including ITK, EGFR, ERBB2, JAK3, BLK, FGR, FYN, HCK 
LCK, LYN, SRC and YES1. Like ibrutinib, acalabrutinib forms a covalent bond with the Cys-
481 residue in the ATP-binding pocket of BTK, but it does so with its butynamide group, 
whereas ibrutinib binds at the Cys-481 residue with an acrylamide group. In biochemical 
assays, ibrutinib is a more potent inhibitor of BTK (IC50 = 1.5 nM) than acalabrutinib (IC50 = 
5.1 nM) (180). However, in vivo studies have shown that acalabrutinib is more effective than 
ibrutinib at a lower dose (acalabrutinib EC50 = 1.3 mg/kg and ibrutinib EC50 = 2.9 mg/kg) (181). 
In clinical studies, ibrutinib is associated with atrial fibrillation and bleeding, but these effects 
are not seen with acalabrutinib (182). Refer to Table 1.14 for a comparison of ibrutinib and 
acalabrutinib.  
 




1st generation BTK inhibitor. 2nd generation BTK inhibitor – more selective. 
FDA approval for mantle cell lymphoma, 
chronic lymphocytic leukaemia, Waldenstrom 
macroglobulinemia, chronic graft vs host 
disease. 
EMA approval for chronic lymphatic 
leukaemia, mantle cell lymphoma and 
Waldenstrom macroglobulinemia. 
FDA approval for mantle cell lymphoma, 
chronic lymphocytic leukaemia or small 
lymphocytic lymphoma. 
EMA approval for chronic lymphocytic 
leukaemia. 
 
Irreversible inhibitor of BTK. Irreversible inhibitor of BTK. 
Forms covalent bond at the cys-481 with its 
acrylamide group. 
Forms covalent bond at the cys-481 with its 
butynamide group 
ED50 2.9 mg/kg ED50 = 1.3 mg/kg 
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1.11.3.3 X-linked immunodeficient mice 
 
X-linked immunodeficient (Xid) mice have a missense mutation within the BTK gene (arginine 
to cysteine at position 28 (R28C)) in the N-terminally located pleckstrin homology domain, 
resulting in expression of a BTK protein that is functionally inactive (183,184). It is similar to 
the mutation found in human X-linked agammaglobulinemia, however, the murine mutation is 
milder form than the human mutation (185). Xid mice result in defective B cell differentiation, 
leading to reduced circulating numbers and are unresponsive to thymus-independent type 2 
antigens. In response to some proteins they present with normal amounts of antibodies but have 
reduced IgM and IgG3 (186,187). 
 
1.12 RNase background 
 
Antimicrobial peptides have been found to play a role in the innate immune system by 
interacting with bacteria, viruses and fungi. All organisms express the antimicrobial peptide 
RNase (ribonuclease) a type of nuclease that catalyses the degradation of RNAs, which are 
classified either as endoribonuclease or exoribonuclease. RNase A is the most researched 
superfamily and is found in mammalian tissues and body fluids. RNase’s are mainly expressed 
in innate immune cells, eosinophils (188), neutrophils (189), macrophages (190) and 
monocytes (191), contributing to host immune response due to their immune modulations and 
antimicrobial activity (192,193). The human RNase A family consists of eight canonical 
members: RNase 1 (pancreatic RNase), RNase 2 (eosinophil-derived cationic protein, EDN), 
RNase 3 (eosinophil cationic protein, ECP), RNase 4, RNase 5 (angiogenin), RNase 6, RNase 
7 (skin-derived RNase) and RNase 8 (194). Below is a table of proposed functions of RNase 
in human host defence (Table 1.15). 
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Table 1.15 The proposed function of the eight human RNase on the host defence. Table adapted 
from (193). 
Ribonuclease  Effect on host defence 
RNase 1 • Degradation of vascular polyRNA 
• Anti-HIV-1 activity 
• Induces maturation and activation of dendritic cells 
RNase 2/EDN • Antiviral activity against HIV-1 and RSV-b 
• Secretion by eosinophil granulocytes and monocyte-derived macrophages 
• TLR2 binding and TH2 polarisation 
• Chemokine and cytokine induction for activation of maturation of dendritic 
cells 
RNase 3/ECP • Antiviral activity against RSV-B  
• Anti-bacterial activity against mycobacteria and gram-positive and Gram-
negative bacteria 
• Induces degranulation of mast cells 
• Anthelmintic activity against Schistosoma mansoni Brugia pahangi and 
Trichinella spiralis 
• Cytotoxic activity against mammalian cells 
RNase 4 • Expression in host-defence associated tissues 
• Coexpression with lactoferrin, lactoferricin and RNase 5 Enhances 
antimicrobial activity of lactoferrin and lactoferricin 
RNase 5 • Increased serum levels during acute-phase response 
• Antiviral activity against HIV-1 
• Activity against Candida 
• Activity against streptococcus 
• Synthesis and secretion by mast cells 
• Proinflammatory stimulation of leukocytes 
• Inhibition of degranulation of neutrophil granulocytes 
RNase 6 • Infection-induced secretion in urinary tract 
• Antibacterial activity against Gram-positive and Gram-negative bacteria 
RNase 7 • Synthesis upon microbial inflammatory and physiochemical challenge in 
epithelial tissues 
• Antibacterial activity against mycobacteria and gram-negative and gram-
positive bacteria  
RNase 8 • Antibacterial and antifungal activity against Gram-positive and Gram-negative 




1.12.1 RNase structure  
 
RNase’s are small secretory proteins (13-15 kDa) with a short signal peptide (25-27 amino acid 
length). Even though there is low sequence identity between family members (approximately 
30%) all RNase’s share a common tertiary protein structure consisting of eight disulphide 
bridges, apart from RNase 5 which only contains six cysteine residues and a conserved motif 
signature (CKXXNTF). The catalytic activity of the protein is determined by a conserved trio 
of two histidine residues and one lysine residue of which the lysine residue is found in the 
CKXXNFT conserved motif (195). The N-terminal sequence on the initial RNase proteins 
directs the protein biosynthesis within the endoplasmic reticulum to finally become secretory, 
it has been found that the N-terminal of RNase is required for its antimicrobial activity, whereas 
the ribonucleolytic activity appears not to be crucial (196).  
 
1.12.2 Human RNase 1 
 
RNase 1 is expressed in almost all tissues, not just in the pancreas despite its name pancreatic 
RNase (197). It is highly expressed in endothelial cells (198,199) and in the blood, regulating 
vascular homeostasis (200). RNase 1 is a potent scavenger of pathogenic RNA and does not 
require any cofactor for its activation. RNase 1 targets single-stranded RNAs over double-
stranded RNA cleaving the 3’ end of unpaired C and U residues to produce a 3’-phosphorylated 
product. RNase 1 has been found to activate human dendritic cells leading to the production of 
pro-inflammatory cytokines, chemokines, growth factors and soluble receptors (201).  
 
1.12.3 RNases role in health and disease 
 
RNases are involved is a variety of tasks such as cellular housekeeping and sterility of body 
fluids ensuring the organism is kept healthy. However, tissue injury and necrotic cell death 
release DAMPS, such as extracellular RNA (eRNA). The eRNA act as proinflammatory 
mediators attracting innate immune cells e.g. macrophages and dendritic cells. The secretion 
of eRNA results in the expression of RNase 1 to contribute to tissue repair, removal of host 
damaged cells and directly killing the invading pathogen. Interestingly, prolonged periods of 
an infection result in downregulation of RNase expression, it is suggested that an adaptive 
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process by the pathogen to inhibit the host response, thus extending the survival life of the 
pathogen. 
 
Genetic deficiencies in RNase leads to immune-related diseases, RNase 5 mutations are 
associated with amyotrophic lateral sclerosis (202,203) and RNaseT2 is associated with the 
neuronal disorder cystic leukoencephalopathy (204,205). In disease elevated levels of human 
RNase 1, 2, 3, 4, 6 and 7 are found in the blood of septic patients and have been proposed as a 
marker for organ failure (206,207). Additionally, RNase 1 is also proposed as a biomarker for 
cancer, specifically cholangiocarcinoma (208). The rise of RNase 3 levels is also used to 
monitor asthma processes (209).  
 
1.12.4 Rodents and RNase 
 
In the mouse and rat genome, RNase 1, 2, 3 and 5 lineages are found, but orthologs of RNase 
6 and 7 are not. In 1996, two orthologs of the eosinophil RNase lineage were discovered and 
named eosinophil-associated ribonucleases (EARs), and since then 11 more have been 
identified (210). Phylogenetic analysis confirmed that the human and mouse loci once shared 
an ancestral gene, but rapid gene duplication has happened in primates and rodents 
independently, leading to high diversification (211). EARs are expressed in a multitude of 
cells/tissues such as lungs, cardiac, liver spleen, macrophages, to name but a few. Similar to 
the human counterpart EARs contribute to the host defence through their antimicrobial 
properties and tissue repair (207). 
 
In animal models of disease, the removal of eRNA by administering RNase showed reduced 
inflammation (measured by TNF-a and IL-1b) after myocardial or hepatic ischaemia-
reperfusion injury (212,213). The cognitive dysfunction induced by hepatic ischemia-
reperfusion injury in aged mice (measured by the Morris water maze test) was also improved 
due to the administration of RNase (212). In a mouse model of atherosclerosis, treatment with 





1.12.5 Ribonuclease inhibitor 1 
 
The human ribonuclease inhibitor 1 (RNH1) is a 50 kDa cytosolic protein that is ubiquitously 
expressed in many tissues. It binds to and inactivates RNase 1, 2 and 4, thus eRNA is no longer 
degraded (215). RNH1 is induced by oxidative stress and limits the activity of RNase, thus 
negatively contributing to host defence functions (216). 
 
1.13 Scientific aims and hypothesis  
 
Sepsis is a major public health problem, and the development of sepsis and sepsis-induced 
cardiac dysfunction are associated with high mortality rates. Further research into new 
therapeutics for sepsis must be undertaken to tackle this global burden. The overall aims of this 
thesis are to investigate potential new therapeutics and determine their mechanisms of action. 
Specifically, I have investigated whether commercially available BTK inhibitors ibrutinib or 
acalabrutinib attenuate sepsis-induced multiple organ dysfunction and if the inhibition of BTK 
is solely responsible for any observed effects and not an off-target effect (by conducting CLP 
in Xid mice). Lastly, I have investigated the role of RNase 1 in the pathophysiology of sepsis 
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Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to an 
infection (8), which affects approximately 50 million people worldwide (13). In the UK, sepsis 
is the second leading cause of death with 48,000 patients dying each year (217) costing the 
NHS approximately £2 billion annually (218). The development of cardiac dysfunction affects 
40% of septic patients (106) and is associated with an increased mortality rate of 70-90% in 
comparison to 20% mortality in patients who do not present with cardiac dysfunction (219). 
However, the mechanisms that underlie this cardiac dysfunction are not well known. Evidence 
suggests that multiple factors contribute to the pathophysiology of the cardiac dysfunction 
associated with sepsis. These include the activation of NF-kB and NLRP3 leading to excessive 
formation of e.g. TNF-α and IL-1, respectively  (108,220). There are currently no drugs for the 
specific treatment of the cardiac dysfunction (or indeed the multiple organ dysfunction) 
associated with sepsis that specifically targets NF-kB and the NLRP3 inflammasome.  
During sepsis, bacterial LPS stimulates TLR4, and PepG stimulates TLR2 (see section 1.5.3 
for detail). BTK is involved in the activation of TLRs by specifically binding to the TIR domain 
of MyD88 and Mal, leading to the downstream activation of NF-kB (see section 1.11 for 
detail). BTK also regulates the assembly and, hence, activation of the NLRP3 inflammasome 
by binding to the ASC component (166,167). The activation of NF-kB and the NLRP3 
inflammasome leads to the production of pro-inflammatory cytokines involved in the 
pathophysiology of sepsis. BTK inhibitors have been shown to inhibit the activation of NF-kB 
and its related cytokines/chemokines (168). 
Given the importance of the activation of TLRs, NF-kB and NLRP3 in the pathophysiology of 
sepsis, I hypothesised that BTK inhibitors, such as ibrutinib (first-generation and non-specific) 
or acalabrutinib (second-generation and specific), may attenuate the cardiac dysfunction in 
murine models of sepsis.  
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Specifically, in this chapter I set out to: 
1) Establish a model of endotoxemia – administration of LPS/PepG in order to investigate 
the effects 
a) of pre-treatment with oral ibrutinib (30 mg/kg, 1 h before LPS/PepG) on the cardiac 
dysfunction caused by LPS/PepG in mice.  
b) of intravenous administration of ibrutinib (3 or 30 mg/kg, 1 h after LPS/PepG) on 
the cardiac dysfunction caused by LPS/PepG in mice. 
 
2) Establish a surgical model of sepsis - caecal ligation and puncture (CLP) in order to 
investigate 
a) whether administration of ibrutinib (3 mg/kg & 30 mg/kg) or acalabrutinib 
attenuates sepsis-induced multiple organ failure (cardiac dysfunction, renal 
dysfunction and liver injury). 
b) whether the activation of BTK, NF- kB and NLRP3 inflammasome are involved in 
the pathophysiology of sepsis-induced cardiac dysfunction. 
c) whether delayed administration of BTK inhibitors reduce the activation of BTK, 
NF-kB and NLRP3 inflammasome in septic cardiac tissue. 





2.2 Methods and materials 
 
2.2.1 Ethical statement 
 
The Animal Welfare Ethics Review Board of Queen Mary University of London approved all 
experiments in accordance with the Home Office guidance on the operation of Animals 
(Scientific Procedures Act 1986) published by Her Majesty’s Stationery Office and the Guide 
for the Care and Use of Laboratory Animals of the National Research Council. Work was 




This study was carried out on 10-week old male C57BL/6 mice (Charles River Laboratories 
UK Ltd., Kent, UK) weighing 20-30 g and kept under standard laboratory conditions. The 
animals were allowed to acclimatise to laboratory conditions for at least one week before 
undergoing experiments. Six mice were housed together in ventilated cages lined with 
absorbent bedding material. Tubes and chewing blocks were placed in the cage for 
environmental enrichment. They were subjected to 12-h light and dark cycle with the 
temperature maintained at 19-23oC. All animals had free access to a chow diet and water ad 
libitum. The cages were cleaned regularly approximately every three days, with water being 
changed daily. Research staff inspected the animals each day for any signs of illness or 
abnormal behaviour. 
 
2.2.3 Establishing a model of LPS/PepG-induced cardiac dysfunction 
 
Ten-week-old, male C57BL/6 mice received LPS (derived from Escherichia coli 0111:B4) and 
PepG at either: 6 mg/kg/0.1 mg/kg, 6 mg/kg/1 mg/kg or 7 mg/kg/1 mg/kg in PBS via 
intraperitoneal (i.p.) administration (Table 2.1). Sham-operated mice were injected with PBS 
only (i.p.) but were otherwise treated identical to LPS/PepG-mice. Cardiac dysfunction was 
examined in vivo by echocardiography at 18 h after LPS/PepG co-administration under 
anaesthesia as described below (Figure 2.1). 
 
 75 











Figure 2.1 Schematic representation of LPS/PepG model. At 0 h, 10-week-old C57BL/6 male mice 
were administered with LPS/PepG i.p. to induce cardiac function. At 18 h cardiac function was assessed 




0 h 18 h
LPS/PepG i.p. Echocardiography + 
organ & serum analysis




Sham  6 
LPS (6 mg/kg) + PepG (0.1 mg/kg) 3 
LPS (6 mg/kg) + PepG (1 mg/kg) 3 
LPS (7 mg/kg) + PepG (1mg/kg) 5 
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2.2.4 Pre-treatment with ibrutinib via oral gavage  
 
One hour before LPS (7 mg/kg)/PepG (1 mg/kg) i.p. administration, animals were randomised 
to receive either ibrutinib (30 mg/kg p.o.) or vehicle (5% DMSO + 30% cyclodextrin p.o.). 
Sham-operated mice received PBS (5 ml/kg i.p.) (Table 2.2). Cardiac dysfunction was 
examined in vivo by echocardiography at 18 h after LPS/PepG co-administration under 
anaesthesia (see below). At the end of the experiment, all mice were deeply sedated by 
inhalation of 3% isoflurane and delivered in 0.4 L/min oxygen. Approximately 0.7 ml of blood 
was obtained via cardiac puncture; the mice were then killed by removal of the heart, lungs, 
liver, kidney and spleen were all collected and stored at -80oC for further analyses (see below). 
The blood samples were centrifuged for 3 min at 9000 RPM and serum was collected and 
frozen at -80oC (Figure 2.2).  
 
Table 2.2 Experimental groups used to investigate whether pre-treatment with oral ibrutinib (30 










Sham  PBS (5 ml/kg i.p.) 5 
Control + vehicle 5% DMSO + 30% cyclodextrin p.o. 1 h 
before LPS (7 mg/kg) + PepG (1 mg/kg) 
i.p.  
5 
LPS/PepG + ibrutinib 
(30 mg/kg p.o.)  
Ibrutinib (30 mg/kg) p.o. 1 h before LPS 




Figure 2.2 Schematic representation of LPS/PepG model to investigate whether pre-treatment 
with ibrutinib attenuates LPS/PepG-induced cardiac dysfunction. At -1 h, 10-week-old C57BL/6 
mice were administered ibrutinib (30 mg/kg p.o.). One hour later mice were injected with LPS (7 
mg/kg) and PepG (1 mg/kg) i.p. to induce cardiac function. At 18 h cardiac function was assessed by 
echocardiography in vivo. At the end of the experiment blood samples and organs were collected to 
quantify organ dysfunction. 
 
2.2.5 Post-treatment with intravenous Ibrutinib  
 
One hour after i.p. injection of LPS (7 mg/kg)/ PepG (1 mg/kg) animals were randomised to 
receive either ibrutinib (3 mg/kg), ibrutinib (30 mg/kg) or vehicle (5% DMSO + 30% 
cyclodextrin) intravenously. Sham-operated mice only received PBS (5 ml/kg i.p.) (Table 2.3). 
Cardiac dysfunction was examined in vivo by echocardiography at 18 h after LPS/PepG co-
administration under anaesthesia (see below). At the end of the experiment, all mice were 
deeply sedated by inhalation of 3% isoflurane delivered in 0.4 L/min oxygen and 
approximately 0.7 ml of blood were obtained via cardiac puncture; the mice were then killed 
by removal of the heart. Heart, lungs, liver, kidney and spleen were all collected and stored at 
-80oC for further analyses (see below). The blood samples were centrifuged for 3 min at 9000 
RPM and the plasma was collected and also frozen at -80oC (Figure 2.3). 
  
-1 h 0 h 18 h
LPS/PepG i.p.Ibrutinib p.o. Echocardiography + 
organ & serum analysis
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Table 2.3 Experimental groups used to investigate whether post-treatment of ibrutinib (3 mg/kg 
or 30 mg/kg) attenuates LPS/PepG-induced cardiac dysfunction. 




Sham + vehicle 0 h PBS (5 ml/kg i.v.) 10 
Control + vehicle 0 h - LPS (7 mg/kg) + PepG (1 mg/kg) i.p.  
1 h - 5% DMSO + 30% cyclodextrin i.v.  
10 
LPS/PepG + ibrutinib  
(3 mg/kg i.v.) 
0 h - LPS (7 mg/kg) + PepG (1 mg/kg) i.p.  
1 h – (ibrutinib 3 mg/kg i.v.) 
10 
LPS/PepG + Ibrutinib  
(30 mg/kg i.v.)  
0 h - LPS (7 mg/kg) + PepG (1 mg/kg) i.p. 





Figure 2.3 Schematic representation of LPS/PepG model to investigate whether delayed 
intravenous administration of ibrutinib (3 mg/kg or 30 mg/kg) attenuates LPS/PepG-induced 
cardiac dysfunction.  At 0 h, 10-week-old C57BL/6 mice were injected with LPS (7 mg/kg) and PepG 
(1 mg/kg) via i.p. to induce cardiac dysfunction. At 1 h ibrutinib 3 mg/kg or 30 mg/kg was administered 
via i.v. At 18 h cardiac function was assessed by echocardiography in vivo. At the end of the experiment 
blood samples and organs were collected to quantify organ dysfunction.  
 
  
1 h 18 h
Ibrutinib 3mg/kg
or 30 mg/kgi.v.
LPS/PepG i.p. Echocardiography + 
organ & serum analysis
0 h
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2.2.6 Caecal ligation and puncture (CLP) surgery  
 
Ten-week-old C57BL/6 mice were randomly selected to undergo CLP or sham-operated 
surgery. Buprenorphine (0.05 mg/kg i.p.) was administered as an analgesic at the start of the 
experiment. Mice were initially anaesthetised with 3% isoflurane and delivered with 1 L/min 
oxygen in an anaesthetic chamber, after which maintenance was kept at isoflurane 2% and 
delivered with 1 L/min oxygen via a facemask throughout the surgery. The temperature of the 
mice was monitored throughout the experiment by a rectal thermometer and maintained at 37oC 
via a homoeothermic blanket. The fur is removed from the abdominal area by Veet hair 
removal cream and the area is cleaned with 70% ethanol. The abdomen of the animals was then 
opened up by a 1.5 cm midline incision, where the caecum is exposed. The caecum was fully 
ligated below the ileocaecal valve and a G-18 needle was used to puncture both ends of the 
ligated caecum, where a small amount of faeces was then squeezed out (Figure 2.4). The 
caecum was returned to the abdomen in its anatomical position and 5 ml/kg of normal saline 
(0.9 % NaCl) was administered into the abdomen before its closure. Saline (10 ml/kg) is also 
administered s.c. directly after surgery for fluid resuscitation. Antibiotics 
(Imipenem/Cilastatin; 20 mg/kg dissolved in the resuscitation fluid s.c.) and an analgesic 
(buprenorphine; 0.05 mg/kg i.p.) were administered at 6 h and 18 h after surgery. After 24 h, 
cardiac function was assessed by echocardiography in vivo. Mice were anaesthetised with 
isoflurane and cardiac puncture took place to obtain blood samples. Mice were then killed by 
removal of the lungs and heart. The organs and blood collected were used to quantify injury. 
Mice that underwent sham-operated surgery were not subjected to ligation or perforation of the 
caecum but were otherwise treated the same way. 
 
A reduction in temperature to <30oC or a change of 5oC over time in each animal has been 
reported to predict death in mice with CLP (221). As mortality of animals is not an acceptable 
routine endpoint in the UK, I used the reduction in rectal temperature <30oC as a surrogate 
marker for mortality. 
 
A clinical score for monitoring the health of experimental mice was used to evaluate the 
symptoms consistent with murine sepsis. The maximum score of 6 comprised the presence of 
the following signs: lethargy, piloerection, tremors, periorbital exudates, respiratory distress, 
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and diarrhoea. Mice with a clinical score >3 were defined as exhibiting severe sepsis, against a 
moderate sepsis for a score ≤3.  
 
 
Figure 2.4 Schematic representation of the caecal ligation and puncture model. Mice were initially 
anaesthetised with 3% isoflurane, delivered in 1 L/min oxygen and maintained at 2% isoflurane and 1 
L/min oxygen through nosecone. (A) Veet is applied to abdomen. (B) Veet cream is removed and skin 
is cleaned with ethanol. (C) A small incision in the midline of the abdomen. (D) Second incision on 
epithelia layer. (E) The caecum is taken out of the abdomen. (F) The caecum is completely ligated 
below the ileocaecal valve (roughly 1.5 cm from end of cecum). (G) A G-18 needle is used to puncture 
the top and end of the caecum and a small amount of faeces is squeezed out (roughly 3-4mm). (H) The 
caecum is then placed back into cavity and sutured up with proline 5mm needles.  
 
2.2.7 The development of CLP-induced cardiac dysfunction over 24 h 
 
10-week-old C57Bl/6 male mice underwent CLP surgery, or sham-operated surgery. At 0, 1, 
3, 6, 12 and 24 h the development of cardiac dysfunction was assessed in vivo by 
echocardiography (Table 2.4).  
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2.2.8 BTK inhibitors 
 
Ibrutinib and acalabrutinib were purchased from Selleck Chemicals. Stock solutions were made 
in DMSO 5% and cyclodextrin 30% (vehicle).  
 
2.2.9 Post-treatment with ibrutinib or acalabrutinib after CLP surgery 
 
One hour after CLP surgery, animals were randomised to receive either ibrutinib (3 mg/kg i.v.), 
ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% 
cyclodextrin 3 ml/kg i.v.). Sham-operated mice were not subjected to ligation or perforation of 
the caecum but were otherwise treated the same way and received the vehicle 1 h after surgery 
(Table 2.5). Cardiac dysfunction was examined in vivo by echocardiography at 24 h after CLP 
surgery under anaesthesia (as described below) (Figure 2.5). At the end of the experiment, all 
mice were deeply sedated by inhalation of 3% isoflurane delivered in 0.4 L/min oxygen and 
approximately 0.7 ml of blood was obtained via cardiac puncture; the mice were then killed by 
removal of the heart. Heart, lungs, liver, kidney and spleen were all collected and stored at -
80oC for further analyses. The blood samples were centrifuged for 3 min at 9000 RPM and the 
serum was collected and frozen at -80oC for further analysis (as described below). 
 




























Table 2.5 Experimental groups used to investigate the post-treatment with ibrutinib (3 mg/kg or 
30 mg/kg) or acalabrutinib in CLP-induced cardiac dysfunction. 
 




Sham + vehicle Sham surgery, then 5% DMSO + 30% cyclodextrin (3 ml/kg) 
i.v. at 1 h 
10 
Control + vehicle CLP surgery at 0 h, then 5% DMSO + 30% cyclodextrin (3 
ml/kg) i.v. at 1 h  
10 
CLP + ibrutinib  
(3 mg/kg i.v.) 
CLP surgery at 0 h, then ibrutinib (3 mg/kg i.v.) at 1 h 10 
CLP + ibrutinib  
(30 mg/kg i.v.)  
CLP surgery at 0 h, then ibrutinib (30 mg/kg i.v.)  at 1 h 10 
 CLP + acalabrutinib (3 
mg/kg i.v.) 




Figure 2.5 Schematic representation of caecal ligation and puncture model to investigate whether 
delayed intravenous administration of ibrutinib (3 mg/kg or 30 mg/kg) or acalabrutinib (3 mg/kg) 
attenuates CLP-induced cardiac dysfunction. At 0 h, 10-week-old, C57BL/6 mice underwent caecal 
ligation and puncture surgery to induce cardiac dysfunction. At 1 h, ibrutinib (3 mg/kg or 30 mg/kg), 
acalabrutinib (3 mg/kg), or vehicle (5% DMSO + 30% cyclodextrin) was administered intravenously. 
At 6 and 18 h antibiotics and analgesic were administration. At 24 h, cardiac function was assessed by 
echocardiography in vivo. At the end of the experiment blood samples and organs were collected to 



















2.2.10 Assessment of cardiac function in vivo (echocardiography)  
 
Cardiac function in mice was assessed by echocardiography in vivo by the Vevo 3100 imaging 
system (VisualSonics, Toronto, Ontario, Canada) (Figure 2.6). Mice were initially 
anaesthetised with 3% isoflurane (and received 1 - 0.4 L/min oxygen), and then anaesthesia 
was maintained between 2 - 1% isoflurane (and 1 - 0.4 L/min oxygen). Mice were left to 
stabilise for 10 min before assessment began. During echocardiography, the heart rate was 
maintained between 400 – 500 bpm. Mice were placed on a thermoregulatory platform (set at 
42oC) and a rectal thermometer was used to measure core body temperature, which maintained 
the body temperature at 37oC. Electro-conducting gel was applied to the metal ECG pads and 
the paws of the animal were taped onto the ECG leads. Veet hair removal cream was applied 
to remove the fur from the chest and the chest was cleaned with 70% ethanol. Warmed 
ultrasound transmission gel was placed onto the shaven chest and the heart was imaged with 
the MX550D probe, whilst the platform was positioned pointing downwards slightly to the left 




Figure 2.6 Vevo 3100 imaging system. Echocardiography was carried out on mice anesthetised with 
isoflurane. Mice were anesthetised in an aesthetic chamber. Once fully unconscious the mouse was 
moved onto the mouse handling platform where anaesthesia and oxygen were continuously supplied to 
the mouse through a nosecone. The platform could be adjusted by x/y stage adjustment. The paws were 
sellotaped to the ECG leads on the platform, where the heart rate was obtained from the ECG trace. The 
temperature was monitored throughout the experiment by a rectal probe. MX550D probe was connected 
to the RMV clamp. The clamp adjustment handle and the up/down adjustment scroll could be used to 
change the orientation of the RMV clamp and therefore the probe. All images were recorded on the 





To obtain the two-dimensional B-mode trace of the left ventricle (LV), the transducer was 
placed along the long axis of LV and directed towards the right of the mouse. The probe was 
then rotated clockwise by 90o to visualise the short axis (Figure 2.7). Percentage fraction area 
change (FAC) was calculated from two-dimensional B-mode LV image 100 x ([LV end-
diastolic area – LV end-systolic area)/ LV end-diastolic area]. This was done by tracing the 




Figure 2.7 Representative B-mode echocardiography image of the mouse heart. The image was 
taken in the parasternal short-axis view showing the left ventricle (LV) in the centre and the papillary 







Figure 2.8 Endocardial tracing. In the parasternal short-axis B-mode view, measurements were taken 
by tracing the endocardial surface of the LV at the LV end-diastolic area and LV end-systolic area to 




One-dimensional M-mode images were obtained in the parasternal short-axis view of the 
papillary muscles (Figure 2.9) where the following was measured by LV trace (Figure 2.10): 
• Ejection fraction (EF %) = 100 x [(LVIDd3 – LVIDs)3) / LVIDd3] 
• Fractional shortening (FS %) = 100 x [(LVIDd – LVIDs) / LVIDd]  
• End diastole volume (EDV  µL) = !.#$.%&'()*;,	 	× 	 (0123; 4)3 x 1000 
• End systole volume (ESV µL) = !.#$.%&'()*;6	 	× 	(0123; 7)3 x 1000 
• Stroke volume (SV µL) = EDV - ESV 




Figure 2.9 Representative M-mode echocardiography image of the mouses heart. The M-mode is 
a representative line of motion over time of the cardiac cycle, which is detected from the B-mode 
imaging in the parasternal short axis view at the level of the papillary muscles. IVS = Interventricular 
septum thickness, LVID = left ventricular internal diameter, LVPW = left ventricular posterior wall. 
 
 
Figure 2.10 Left Ventricle (LV) trace. From this image ejection fraction (EF), fractional shortening 
(FS), cardiac output (CO), stroke volume (SV), end-diastolic volume and end-systolic volume, can be 
calculated, by measuring left ventricle internal dimension (LVID) in the diastolic and systolic phase. 
The measurements were taken from the inner surface of the interventricular septum (IVS) to the inner 
surface of the LV posterior wall (LVPW), whilst avoiding any interference from papillary muscles. 
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The four-chamber view was used to assess the diastolic dysfunction of the left side of the heart 
by measuring the blood flow in the mitral valve via pulsed wave Doppler (Figure 2.11). The 
following calculations were carried out: 
• E/A ratio  
• Myocardial performance index = (IVCT + IVRT)/ET or (NFT – AET)/ ET 
 
 
Figure 2.11 Representative four chamber view of the mitral valve blood flow in the mouse heart. 
The pulsed wave Doppler is used to measure the diastolic function of the left side of the heart through 
the mitral valve. The following measurements can be taken: the peak velocity of the early (E) and atrial 
(A) peak, isovolumic relaxation times (IVRT), isovolumic contraction times (IVCT), the no-flow time 






Blood flow in the pulmonary artery was measured by pulsed wave Doppler (Figure 2.12). The 
following measurements are taken: 
• Pulmonary valve peak velocity, which is an indicator of contractility. 
• Pulmonary valve velocity-time integral (VTI), which indicates how far blood travels 
during the flow period. 
 
 
Figure 2.12 Representative blood flow in the pulmonary artery. The pulsed wave Doppler was used 
to measure the velocity and gradient of the blood flow through the pulmonary valve. The PA peak 
measures the peak velocity of blood flow and PA VTI measures the velocity-time integral. 
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2.2.11 Quantification of renal dysfunction and hepatocellular injury  
 
Renal dysfunction and hepatocellular injury were analysed in all mice. The mice were 
anaesthetised with 3% isoflurane and delivered in 0.4 L/min. Full sedation was confirmed by 
no withdrawal response upon pain stimulation to the paws. The cardiac puncture was carried 
out with a G-26 needle and non-heparinized syringes to obtain approximately 0.7 ml of blood. 
The blood was immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, 
Germany). The heart and lungs were then removed. Blood samples were left to coagulate for 
at least 10 min at room temperature, then samples were centrifuged at 9000 rpm for 3 min to 
separate the serum. Then 100 µL of serum was pipetted into a 1.5 ml Eppendorf and snap-
frozen in liquid nitrogen. Serum and organs were stored at -80oC for further analysis. The serum 
was then sent to an independent veterinary testing laboratory (MRC, Harwell) to blindly 
quantify serum urea, creatinine (markers of renal dysfunction), alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) (markers of hepatocellular injury). 
 
2.2.12 Western blot 
 
Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative 
western blotting analysis.  
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2.2.12.1 Solutions and reagents  
 
Solutions Components Solutions Components 
Homogenization buffer 20 mM Hepes-KOH pH 7.9 
1 mM MgCl2 
0.5 mM EDTA 
1 mM EGTA 
1% NP-40  
100 ml dH2O 
Protease inhibitors (add just before use) 
1  µl/ml protease inhibitor cocktail (PIC) 
0.5 mM PMSF 
0.1 mM DL-Dithiethrectol (DTT) 
 
Extraction buffer 20 mM Hepes-KOH pH 7.9 
1.5 mM MgCl2 
0.2 mM EDTA 
1 mM EGTA 
20 % glycerol 
420 mM NaCl 
50 ml dH2O 
Protease inhibitors (add just before 
use) 
1  µl/ml (PIC) 
0.5 mM PMSF 
0.1 mM (DTT) 
 
Loading buffer 4% SDS 
20% glycerol 
0.004% Bromophenol blue 
0.125 MTris-HCl 
Running buffer 25 mM TRIS 
190 mM glycine 
0.1% SDS 
dH2O 
Transfer buffer 48 mM TRIS 









0.1% Tween  
5% milk 
1:1000 rabbit anti-Ser176/180-IKKα/β 
1:1000 rabbit anti-total IKKα/β 
1:1000 mouse anti-Ser32/36-IkB   
1:1000 mouse anti-total IkB  , 
1:1000 rabbit anti-NF-kB, 
1:1000 rabbit anti-total BTK, 
1:1000 rabbit anti-Tyr1217 PLCg, 
1:1000 rabbit anti-total PLCg (from Cell 
Signaling), 
1:1000 rabbit anti-Tyr223-BTK, 
1:5000 rabbit anti NLRP3 inflammasome 
(from Abcam), 





25 ml TBS  
5% milk 
Dilution 1:50000 secondary antibody 
conjugated with horseradish 
peroxidase (HRP) 
0.005% StrephTactin-HRP 





2.2.12.2 Tissue homogenization and cytosolic and nuclear protein collection 
 
1. The apex of the heart was taken and homogenized with homogenization buffer in ice at 
a concentration of 1:10 (e.g. 30 g of tissue in 300 µl of homogenization buffer). 
2. Centrifuge at 4000 RPM (1320 G) for 5 min at 4oC. 
3. Separate the supernatant (supernatant 1) from the pellet (pellet 1). 
4. Centrifuge the supernatant 1 at 14000 RPM (16215 G) for 40 min at 4oC. The obtained 
supernatant (supernatant 2) contains the cytosolic proteins. 
5. Resuspend the Pellet 1 in extraction buffer at a concentration of 1/3 compared to the 
homogenization buffer (e.g. 100 µl). 
6. Incubate for 30 min in ice vortexing occasionally. 
7. Centrifuge at 14000 RPM (16215 G) for 20 min at 4oC. The obtained supernatant 
(supernatant 3) contains the nuclear proteins. 
8. Freeze the supernatant 2 (cytosolic proteins) and supernatant 3 (nuclear proteins) at -
80oC for future use. Refer to Figure 2.13 for schematic diagram. 
 
Figure 2.13 Diagram of extracting cytosolic and nuclear proteins from homogenised tissue. 
Homogenized tissue
Centrifuge at 4000 RPM for 5 min at 
4oC
Centrifuge at 14000 RPM for 40 min 
at 4oC
• Resuspend in extraction buffer
• Incubate for 30 min on ice
• Centrifuge 14000 RPM for 20 
min at 4oC
Supernatant 1 Pellet 1
Supernatant 2 Pellet 2 Supernatant 3 Pellet 3
Cytosolic proteins Discard Nuclear proteins Discard
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2.2.12.3 Bicinchoninic acid (BCA) protein assay 
 
Protein concentrations were quantified by bicinchoninic acid (BCA) protein assay (Thermo 
Fisher Scientific Rockford, IL) refer to Figure 2.14 for mechanism of the assay. 
 
Figure 2.14 Schematic diagram of the mechanism of action of the Bicinchoninic acid (BCA) 
protein assay. First step - the biuret reaction: proteins reduce Cu+2 to Cu+ in an alkaline solution. 














A = 562 nm
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Make up BCA standard curve albumin. 
1. Make up BCA buffer by adding buffer A to buffer B at 50:1. 
2. Add 3 µl of cytosolic or nuclear protein sample, 27 µl of distilled water and 570 µl 
BCA solution to each well (in duplicates). 
3. Negative control – add 30 µl of distilled water and 570 µl of BCA solution into one 
well.  
4. Incubate at 37oC for 30 min in the dark for the reaction to take place (Figure 2.15). 
5. Read plate (program, 560 nm). 
6. Calculate protein concentrations.  
 
Figure 2.15 Plate after incubation of BCA. The purple BCA/copper complex results in strong linear 




Water + BCA solution  
Protein sample + BCA 
solution
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2.2.12.4 Loading and running the gel 
 
1. Load 60 µg total cytosol protein samples or 30 µg of nuclear protein samples into the 
wells of 8% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), along with 5 µl molecular weight markers. Empty wells were loaded with 5 µl 
sample buffer. 
2. Total loading volume for protein sample loaded well was 15 µl (e.g. 4.96 µl protein 
sample + 7.04 µl distilled water (12 µl total) + 3 µl sample buffer). 
3. Before loading boil the sample at 60oC for 10 min to accelerate the effect of SDS in 
breaking 3rd protein structures. 
4. Vortex samples for 30 sec. 
5. Load samples into the wells – load molecular weight sample first (5 µl of precision plus 
protein western standard). Slowly pipette and avoid bubbles.  
6. Run the gel for 35 min at 200 V (the smaller the protein the faster it runs). 
 
2.2.12.5 Transferring protein from the gel to polyvinyldenedifluroide (PVDF) paper 
membrane  
 
1. Cut filter 8.5 cm by 5.5 cm. 
2. Place filter in methanol for 10 sec. 
3. Place membrane into transfer buffer for 5 min. 
4. Make transfer sandwich (Figure 2.16). 
5. Place into machine and put a magnet at the bottom and a block of ice fill with transfer 
buffer. Place on a magnetic stirrer and running for 70 min at 100 V, 180 mA.  
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Figure 2.16 Transfer sandwich. 
 
2.2.12.6 Antibody incubation  
1. Remove PVDF membrane and wash in washing buffer for 10 min.  
2. Block membrane for 30 min at 4°C.  
3. Wash membrane with washing buffer for 10 sec.  
4. Incubate membrane with appropriate dilutions of primary antibody in 5% blocking 
solution overnight at 4°C.  
5. Wash membrane with washing buffer 3 x 5 min.  
6. Incubate membrane with secondary antibody solution for 30 min at room temperature.  
7. Wash membrane with washing buffer 3 x 5 min.  
2.2.12.7 Visualisation  
1. ECL: add buffer 1 to buffer 2 (2 ml in total for 1 filter 1:1 concentration) stand 1 min 
then pour the solution onto membrane.  
2. Leave in the dark for 10 min then discard.  
3. Cover the membrane in transparent plastic wrap, place it into film cassette in dark room, 
and place a film on it.  
4. Place film into developing solution for 10 sec, then stop the reaction by placing it into 
water, fix film in fixing solution.  
5. Ensure all light sensitive products have been put away before turning on the light. 
6. Strip membrane (add Invitrogen Western stripping solution. Incubate 10 min/ RT/ 
shaking). 
 98 
7. Wash membrane in washing buffer 3 x 5 min. 
8. Incubate in blocking buffer for 30 min shaking at room temperature. 
9. Store in fridge, or reprobe with another primary antibody. 
10. The immunoreactive bands were analysed by the Bio-Rad Image Lab SoftwareTM 6.0.1 
and results were normalized to the sham bands.   
2.2.13 Multiplex flow immunoassay 
 
The principle of multiplex flow immunoassay technology has been reviewed previously 
(222,223). Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex 
Pro Mouse Chemokine 33-plex panel assay (Bio-Rad, Kabelsketal, Germany). The cytokines 
IL-1ß, -2, -4, -6, -10, -16, CCL1, -2, -3, -4, -5, -7, -11, -12, -17, -19, -20, -22, -24, -25, -27, 
IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1, -2, -5, -10, -11, -12, -13, -16 and the 
growth factor GM-CSF were measured according to the manufacturer’s instructions. The 
assays were performed in one batch, with samples randomly distributed (Figure 2.17). The 
lower detection limit was 3.2 pg/ml for all the analytes. Data were collected and analysed using 
a Bio-Plex® 200 instrument equipped with Bio-Plex Manager software (Bio-Rad). 
1. Add 50 µl of 1 x beads to each well. 
2. Wash the plate twice with 100 µl of Bio-plex wash buffer per well. 
3. Add 50 µl standards, samples, controls and incubate on shaker at 850 RPM for 30 min 
at room temperature. 
4. Wash the plate three times with 100 µl of Bio-plex wash buffer per well. 
5. Add 25 µl 1 x detection antibody and incubate on shaker at 850 RPM for 30 min at 
room temperature. 
6. Wash three times. 
7. Add 50 µl 1 x streptavidin-PE and incubate on shaker at 850 RPM for 10 min at room 
temperature. 
8. Wash three times. 
9. Resuspend in 125 µl assay buffer and shake at 850 RPM for 30 sec. 
10. Acquire data on Bio-Plex system. 
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Figure 2.17 Diagram of multiplex layout 
 
2.2.14 Peritoneal lavage 
 
Mice were anaesthetised by overdose of isoflurane. Once confirmed dead, peritoneal cells were 
obtained by injecting 5 ml of 2mM EDTA + PBS -/- using a 25-G needle. Cells attached were 
dislodged by gentle massage of the peritoneum and collected by using an 18-G needle. 
Approximately 4 ml of the peritoneal fluid was obtained and decanted into 15 ml falcon tubes 




2.2.15 Quantification of immune cells in the peritoneum  
 
One ml of peritoneal exudate was added to FACS tubes and immediately washed in 1 ml FACS 
buffer (0.05 % BSA, 2 mM EDTA in PBS pH 7.4). Tubes were then centrifuged at 300 G for 
5 min. After centrifugation, the supernatant was discarded. Before staining for cell surface 
markers Fc receptors were blocked using anti-CD16/32 (Biolegend) for 10 min at 4oC. The 
cells were then washed with FACS buffer, centrifuged and the supernatant was discarded. 
Peritoneal cells were incubated for 30 min at 4oC in the dark with anti-CD45 (clone 30-F11; 
BioLegend), anti-CD11b (clone M1/70; BioLegend), anti-F4/80 (clone BM8; BioLegend), 
anti-Ly6G (clone 1A8; BioLegend), anti-CD3 (clone 145–2C11; BioLegend) and anti-B220 
(clone. RA-3–6B2; BioLegend) antibodies, all at 1:200 concentration. After 30 min the cells 
were washed with FACS buffer, centrifuged and the supernatant was discarded. The cells were 
then fixed in 200 µl of 2% PFA ready for FACS analysis and stored in the dark at 4oC to be 
analysed within 48 hours. On the day of analysis, 10 µl of counting beads (Biolegend) was 
added. Data were acquired using BD LSR II Fortessa (Becton Dickinson) and analysed using 




Figure 2.18 Flow cytometry gating strategy for infiltrating immune cells in sham-operated and 





2.2.16 Bacteria quantification 
 
Accurate evaluation of the number of bacteria in peritoneal lavage fluid was performed by flow 
cytometry using the SYTO BC bacteria counting kit (Thermo Fischer Scientific). One ml of 
peritoneal exudate was centrifuged at 300 G for 5 min at 4oC. The supernatant was discarded, 
and the cells were stained with SYTO® BC bacteria stain (1:1000) at room temperature for 15 
min. Cells were then washed in PBS, centrifuged at 300 G for 5 min at 4oC and the supernatant 
was discarded afterwards. Cells were then resuspended in 990 µl PBS and 10 µl of 
Microspheres (counting beads) were added ready for analysis.  
 
2.2.17 Statistical analysis 
 
All data are expressed as mean ± standard error mean (SEM) where n represents the number 
of animals studied. Statistical differences were determined using a one-way ANOVA, followed 
by Bonferroni post hoc test. Correlations coefficients were determined by Pearson's correlation 
with P-values based on two-tailed tests. All statistical tests were carried out on GraphPad Prism 
8.0 (GraphPad Software, Inc., La Jolla, CA, USA) and differences were considered to be 






2.3 Results – LPS/PepG model 
 
2.3.1 LPS (7 mg/kg) and PepG (1 mg/kg) caused sufficient cardiac dysfunction in 10-week-
old C57BL/6 mice 
 
Left ventricular function was assessed by echocardiography 18 h after i.p. administration of 
LPS/PepG or vehicle (PBS). When compared to sham-operated mice, co-administration of LPS 
(6 mg/kg) and PepG (0.1 mg/kg) had no significant effect on any of the parameters of cardiac 
dysfunction (EF, FS and FAC). The dose of PepG was then increased from 0.1 mg/kg to 1 
mg/kg. When compared to sham-operated mice, the co-administration of LPS (6 mg/kg) and 
PepG (1 mg/kg) resulted in a significant reduction of EF and FS (Figure 2.19 A-C), but only a 
small (nonsignificant) decrease was observed for FAC (Figure 2.19 D). The dose of LPS was 
then increased from 6 mg/kg to 7 mg/kg. When compared to sham-operated, co-administration 
of LPS (7 mg/kg) and PepG (1 mg/kg) resulted in significant reductions for all parameters of 
cardiac function (Figure 2.19 A-D). Thus, I selected the following dose of LPS (7 mg/kg) and 





Figure 2.19 LPS (7 mg/kg) and PepG (1 mg/kg) caused sufficient cardiac dysfunction in 10-week-
old C57BL/6 mice. Mice were randomly selected to be injected with either LPS/PepG or PBS i.p. 18 
h later cardiac function was assessed via echocardiography. (A) Representative M-mode 
echocardiograms. (B) Ejection fraction (%). (C) Fractional shortening (%). (D) Fractional area change 
(%).  The following groups were studied, sham (n = 6), LPS (6 mg/kg) + PepG (0.1 mg/kg) (n = 3), 
LPS (6 mg/kg) + PepG (1 mg/kg) (n = 3), LPS (7 mg/kg) + PepG (1 mg/kg) (n = 5). All data are 
expressed as mean ± SEM for n number of observations.  A value of *P < 0.05 was considered to be 

































































2.3.2 The effects of oral ibrutinib pre-treatment on heart rate and temperature in mice 
subjected to LPS/PepG  
 
When compared to sham-operated animals, mice subjected to LPS/PepG and treated with 
vehicle resulted in a significant decrease in temperature. When compared to LPS/PepG mice 
treated with vehicle, the administration of ibrutinib 1 h before LPS/PepG attenuated 
LPS/PepG-induced hypothermia (demonstrated as a significant rise in temperature). No 
significant differences were observed for the changes in mean heart rates for all groups (Table 
2.6). 
 
Table 2.6 The effects of oral ibrutinib pre-treatment on heart rate and temperature in mice 
subjected to LPS/PepG 
 Sham  LPS/PepG + 
vehicle 
LPS/PepG + ibrutinib (30 mg/kg 
p.o.) 
Number 5 5 5 
Temperature (oC) 36.24 ± 0.103* 28.74 ± 1.422 32.02 ± 1.317* 
Heart rate (bpm) 456.8 ± 21.15 392.8 ± 32.01 440.4 ± 12.31 
Mice received LPS/PepG or vehicle (PBS) (i.p.). One hour later, mice were treated with either ibrutinib 
(30 mg/kg p.o.) or vehicle (5% DMSO + 30% cyclodextrin p.o.). Heart rate and temperature were 
recorded 18 h after LPS/PepG administration. All data are expressed as mean ± SEM for n number of 
observations. A value of *P < 0.05 was considered to be statistically significant when compared to 





2.3.3 Pre-treatment of oral ibrutinib attenuates LPS/PepG-induced cardiac dysfunction. 
 
When compared to sham-operated animals, mice subjected for 18 h to LPS/PepG and treated 
with vehicle demonstrated a significant reduction in left ventricular EF, FS and FAC indicating 
the development of systolic cardiac dysfunction (Figure 2.20 A-D). In contrast, pre-treatment 
of ibrutinib (30 mg/kg p.o.) 1 h before LPS/PepG significantly prevented the decline in 
percentage EF, FS and FAC (Figure 2.20A-D).  
 
 
Figure 2.20 Pre-treatment of oral ibrutinib (30 mg/kg) attenautes LPS/PepG-induced cardiac 
dysfunction. Mice were pre-treated with ibrutinib (30 mg/kg p.o.) or vehicle (5% DMSO + 30% 
cyclodextrin p.o.) 1 h before administration of LPS/PepG (i.p.). Cardiac function was assessed 18 h 
after LPS/PepG administration. (A) Representative M-mode echocardiograms. (B) Ejection fraction 
(%). (C) Fractional shortening (%). (D) Fractional area change (%). The following groups were studied 
sham, LPS/PepG + vehicle, LPS/PepG + ibrutinib (30 mg/kg p.o.). All data are expressed as mean ± 
SEM for n = 5 per group.  A value of **P < 0.01, ****P < 0.0001 was considered to be statistically 
significant when compared to LPS/PepG + vehicle by one-way ANOVA followed by a Bonferroni’s 



























































LPS/PepG + vehicle 
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2.3.4 The effects of oral ibrutinib pre-treatment on LPS/PepG-induced renal dysfunction and 
hepatocellular injury  
 
When compared to sham-operated mice, mice subjected to LPS/PepG and treated with vehicle 
resulted in a significant increase in serum urea and ALT (Figure 2.21 A&B). However, the 
increase in AST caused by LPS/PepG was not significant (Figure 2.21 C). In comparison to 
LPS/PepG mice pre-treated with vehicle, mice pre-treated with ibrutinib 1 h before LPS/PepG 
had lower serum levels of urea, ALT and AST, but these effects were not significant (Figure 
2.21 A-C).  
 
Figure 2.21 The effects of oral ibrutinib pre-treatment on LPS/PepG-induced renal dysfunction 
and hepatocellular injury. Mice were pre-treated with ibrutinib (30 mg/kg p.o.) or vehicle (5% DMSO 
+ 30% cyclodextrin p.o.) 1 h before administration of LPS/PepG (i.p.). 18 h after LPS/PepG 
administration blood samples were collected for analyses. (A) Serum urea (mmol/L). (B) Alanine 
aminotransferase (ALT) (U/L). (C) Aspartate transaminase (AST) (U/L). The following groups were 
studied sham, LPS/PepG + vehicle and LPS/PepG + ibrutinib (30 mg/kg p.o.). All data are expressed 
as mean ± SEM for n = 5 per group. A value of *P < 0.05 was considered to be statistically significant 






































LPS/PepG + vehicle 
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2.3.5 The effects of delayed administration of ibrutinib (3 mg/kg or 30 mg/kg) in a model of 
endotoxemia 
 
When compared to sham-operated mice, mice subjected to LPS/PepG and treated with vehicle, 
resulted in a decrease in mean heart rate. When compared to LPS/PepG mice treated with 
vehicle, the administration of ibrutinib (3 mg/kg or 30 mg/kg i.v.) resulted in no significant 
difference of mean heart rate (Table 2.7).  
 
When compared to sham-operated mice, mice subjected to LPS/PepG and treated with vehicle 
resulted in a decrease in temperature. When compared to LPS/PepG mice treated with vehicle, 
the administration of ibrutinib (3 mg/kg or 30 mg/kg i.v.) resulted in no significant differences 
in temperature (Table 2.7).  
 
When compared to sham-operated mice, mice subjected to LPS/PepG and treated with vehicle 
developed, at 18 h, significant increases in urea and AST (Table 2.7), while the increase in 
ALT was not significant (Table 2.7). In contrast, mice treated with (3 mg/kg or 30 mg/kg i.v.) 
1 h after LPS/PepG showed no significant differences in serum urea, ALT and AST when 




Table 2.7 Heart rate, temperature, renal dysfunction and hepatocellular injury responses to 
intravenous administrated ibrutinib at low (3 mg/kg) and high concentrations (30 mg/kg) in 
LSP/PepG mice. 
 Sham LPS+PepG + 
vehicle 
LPS/PepG + 





Number 10 10 10 10 
Temperature (oC) 36.1 ± 0.1* 28 ± 0.9 30.3 ± 1.1 31.7 ± 1.2 
Heart rate (bpm) 444 ± 7* 372 ± 26 422 ± 20 414 ± 22 
Urea (mmol/L) 9.060 ± 0.337* 38.01 ± 2.728 32.64 ± 2.886 34.77 ± 3.816 
ALT (U/L) 36.6 ± 5.81 98.1 ± 19.04 124.5 ± 32.16 100.2 ± 16.24 
AST (U/L) 109.2 ± 14.2* 303.6 ± 57.12 280.2 ± 42.07 322.1 ± 41.35 
 
Mice received LPS (7 mg/kg) and PepG (1 mg/kg), or vehicle (i.p.). One hour later, mice were treated 
with ibrutinib (3 mg/kg i.v.), ibrutinib (30 mg/kg i.v.) or vehicle (5% DMSO + 30% cyclodextrin i.v.). 
The heart rate, temperature, serum urea, ALT and AST were measured in mice 18 h after co-
administration of LPS/PepG. All data are expressed as mean ± SEM for n number of observations. A 
value of *P < 0.05 was considered to be statistically significant when compared to LPS/PepG + vehicle 




2.3.6 Delayed administration of ibrutinib (3 mg/kg or 30 mg/kg) attenuates LPS/PepG-
induced cardiac dysfunction 
 
When compared to sham-operated mice, mice subjected for 18 h to LPS/PepG and treated with 
vehicle demonstrated a significant reduction in percentage EF, FS and FAC (Figure 2.22 A-
D). When compared to LPS/PepG mice treated with vehicle, the administration of ibrutinib (3 
mg/kg or 30 mg/kg i.v.) 1 h after LPS/PepG significantly attenuated the decline in EF, FS and 
FAC caused by LPS/PepG (Figure 2.22 A-D). No significant difference in effect size was 
observed for any of the cardiac parameters between the two doses of ibrutinib used (3 mg/kg 





Figure 2.22 Intravenous ibrutinib (3 mg/kg or 30 mg/kg) attenuates LPS/PepG induced cardiac 
dysfunction. Mice received LPS (7 mg/kg) and PepG (1 mg/kg), or vehicle (i.p.). One hour later, mice 
were treated with ibrutinib (3 mg/kg i.v.), ibrutinib (30 mg/kg i.v.) or vehicle (5% DMSO + 30% 
cyclodextrin i.v.). Cardiac function was assessed 18 h after LPS/PepG administration. (A) 
Representative M-mode echocardiograms. (B) Ejection fraction (%). (C) Fractional shortening (%). (D) 
Fractional area change (%). The following groups were studied sham, LPS/PepG + vehicle, LPS/PepG 
+ ibrutinib (3 mg/kg i.v.) and LPS/PepG + ibrutinib (30 mg/kg i.v.). All data are expressed as mean ± 
SEM for n =10 per group. A value of *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 was 
considered to be statistically significant when compared to LPS/PepG + vehicle by one-way ANOVA 
































































2.4 Results – CLP model 
 
2.4.1 Physiological parameters of mice subjected to CLP for 24 h 
 
When compared to sham-operated mice, mice subjected to CLP for 24 h showed an increase 
in severity score. At 12 h, the severity score in CLP mice was >3 indicating severe sepsis, 
whereas sham-operated mice remained at 0, showing no physical indication of disease. Before 
12 h, the severity score in CLP mice remained ≤3 indicating moderate sepsis (Figure 2.23 A). 
When compared to sham-operated mice, the heart rate of CLP-mice dropped below 400 bpm 
at 24 h, whereas in sham-operated mice, the heart rate remained between 400-500 bpm (Figure 
2.23 B). Over 24 h the temperature of sham-operated mice remained at physiological 
temperature, 36oC. In contrast, CLP mice experienced a significant drop in temperature 1 h 
after the surgery, and the temperature slowly decreased to < 30oC over the remainder of the 
experiment (Figure 2.23 C). A drop of temperature below 30oC has been reported to be a 
reliable marker of mortality. Sham-operated mice resulted in predicted mortality of 0% for all 
time points. At 1 and 3 h after CLP mice had predicted mortality of 0%, however, 6 h after 





Figure 2.23 Physiological parameters of mice subjected to CLP for 24 h. Mice were randomly 
assigned to undergo sham-operated or CLP surgery. At 1 h, 3 h, 6 h, 12 h, 24 h after surgery mice were 
assessed on (A) Severity score. (B) Heart rate (bpm). (C) Temperature oC. (D) Predicted percentage of 
survival (%). Sham-operated mice (n = 3) and CLP (n = 4). All data are expressed as mean ± SEM for 
n number of observations. A value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was 
considered to be statistically significant when compared to CLP by two-way ANOVA followed by a 
Bonferroni’s post hoc test.  
 
  




















































































2.4.2 Changes in left ventricular cardiac systolic parameters of septic mice over 24 h 
 
Sham-operated mice exhibited no significant alterations in any of the cardiac parameters 
measured over the 24 h experimental period. When compared to sham-operated mice, mice 
subjected to CLP exhibited a gradual and continuous decline in EF, FS, FAC, CO, SV, over 24 
h (Figure 2.24 A-F). Most notably, I observed a significant decrease in CO and SV in CLP 
mice as early as 1 h after CLP, which remained decreased throughout the experimental period 
(Figure 2.24 E&F). The end systolic volume measured in CLP-mice was not different from the 
end-systolic volume measured in sham-operated mice. However, in CLP-mice, I found a 
decrease in the end-diastolic volume as early as 1 h after CLP when compared to sham-operated 
mice. End-diastolic volume remained decreased throughout the experimental period (Figure 





Figure 2.24 Changes in cardiac parameters of septic mice over 24 h. Mice were randomly assigned 
to undergo sham or CLP surgery. Cardiac function was assessed at 1 h, 3 h, 6 h, 12 h, 24 h after surgery 
via echocardiography (A) M-mode echocardiograms representatives. (B) Ejection Fraction (%). (C) 
Fractional shortening (%). (D) Fractional area change (%). (E) Stroke volume (µL). (F) Cardiac output 
(mL/min). (G) End systolic volume (µL). (H) End diastolic volume (µL). Sham-operated (n = 3) and 
CLP (n = 4). All data are expressed as mean ± SEM for n number of observations. A value of ****P < 
0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant when 
compared to CLP by a two-way ANOVA followed by a Bonferroni’s post hoc test.  
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2.4.3 Changes in left ventricular diastolic function in septic mice over 24 h  
 
Sham-operated mice exhibited no significant alterations in any of the cardiac parameters 
measured over the 24 h experimental period. When compared to sham-operated mice, mice 
subjected to CLP resulted in a significant decline of E/A ratio and an increase in the myocardial 




Figure 2.25 Changes in left ventricular diastolic function in septic mice over 24 h. Mice were 
randomly assigned to undergo sham-operated or CLP surgery. Cardiac function was assessed at 1 h, 3 
h, 6 h, 12 h, 24 h after surgery via echocardiography. (A) E/A ratio. (B) Myocardial performance index. 
Sham-operated (n = 3) and CLP (n = 4). All data are expressed as mean ± SEM for n number of 
observations. A value of *P < 0.05 was considered to be statistically significant when compared to CLP 
by two-way ANOVA followed by a Bonferroni’s post hoc test.  
 
  






































2.4.4 Changes in pulmonary artery flow in septic mice over 24 h  
 
Sham-operated mice exhibited no significant alterations in any of the cardiac parameters 
measured over the 24 h experimental period. When compared to sham-operated mice, mice 
subjected to CLP resulted in a significant decline of pulmonary artery VTI and peak velocity 




Figure 2.26 Changes in pulmonary artery flow in septic mice over 24 h. Mice were randomly 
assigned to undergo sham-operated or CLP surgery. Cardiac function was assessed at 1 h, 3 h, 6 h, 12 
h, 24 h after surgery via echocardiography. (A) Pulmonary artery flow VTI (mm). (B) Pulmonary artery 
peak velocity (mm/s). Sham-operated (n = 3) and CLP (n = 4). All data are expressed as mean ± SEM 
for n number of observations. A value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was 
considered to be statistically significant when compared to CLP by two-way ANOVA followed by a 
Bonferroni’s post hoc test.  
  
























































2.4.5 Changes in bacteria and infiltrating immune cells in the peritoneal cavity of septic mice 
over 24 h  
 
When compared to sham-operated mice, mice subjected to CLP resulted in no significant 
differences in the number of bacteria in the peritoneal cavity between 1 - 12 h. However, 24 h 
after CLP the number of bacteria in the peritoneal cavity is significantly higher than sham-
operated mice (Figure 2.27 A).  
 
When compared to sham-operated mice, mice subjected to CLP resulted in a significant 
increase in the number of macrophages and neutrophils in the peritoneal cavity at 12 h and 24 
h after surgery (Figure 2.27 B&C). A significant increase of T cells and B cells in the peritoneal 
cavity of CLP-mice was only observed at 24 h after surgery when compared to sham-operated 




Figure 2.27 Changes in bacteria and immune cell in the peritoneal cavity of septic mice over 24 
h. Mice were randomly assigned to undergo sham-operated or CLP surgery. At 1 h, 3 h, 6 h, 12 h, 24 h 
after surgery peritoneal lavage fluid from mice were assessed. (A) Bacteria cell count (ml). (B) 
Macrophage cell count (ml). (C) Neutrophil cell count (ml). (D) B cell count (ml). (E) T cell count (ml). 
Sham-operated (n = 3) and CLP (n = 4). All data are expressed as mean ± SEM for n number of 
observations. A value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to be 
statistically significant when compared to CLP by two-way ANOVA followed by a Bonferroni’s post 
hoc test.  








































































































2.4.6 Changes in physiological parameters in responses to post-treatment of ibrutinib (3 
mg/kg or 30 mg/kg), or acalabrutinib (3 mg/kg) 1 h after CLP surgery 
 
Sham-surgery resulted in a severity score of 0 at 24 h, demonstrating that sham-operated mice 
experienced no clinical symptoms of sepsis and had recovered well from the surgical 
procedure. When compared to sham-operated mice, CLP-mice showed severe clinical signs of 
sepsis, with 80% having a score of >3. In contrast, CLP-mice treated with ibrutinib (3 mg/kg) 
resulted in 80% with a score of ≤3. All CLP-mice which received ibrutinib (30 mg/kg) and 
acalabrutinib (3 mg/kg) had a score of ≤3 indicating moderate sepsis (Figure 2.28 A). 
 
When compared to sham-operated animals, the mean values for the heart rate of the CLP-
animals were significantly reduced. When compared to CLP-mice treated with vehicle, the 
initial heart rate was significantly increased in ibrutinib (30 mg/kg) and acalabrutinib (3 
mg/kg), while no significant increase in heart rate was observed for ibrutinib (3 mg/kg) (Figure 
2.28 B). 
 
When compared to sham-operated mice, mice subjected to CLP and treated with vehicle for 24 
h resulted in hypothermia (temperature < 30oC) this equated to a predicted mortality of 90% in 
CLP-mice. When compared to CLP + vehicle mice, mice subjected to CLP and treated with 
ibrutinib (3 mg/kg or 30 mg/kg) or acalabrutinib (3 mg/kg) 1 h after surgery prevented 
hypothermia, this equated to a predicted mortality of 30% for low dose ibrutinib (3 mg/kg) and 
20% predicted mortality for high dose ibrutinib (30 mg/kg) and acalabrutinib (3 mg/kg) (Figure 




Figure 2.28 Physiological changes to post-treatment of ibrutinib (3 mg/kg or 30 mg/kg) or 
acalabrutinib (3 mg/kg) 1 h after CLP surgery. Mice underwent CLP surgery or sham operated 
surgery. One hour later, mice were treated with ibrutinib (3 mg/kg i.v.), ibrutinib (30 mg/kg i.v.), 
acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h after surgery mice 
were assessed on the following (A) Severity score. (B) Heart rate (bpm). (C) Temperature oC. (D) 
Predicted percentage of survival (%). All data are expressed as mean ± SEM for n = 10 per group. A 
value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically 
significant when compared to CLP + vehicle by two-way ANOVA followed by a Bonferroni’s post hoc 











































































2.4.7 Intravenous ibrutinib or acalabrutinib attenuates sepsis-induced cardiac dysfunction  
 
When compared to sham-operated animals, mice subjected for 24 h to CLP demonstrated a 
significant reduction in percentage EF, FS, FAC, SV, CO and EDV (Figure 2.29 A-H) 
indicating the development of systolic, cardiac dysfunction. When compared to CLP-mice 
treated with vehicle, the delayed administration of ibrutinib (3 mg/kg), ibrutinib (30 mg/kg), 
or acalabrutinib (3 mg/kg) at 1 h after CLP significantly attenuated the decline in EF, FS, FAC, 
SV and CO caused by CLP (Figure 2.29 A-F). Only acalabrutinib significantly attenuated the 
decline of EDV, while no significant differences were observed for ibrutinib (3 mg/kg and 30 
mg/kg).  No change in ESV was observed between any of the groups studied. No significant 
differences were observed in any of the cardiac parameters measured when comparing the data 




Figure 2.29 Intravenous ibrutinib (3 mg/kg or 30 mg/kg) or acalabrutinib (3 mg/kg) attenuates 











































































































































Mice were randomly assigned to undergo CLP surgery or sham-operated surgery. One hour later, mice 
were treated with ibrutinib (3 mg/kg i.v.), ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or 
vehicle (5% DMSO + 30% cyclodextrin i.v.). Cardiac function was assessed 24 h after CLP surgery via 
echocardiography. (A) Representative M-mode echocardiograms. (B) Ejection fraction (%). (C) 
Fractional shortening (%). (D) Fractional area change (%). (E) Cardiac output (ml/min). (F) Stroke 
volume (µL). (G) End systolic volume (µL). (H) End diastolic volume (µL). The following groups were 
studied sham + vehicle, control + vehicle, CLP + ibrutinib (3 mg/kg i.v.), CLP + ibrutinib (30 mg/kg 
i.v.) and CLP + acalabrutinib (3 mg/kg i.v.). All data are expressed as mean ± SEM for n = 10 per group. 
A value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to be statistically 





2.4.8 Post-treatment of ibrutinib or acalabrutinib on sepsis-induced renal dysfunction and 
hepatocellular injury  
 
When compared to sham-operated mice, mice subjected to CLP for 24 h and treated with 
vehicle developed both kidney dysfunction (rise in urea and creatinine) and hepatocellular 
injury (rise in ALT) (Figure 2.30 A-C). When compared to CLP-animals treated with vehicle, 
CLP-animals treated with ibrutinib (3 mg/kg or 30 mg/kg i.v.) or acalabrutinib (3 mg/kg i.v.) 
at 1 h after CLP showed significant decreases in serum urea (Figure 2.30 A), but only the high 
dose of ibrutinib (30 mg/kg) and acalabrutinib (3 mg/kg) significantly prevented the rise in 
serum creatinine caused by sepsis. In contrast, the BTK-inhibitors did not affect the rise in 






Figure 2.30 Post-treatment of ibrutinib or acalabrutinib on sepsis-induced renal dysfunction or 
hepatocellular injury. Mice were randomly assigned to undergo CLP surgery or sham-operated 
surgery. One hour later, mice were treated with ibrutinib (3 mg/kg i.v.), ibrutinib (30 mg/kg i.v.), 
acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). 24 h after CLP surgery 
blood samples were collected for analyses. (A) Serum urea (mmol/L). (B) Creatinine (µmol/L). (C) 
Alanine aminotransferase (U/L). The following groups were studied sham + vehicle, control + vehicle, 
CLP + ibrutinib (3 mg/kg i.v.), CLP + ibrutinib (30 mg/kg i.v.) and CLP + acalabrutinib (3 mg/kg i.v.). 
All data are expressed as mean ± SEM for n = 10 per group. A value of ****P < 0.0001, *** P < 0.001, 
**P < 0.01, *P < 0.05 was considered to be statistically significant when compared to CLP + vehicle 
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2.4.9 Ibrutinib or acalabrutinib attenuate the formation of chemokine biomarkers of left 
ventricular dysfunction caused by CLP-sepsis 
 
When compared to sham-operated animals, mice subjected for 24 h to CLP demonstrated a 
significant rise in the serum levels of known biomarkers of left ventricular dysfunction, the 
chemokines CXCL10 and CXCL11 (Figure 2.31 A-B). The rise of the chemokines CXCL10 
and CXCL11 also negatively correlated to the reduction in EF (Figure 2.31 C-D). The rise in 
the serum levels of the chemokines CXCL10 and CXCL11 caused by CLP were also 
significantly reduced by either ibrutinib or acalabrutinib (Figure 2.31 A-B). No significant 
differences were observed in any of the cardiac parameters or cytokines measured in CLP 






Figure 2.31 Ibrutinib or acalabrutinib attenuate the formation of chemokine biomarkers of left 
ventricular dysfunction caused by CLP-sepsis. Mice were randomly assigned to undergo CLP or 
sham-operated surgery. One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib 
(3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). Cardiac function was assessed 24 h 
after CLP surgery. (A) CXCL10 serum concentration (pg/ml). (B) CXCL11 serum concentration 
(pg/ml). (C) Correlation of ejection fraction and CXCL10 serum concentration. (D) Correlation of 
ejection fraction and CXCL11 serum concentration. All data are expressed as mean ± SEM for n = 8 
per group. A value of ****P < 0.0001, ***P < 0.001 and **P < 0.01, was considered to be statistically 
significant when compared to CLP + vehicle by one-way ANOVA followed by a Bonferroni’s post hoc 




















































































2.4.10 Cardiac BTK is activated in CLP mice and reduced by ibrutinib or acalabrutinib  
 
Using Western blot analysis, I investigated whether CLP-sepsis leads to an activation of BTK 
in the heart. The activation of BTK and the subsequent activation of BTK-signalling involves 
the phosphorylation of BTK at Tyr223 and the phosphorylation of PLCg at Tyr1217 by 
phosphorylated (activated) BTK as the first step in the BTK-signalling cascade.  
When compared to sham-operated mice, CLP mice treated with vehicle demonstrated 
significant increases in the phosphorylation of cardiac BTK at Tyr223 and the phosphorylation 
of PLCg at Tyr1217, indicating that BTK is activated in septic hearts (Figure 2.32 A&B). When 
compared to CLP mice treated with vehicle, delayed administration of ibrutinib (30 mg/kg), or 
acalabrutinib (3 mg/kg) in CLP mice resulted in a significant decrease in the phosphorylation 
of cardiac BTK at Tyr223 and the phosphorylation of PLCg at Tyr1217 (Figure 2.32 A&B) 
demonstrating that both BTK inhibitors caused significant inhibition of BTK-signalling in the 
heart. No significant differences were observed in the degree of phosphorylation of cardiac 
BTK at Tyr223 and the phosphorylation of PLCg at Tyr1217 in CLP-animals treated with either 




Figure 2.32 Cardiac BTK is activated in CLP mice and reduced by delayed administration of 
ibrutinib or acalabrutinib. Mice were randomly assigned to undergo CLP or sham-operated surgery. 
One hour later, mice were treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle 
(5% DMSO + 30% cyclodextrin i.v.). At 24 h after CLP surgery, the activation of BTK in the heart was 
analysed by western blot analysis. Specifically, densitometric analysis of the bands is expressed as 
relative OD of (A) phosphorylation of BTK at Tyr223 corrected for the corresponding total BTK and 
normalised using the related sham band. (B) Phosphorylation of PLCg at Tyr1217 corrected for the 
corresponding total PLCg. All data are expressed as mean ± SEM for n = 5 per group. A value of ****P 
< 0.0001 was considered to be statistically significant when compared to CLP + vehicle by one-way 












































































2.4.11 Cardiac activation of NF-kB in septic mice is reduced by ibrutinib or acalabrutinib 
 
To understand the signalling mechanism(s) associated with the observed cardiac dysfunction, 
I investigated the effect of BTK inhibition on the activation of key signalling pathways of 
inflammation including pathways leading to the activation of NF-kB. When compared to sham-
operated mice, CLP mice treated with vehicle had significant increases in the phosphorylation 
of IKKa/b at Ser176/180, the phosphorylation of IkBa at Ser32/36 and the translocation of p65 to 
the nucleus (Figure 2.33 A-C). When compared with CLP mice treated with vehicle, treatment 
of CLP mice with ibrutinib (30 mg/kg) or acalabrutinib (3 mg/kg) significantly attenuated the 
increases in cardiac phosphorylation of IKKα/β at Ser176/180 and IkBα at Ser32/36 and the nuclear 
translocation of p65 (Figure 2.33 A-C). No significant differences were observed in the degree 
of phosphorylation of IKKa/b at Ser176/180, the phosphorylation of IkBa at Ser32/36 and the 
translocation of p65 to the nucleus in CLP animals treated with either ibrutinib or acalabrutinib 
(Figure 2.33 A-C).   
 131 
 
Figure 2.33 BTK inhibitors reduce cardiac NF-kB activation in septic mice. Mice were randomly 
assigned to undergo CLP or sham-operated surgery. One hour later, mice were treated with ibrutinib 
(30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). At 24 h 
cardiac tissue was collected, and signalling was assessed. Densitometric analysis of the bands is 
expressed as relative OD of (A) phosphorylation of IKKa/b at Ser176/180 corrected for the corresponding 
total IKKa/b and normalised using the related sham band. (B) Phosphorylation of IkBa at Ser32/36 
corrected for the corresponding total IkBa and normalised using the related sham band. (C) NF-kB p65 
in both nucleus and cytosol and expressed as a ratio, normalised using the sham related bands. All data 
are expressed as mean ± SEM for n = 5 per group. A value of ****P < 0.0001 was considered to be 
statistically significant when compared to CLP + vehicle by one-way ANOVA followed by a 
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2.4.12 Cardiac NLRP3 activation in septic mice is reduced by ibrutinib or acalabrutinib 
 
I next assessed the potential involvement of the activation of the NLRP3 inflammasome in the 
cardiac dysfunction of CLP mice. When compared to sham-operated mice, CLP-sepsis 
(vehicle-treatment) exhibited an increased expression of the NLRP3 inflammasome and an 
increase in the cleavage of pro-caspase-1 to caspase-1 in the heart, which was associated with 
a rise in serum IL-1b (Figure 2.34 A-C). When compared to CLP mice treated with vehicle, 
treatment of CLP mice with ibrutinib or acalabrutinib significantly inhibited the expression of 
the NLRP3 inflammasome, cleavage of pro-caspase-1 to caspase-1 and this was associated 
with lower levels of serum IL-1b (Figure 2.34 A-C). There were no significant differences 




Figure 2.34 Cardiac NLRP3 activation in septic mice is reduced by ibrutinib or acalabrutinib. 
Mice were randomly assigned to undergo CLP or sham surgery. One hour later, mice were treated with 
ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin i.v.). 
At 24 h after CLP surgery, the assembly and activation of NLRP3 in the heart was analysed by western 
blot analysis. Specifically, densitometric analysis of the bands is expressed as relative OD of (A) 
NLRP3 activation, corrected against tubulin and normalised using the sham related bands (n = 5 per 
group). (B) Pro-caspase-1 against activated caspase-1 and normalised using the sham related bands (n 
= 5 per group). (C) IL-1b serum concentration analysed by multiplex assay (n = 8 per group). All data 
are expressed as mean ± SEM for n number of observations. A value of ****P < 0.0001 and **P < 
0.01, were considered to be statistically significant when compared to CLP + vehicle by one-way 
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2.4.13 Relationship between BTK activation and cardiac dysfunction in CLP-sepsis  
 
To address the question whether the degree of activation of BTK correlates with the observed 
alterations in cardiac function, I correlated the degree of phosphorylation of BTK at Tyr223 
(Figure 2.35 A) and the phosphorylation of PLCg at Tyr1217 (Figure 2.35 B) with EF. I found a 
highly significant negative correlation between the degree of BTK and PLCg activation and the 
decline in EF, strongly suggesting that BTK activation drives or precedes the cardiac 
dysfunction associated with sepsis. To address the question whether the degree of activation of 
BTK also correlates with alterations in the activation of NF-kB, I correlated the degree of 
phosphorylation of BTK at Tyr223 with the translocation of p65 (Figure 2.35 C) and the 
phosphorylation of IKKa/b at Ser176/180 (Figure 2.35 D). I found a highly significant positive 
correlation between the degree of BTK activation and the activation of NF-kB when measured 
as either the translocation of p65 (Figure 2.35 C) and the phosphorylation of IKKa/b at Ser176/180 
(Figure 2.35 D). To address the question whether the degree of activation of BTK also 
correlates with alterations in the assembly and activation of the inflammasome, I correlated the 
degree of phosphorylation of BTK at Tyr223 with either NLRP3 assembly (Figure 2.35 E) or the 
activation of caspase-1 (Figure 2.35 F). I found a highly significant positive correlation 
between the degree of BTK activation and the NLRP3 (Figure 2.35 E) increased expression 
and the activation of caspase-1 (Figure 2.35 F).  
 135 
 
Figure 2.35 Relationship between BTK activation and cardiac dysfunction in CLP-sepsis. 
Correlation data to show (A) ejection fraction (%) vs. phosphorylation of BTK at Tyr223. (B) Ejection 
fraction (%) vs. of PLCg at Tyr1217. (C) Phosphorylation of BTK at Tyr223 vs. NF-kB p65. (D) 


















) R2 = -0.856
P < 0.0001






























































































































Phosphorylation of BTK at Tyr223 vs. phosphorylation of IKKa/b atSer176/180. (E) Phosphorylation of 
BTK at Tyr223 vs. NLRP3. (F) Phosphorylation of BTK at Tyr223 vs. activated/pro-caspase-1. Data were 
analysed by the Pearson correlation coefficient test to calculate the R value and a two-tailed T-test for 






2.4.14 Systemic inflammation in septic mice is reduced by ibrutinib or acalabrutinib 
 
I also studied the effect of CLP (in the absence and presence of BTK inhibitors) on the synthesis 
of pro-inflammatory cytokines, anti-inflammatory cytokines and pro-inflammatory 
chemokines in the serum. When compared to sham-operated mice, CLP mice treated with 
vehicle showed a significant rise in the serum levels of a) the pro-inflammatory cytokines TNF-
a, IFN-g, IL-6; b) the anti-inflammatory cytokines IL-4 and IL-10, and c) the pro-inflammatory 
chemokines KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24 (Figure 2.36 A-H). The sepsis-
induced increase in these cytokines and chemokines was significantly attenuated by the delayed 
administration of both BTK inhibitors, the only exception being IL-6, which was not 
significantly reduced by ibrutinib. No significant differences were observed in the levels of 
cytokines or chemokines in CLP animals treated with either ibrutinib or acalabrutinib (Figure 
2.36 A-H).  
The data of all other cytokines/chemokines/growth factors that I measured in all groups are 










Figure 2.36 Systemic inflammation in septic mice is reduced by ibrutinib or acalabrutinib. Mice 
were randomly assigned to undergo CLP or sham-operated surgery. One hour later, mice were treated 
with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% cyclodextrin 
i.v.). At 24 h after CLP, blood samples were collected, and the serum concentration of cytokines and 
chemokines were measured by a multiplex assay. (A) TNF-a serum concentration (pg/ml). (B) IL-6 
serum concentration (pg/ml). (C) IFN-g serum concentration (pg/ml). (D) KC/CXCL1 serum 
concentration (pg/ml). (E) Eotaxin-1/CCL11 serum concentration (pg/ml). (F) Eotaxin-2/CCL24 serum 
concentration (pg/ml). (G) IL-10 serum concentration (pg/ml). (H) IL-4 serum concentration (pg/ml). 
All data are expressed as mean ± SEM for n = 8 per group. A value of ****P < 0.0001, ***P < 0.001, 
**P < 0.01 and *P < 0.05, were considered to be statistically significant when compared to CLP + 


































































































































































































































































































































































































































































































































































Figure 2.37 Serum cytokines measured in septic mice treated with or without BTK inhibitors. 
Mice were randomly assigned to undergo CLP or sham-operated surgery. One hour later, mice were 
treated with ibrutinib (30 mg/kg i.v.), acalabrutinib (3 mg/kg i.v.), or vehicle (5% DMSO + 30% 
cyclodextrin i.v.). At 24 h after CLP, blood samples were collected, and the serum concentration of 
cytokines and chemokines were measured by a multiplex assay. All data are expressed as mean ± SEM 
for n = 8 per group. A value of ****P < 0.0001, ***P < 0.001, **P < 0.01 and *P < 0.05, were 
considered to be statistically significant when compared to CLP + vehicle by one-way ANOVA 






In this study, I developed a model of endotoxaemia where LPS (7 mg/kg) and PepG (1 mg/kg) 
were administered systemically to activate TLR4 and TLR2 leading to systemic inflammation 
and the induction of cardiac dysfunction. I report in this chapter that the pre- and post-treatment 
with ibrutinib (3 or 30 mg/kg) attenuates the cardiac dysfunction caused by LPS/PepG, 
indicating that BTK inhibitors suppress the LPS/PepG-induced systemic inflammation. The 
LPS/PepG model is useful to evaluate the efficacy of potential therapeutic interventions, 
however, it is not the “gold standard model” for sepsis research. The LPS/PepG model does 
not reflect the development of sepsis as seen in humans, since it is not an infection of bacteria 
(224). Thus, I developed the caecal ligation and puncture model which is a model of 
polymicrobial sepsis in 10-week-old male C57BL/6 mice to further assess the role of BTK 
inhibitors in sepsis.  
 
Death is a frequently used endpoint in animal studies, but with rising ethical standards over 
animal research a new humane endpoint is required to allow early termination of the 
experiments, thus reducing suffering while still reliably predicting mortality/survival. Body 
temperature is an essential parameter in evaluating the animal’s wellbeing and it has been 
reported that a reduction in temperature to <30oC or a change in temperature of 5oC (or more) 
over 24 h in mice with CLP is a reliable marker to predict death (221). Specifically, Mai et al. 
investigated whether temperature could be used as a predictor of death in the CLP model of 
sepsis by subjecting mice to sham, moderate or severe CLP and measuring the change in body 
temperature via rectal probe and survival of the mouse over 24 h. They conducted ROC 
analyses using the last recorded body temperature and using change from baseline to final 
temperature of survivors and non-survivors. They found that the area under the curve (AUC) 
of 0.88 (95% confidence interval 0.77–0.99) for last recorded temperature indicates that body 
temperature < 30 °C is an independent predictor of outcome for animals that reached endpoint 
in the study, as well as the reduction in body temperature (> 5 °C) over time (AUC 0.89, 95% 
confidence interval 0.78–0.99) in each animal. In a cecal slurry procedure surface temperature 
was measured by non-invasive infrared thermometry on the xiphoid surface, to predict 
mortality. It was found that surface temperature < 30.5oC at 24 h was 90% specific and 84% 
sensitive in predicting mortality of mice. By using temperature reduction as a surrogate 
endpoint, it reduced the animals suffering by 41% and provided an accurate survival rate 
 142 
estimate, as a result only 13 out of 154 mice would have died, 67 would have been euthanized 
at 24 h and only 7 would have been euthanized unnecessarily (225). Mei et al. also assessed 
temperature change as a predictor for mortality in the LPS-endotoxin model via two different 
methods: method 1 core body temperature by implanted radio frequency identification (RFID) 
temperature transponders and method 2 surface temperature by non-contact infrared 
thermometry (226). They found that both methods predicted death with high accuracy resulting 
in a temperature threshold of 28.1oC for core body (96.3% accuracy) and 24.3oC for surface 
temperature (95.3% accuracy). Further studies have also confirmed hypothermia as a reliable 
marker for determining whether mice would survive during infectious disease research (227–
229). These studies highlight the reliability of change in temperature to predict morality and 
encourage researchers to apply a more humane endpoint to their research. The development 
and accuracy of non-contact infrared thermometry reduces the stress of the animals further and 
allows easy monitoring of disease progression.  
 
As mortality of animals is not an acceptable routine endpoint in the UK, I used the reduction 
in rectal temperature <30oC as a surrogate marker for mortality.  Over the course of 24 h, the 
temperature of CLP mice gradually decreased reaching a predicted mortality of 80% at 24 h, 
indicating that this is a severe model of sepsis that I have developed. Here I measured a clinical 
score and also the decrease in temperature.  Over the course of 24 h in CLP mice, I observed 
the development of physiological symptoms of sepsis: lethargy, piloerection, tremors, 
periorbital exudates, respiratory distress, and diarrhoea, with severe sepsis being defined as a 
score of > 3 only observed at 24 h, the clinical score increased with the severity of sepsis 
cardiac dysfunction. However, a clinical score is subjective, an objective measurement is 
change in temperature. 
 
Cardiac dysfunction is commonly reported by measuring the percentage of EF or FS, but it is 
not clear whether these are the most sensitive parameters for determining systolic dysfunction 
in CLP mice? Over 24 h, I measured a multitude of cardiac parameters at varying time intervals. 
Interestingly, I found a significant reduction in SV and CO 1 h after CLP, whereas EF and FS 
were only significantly reduced at 12 h and 24 h after CLP-sepsis. This demonstrates that SV 
and CO are early and sensitive biomarkers of dysfunction and warrant reporting in future 
studies, alongside EF & FS. However, the reduction of CO and SV may be secondary to the 
reduction in preload e.g. vascular leak. Hoffman et al. reported that 2 h after CLP, the CO is 
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significantly decreased and that it is a highly sensitive and specific marker for predicting 
mortality in mice at 48 h (224). It has also been reported in septic patients that reduced CO is 
associated with higher rates of mortality (230). With respect to diastolic dysfunction, 
significant differences in E/A ratio and myocardial performance index are only observed at 24 
h, suggesting that diastolic dysfunction appears at a later onset. 
	
		
The change in body temperature from normothermia to either hypothermia or hyperthermia 
effects cardiac function. During a septic insult, mice exhibit a decrease in temperature called 
inflammation associated hypothermia, which is a CNS-mediated response, impacting the 
autonomic nervous system and, thus, impairing the sympathetic cardiovascular system leading 
to systolic cardiac dysfunction. In contrast, humans with sepsis develop an increase in 
temperature (fever). This raises the question as to what degree does increasing or decreasing 
core body temperature effect the cardiac function? In vivo, acute cold exposure (reducing the 
core body temperature of rats to  15oC) resulted in severe, systolic cardiac dysfunction (231). 
In another study, the decrease in body temperature to 25oC resulted in 20% of rats having 
hypotension, 30% having a low cardiac output and 50% having bradycardia (232). Human 
subjects were exposed to a warm or cool environment via a water-perfused garment (fitted suit 
that covers the body except the hands, feet, neck and head) to measure the effect of heat and 
cold stress on their cardiac function. Heat resulted in a decrease in preload and afterload and 
systolic function increased to maintain or increase stroke volume. In addition, heart rate 
increased and the increase in stroke volume resulted in an increase in cardiac output. During 
exposure to a cold environment, preload and afterload increased and hypothermia results in 
decreased depolarisation of cardiac pacemaker cells, causing bradycardia (233). To what extent 
does treating CLP-induced hypothermia affect the outcome in murine sepsis? Mice which 
underwent CLP and have their hypothermia corrected (by being placed into a heat box 
(maintained at 35oC) resulted in an improvement in survival from 42% to 60% and also reduced 
the levels of IL-6 (234). Most animal studies of sepsis do not maintain physiological 
temperature throughout the study. In my study, cardiac parameters were only measured in all 
groups when temperature returned to normothermia and heart rate was approximately 450bpm 
to mitigate the cofounding variable effects that change in temperature and heart rate have upon 
the cardiac parameters.  
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I investigated the increases of bacteria and infiltrating immune cells throughout 24 h in my 
CLP model. I observed that bacteria levels in the peritoneum remain low till 12 h and this 
corresponds in a gradual increase in phagocytosing immune cells macrophages and neutrophils, 
which plateau out (reach their maximum) at 12 h. At 24 h the bacterial count is significantly 
increased and there is little increase in the numbers of macrophages and neutrophils, this 
demonstrates that at 24 h the immune system has been overwhelmed and is no longer able to 
control the source of infection. Additionally, I find that there is a small number of infiltrating 
B and T cells in my CLP model, with significant increases only being observed at 24 h in CLP 
mice for B cells when compared to sham-operated mice. The data suggests that up to 12 h, the 
body can control the levels of bacteria, indicating a therapeutic window of 12 h to provide an 
intervention to aid the body in clearing a microorganism. I have, however, chosen to provide 
delayed interventions 1 h after CLP, for the reason that 1 h after CLP physical symptoms of 
the mice are observed e.g. a significant decrease in temperature and a drastic decrease in cardiac 
output (which is a sensitive marker for mortality), suggesting that onset of sepsis can be 
documented within 1 h of CLP.  
 
I show here, for the first time, that administration of two structurally different irreversible BTK 
inhibitors (ibrutinib and acalabrutinib) both ameliorate the cardiac dysfunction (measured as 
the decline in EF, FS, FAC, CO and SV by echocardiography) caused by CLP-sepsis. The 
observed decline in EF also was associated with a significant increase in the serum levels of 
two, well-known biomarkers of left ventricular dysfunction, namely CXCL10 and CXCL11 
(235–237). Most notably, ibrutinib or acalabrutinib also attenuated the rises in CXCL10 and 
CXCL11 caused by CLP-sepsis. In addition, ibrutinib or acalabrutinib also reduced renal 
dysfunction (measured as an increase in serum urea or creatinine) caused by CLP-sepsis. Thus, 
both BTK inhibitors reduced the cardiac and renal dysfunction caused by sepsis.  
 
What, then, is the mechanism by which ibrutinib or acalabrutinib reduce the cardiac (renal) 
dysfunction caused by sepsis? Ibrutinib is a potent BTK inhibitor, but not very specific (as it 
also inhibits a multitude of other kinases), which is approved by the FDA and the EMA for the 
use in chronic lymphatic leukaemia, mantle cell lymphoma and Waldenstrom 
macroglobulinemia. Acalabrutinib is a potent, but highly specific BTK inhibitor: at a (relatively 
high) concentration of 1 µM, acalabrutinib strongly inhibited only the following 5 kinases: 
BTK, Bmx, ErbB4, RIPK2 and TEC, while the same concentration of ibrutinib inhibited 35 
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kinases. The activation of BTK and the subsequent activation of BTK signalling involves a) 
phosphorylation of BTK at Tyr223 and b) the phosphorylation of PLCg at Tyr1217 by 
phosphorylated (activated) BTK as the first step in the BTK signalling cascade (238). I report 
here that sepsis results in significant increases in the phosphorylation of cardiac BTK at Tyr223 
and the phosphorylation of PLCg at Tyr1217, indicating that BTK is activated in septic hearts. 
Most notably, the activation of BTK negatively correlated with EF, indicating that activation 
of BTK is associated with the cardiac dysfunction in sepsis. Indeed, inhibition of BTK activity 
with ibrutinib or acalabrutinib in the heart of septic animals reduces the cardiac dysfunction in 
sepsis suggesting that activation of BTK plays a pivotal role in the pathophysiology of the 
cardiac dysfunction in sepsis. It should be noted that the doses of acalabrutinib and ibrutinib 
that I used in our study in the mouse resulted in a similar, approximately 70%, inhibition of 
BTK activity in septic hearts. I, therefore, propose that inhibition of BTK activity explains the 
observed beneficial effects of ibrutinib or acalabrutinib in sepsis. 
 
What are the mechanisms by which the activation of BTK (in the heart) leads to cardiac 
dysfunction in sepsis? There is good evidence that a) the activation of BTK precedes the 
activation of NF-kB (239), and b) the activation of NF-kB plays an important role in the cardiac 
dysfunction in sepsis (240,241). Specifically, inhibition of the activity of NF-kB attenuates the 
cardiac dysfunction in sepsis and the production of pro-inflammatory cytokines/chemokines 
(179,242). I report here, for the first time, that a) activation of BTK is associated activation of 
NF-kB in septic hearts, and b) inhibition of BTK activity with ibrutinib or acalabrutinib reduces 
both the activation of NF-kB in septic hearts and the cardiac dysfunction caused by sepsis. 
Thus, I propose that inhibition of the activation of NF-kB contributes to the observed beneficial 
effects of the BTK inhibitors ibrutinib and acalabrutinib in sepsis. When challenging BTK KO-
mice with LPS, Gabhann and colleagues observed reduced i) activation of NF-kB p65, ii) Akt 
phosphorylation and iii) M2 polarisation of macrophages (243). 
 
Activation of NF-kB drives the formation of a number of pro- and anti-inflammatory cytokines 
and chemokines. I report here that CLP-sepsis leads to a significant increase in the serum levels 
of the pro-inflammatory cytokines TNF-a, IL-6, IFN-g, anti-inflammatory cytokines IL-10, 
IL-4 and the chemokines KC/CXCL1, eotaxin-1/CCL11, eotaxin-2/CCL24, all of which 
importantly contribute to the local and systemic inflammation and organ injury associated with 
sepsis (244). Most notably, the powerful pro-inflammatory cytokine TNF-a is ameliorated by 
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both BTK inhibitors. TNF-a has been implicated in murine models of sepsis and humans with 
sepsis. TNF-a acts in an autocrine and paracrine manner leading to macrophage production 
and activation, resulting in the release of other proinflammatory cytokines such as IL-6 and IL-
8 (245,246).  
 
Similarly, there is also good evidence that activation of BTK plays a crucial role in the 
assembly and activation of the NLRP3 inflammasome (166,167). The activation of the NLRP3 
inflammasome has been suggested to play a role in cardiac dysfunction (247) and the 
pathophysiology of sepsis (105). Others have reported that inhibition of the assembly and 
activation of NLRP3 inflammasome protects against microbial sepsis (105). I report here for 
the first time that a) activation of BTK is associated with the activation of the NLRP3 
inflammasome in septic hearts, and b) inhibition of BTK activity with ibrutinib and 
acalabrutinib reduces both the assembly and subsequent activation of the NLRP3 
inflammasome in septic hearts (and the cardiac dysfunction caused by sepsis). Thus, I propose 
that inhibition of the activation of the NLRP3 inflammasome may also contribute to the 
observed beneficial effects of the BTK inhibitors ibrutinib and acalabrutinib in sepsis. 
 
Activation of the NLRP3 inflammasome drives the formation of IL-1b and IL-18, both of 
which play an important role in the systemic inflammation and/or organ dysfunction in sepsis 
(248). Specifically, inhibition of caspase-1 results in an inhibition of IL-18 and IL-1b secretion, 
which, in turn, attenuated the cardiac dysfunction caused by myocardial ischemia (249). The 
role of the inflammasome in the pathophysiology of sepsis, however, is still controversial: For 
example, survival was similar in wild-type and caspase-1/11 knockout mice with sepsis, while 
the neutralization of IL-1 and IL-18 reduced mortality in endotoxemia (248). Furthermore, 
inhibition of NLRP3 inflammasome with NLRP3 inhibitor MCC950 results in attenuation of 
sepsis-associated encephalopathy (250).  Here I show that BTK inhibition results in reduced 
serum levels of IL-1b, and this was associated with an improvement of cardiac function. 
 
The evaluation of the efficacy of the BTK inhibitors used in our study depends on the 
assumption that the development of organ dysfunction (and specifically cardiac and renal 
dysfunction) correlates with outcome. There is good evidence that the occurrence of cardiac 
and/or renal dysfunction correlates positively with an increase in mortality in patients with 





There are currently no specific treatments, which reduce cardiac dysfunction or, indeed, 
mortality in sepsis. My data shows for the first time that two commercially available BTK 
inhibitors, ibrutinib or acalabrutinib, attenuate the CLP-induced cardiac dysfunction through 
inhibition of the activation of BTK/NF-kB and/or the NLRP3 inflammasome, which in turn 
reduces the formation of many chemokines and cytokines including TNF-a. Notably, no 
significant qualitative or quantitative differences were found with two, chemically distinct 
BTK-inhibitors suggesting that the observed beneficial effects of both compounds in 
experimental sepsis are likely to be a drug class-related effect. Thus, BTK inhibitors are FDA-
approved drugs that may be repurposed for the use in sepsis, but also other diseases associated 












Chapter 3 Xid mice are 
protected against sepsis-
induced multiple organ 




In the previous chapter, I have shown that inhibition of BTK by BTK inhibitors attenuated the 
systemic inflammation and cardiac dysfunction induced by a model of polymicrobial sepsis 
(CLP model). However, the two BTK inhibitors have off-target effects: As seen in the kinome 
array below (Figure 3.1), both BTK inhibitors strongly inhibit four other kinases: RIPK2, 
ErbB4, Tec and BMX. This triggered two important questions: (1) Does inhibition of BTK 
activity alone account for the observed beneficial effects? And (2) Does inhibition of systemic 
inflammation reduce the host response to infection and ultimately cause increased harm? 
Interestingly, of the kinases which are strongly inhibited by ibrutinib and acalabrutinib, 
expression of ErbB4 (rather than its activation) may play a role in the cardiac dysfunction and 
cognitive impairment associated with sepsis (251). In contrast, RIPK2 kinase is unlikely to 
play a significant role in sepsis, as the CLP-induced septic peritonitis was similar in RIPK2 
knockout mice and their wild-type littermates (252).  
  
Figure 3.1 Kinome array of ibrutinib and acalabrutinib. Ibrutinib and acalabrutinib were profiled 
for 395 human kinases at 1 μM via DiscoverRx kinase assay. The size of the red circles represents the 
extent of inhibition with larger circles meaning stronger inhibition. Image is taken from (181). 
 
To investigate whether inhibition of BTK, indeed, accounts for the inhibition of NF-kB and 
the NLRP3 inflammasome and ultimately the observed beneficial effects in sepsis, I repeated 
the sepsis model in X-linked immunodeficient (Xid) mice, which have a deficiency in the 
activation of BTK due to a single point mutation in the BTK gene. Specifically, Xid-mice have 
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a C to T transition point mutation at position 219, which changes amino acid 28 from arginine 
to cysteine (183,184). The Xid mice are a model of the human X-linked agammaglobulinemia 
and are in the background of CBA mice, in contrast to my previous work, which was done in 
C57BL/6 mice. Both mice and humans with BTK deficiency experience reduced numbers of 
B cells, however, this B cell depletion is more severe in humans than mice. The expression of 
BTK is not restricted to B cells, as BTK is also expressed in cells of the myeloid lineage, 
including macrophages and neutrophils (253), activation of which contributes to the 
pathophysiology of sepsis. 
Having developed a model of sepsis in Xid mice (and wild-type mice, CBA background), in 
this chapter I have investigated the following: 
1) Whether Xid mice are protected from sepsis-induced multiple organ failure (cardiac, 
renal and liver dysfunction). 
2) Whether Xid mice result in reduced activation of BTK, NF-kB and NLRP3 
inflammasome in cardiac tissue when under septic insult. 
3) The production of sepsis-associated cytokines and chemokines in Xid mice. 
4) Determine the ability of Xid mice to remove bacteria by measuring: 
a) Bacteria in the peritoneal cavity and blood. 
b) The number of infiltrating immune cells in the peritoneal cavity. 







3.2.1 Animals  
 
This study was carried out on twenty-three 10-week-old, male CBA mice (Charles River 
Laboratories UK Ltd., Kent, UK) and twenty-one 10-week-old, male CBA/CaHN-Btkxid/J (Xid) 
mice (from Jackson laboratory), weighing 25–30 g and kept under standard laboratory 
conditions. The animals were allowed to acclimatise to laboratory conditions for at least one 
week before undergoing experiments. Six mice were housed together (in each cage) with access 
to a chow diet and water ad libitum. They were subjected to a 12-h light and dark cycle with a 
temperature maintained at 19–23°C. The cages were cleaned regularly approximately every 
three days, with water being changed daily. Research staff inspected the animals each day for 
any signs of illness or abnormal behaviour. 
 
3.2.2 Caecal ligation and puncture (CLP) surgery 
 
Caecal ligation and puncture (CLP) surgery was performed in 10-week-old male CBA (wild 
type) or Xid mice as previously described in chapter 2 (Table 3.1). Mice were randomly 
assigned to undergo CLP or sham-operated surgery, the surgeon was blinded to the genotype 
of the mouse. Briefly, mice were anaesthetised with isoflurane (2% delivered in O2) and the 
caecum was fully ligated below the ileocaecal valve. A double puncture was made with an 18-
G needle into the caecum and a small amount of faeces was squeezed out after which the 
caecum was returned to its anatomical position, then the laparotomy was closed. All animals 
received fluids (5 ml/kg saline into the abdomen before closure and 10 ml/kg saline s.c., 
immediately after surgery), antibiotics (Imipenem/Cilastatin; 20 mg/kg dissolved in 7.5 ml/kg 
of saline s.c.), and analgesics (buprenorphine; 0.05 mg/kg i.p.) at 6 h and 18 h after surgery. 
Sham-operated mice underwent the same procedure, but without CLP. At 1 h after CLP, WT 
or Xid mice received 30 mg/kg ibrutinib (Selleck Chemicals) intravenously. At the end of the 
study, mice were sacrificed, peritoneal lavage fluid and organs were collected under sterile 
conditions, and blood was withdrawn by cardiac puncture. 
 
A clinical score for monitoring the health of experimental mice was used to evaluate the 
symptoms consistent with murine sepsis. The maximum score of 6 comprised the presence of 
the following signs: lethargy, piloerection, tremors, periorbital exudates, respiratory distress, 
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and diarrhoea. Mice with a clinical score >3 were defined as exhibiting severe sepsis, against 
moderate sepsis for a score ≤3. Animals were culled at 24 h after the onset of sepsis (CLP).   
 
Table 3.1 Groups used in the study to evaluate the effects of CLP-induced cardiac dysfunction. 





Sham + vehicle Sham surgery at 0 h 5 
CLP + vehicle  CLP surgery at 0 h 10 
CLP + ibrutinib  CLP surgery at 0 h, then ibrutinib (30 mg/kg i.v.)  at 1 h 8 
Xid mice  Sham + vehicle Sham surgery at 0 h 5 
CBA background CLP + vehicle CLP surgery at 0 h 10 
 CLP + ibrutinib  CLP surgery at 0 h, then ibrutinib (30 mg/kg i.v.)  at 1 h 6 
 
3.2.3 Assessment of cardiac function in vivo 
 
At 24 h post CLP, mice were anaesthetised (0.5 - 2% isoflurane in O2); body temperature was 
maintained at 37oC and heart rate was maintained at 450 bpm. Then, cardiac function was 
assessed by M-mode and B-mode echocardiography using the VisualSonics Vevo 3100 
echocardiographic system and an MX550D transducer as previously described in chapter 2. 
The following parameters were measured: left ventricular EF, FS, FAC, CO, SV, MPI, global 
longitudinal strain and global circumferential strain.  
 
3.2.4 Quantification of renal dysfunction, hepatocellular injury and cell injury 
 
After 24 h, mice were sacrificed by terminal cardiac puncture, where terminal blood samples 
were immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). 
Blood was left to coagulate for at least 10 min at room temperature, then samples were 
centrifuged at 9000 rpm for 3 min to separate the serum.  Then 100 µl of serum was snap-
frozen in liquid nitrogen and sent to an independent veterinary testing laboratory (MRC 
Harwell Institute, Oxford, UK) to evaluate the following biomarkers in a blinded fashion: Urea 
and creatinine (as markers of renal dysfunction), ALT, AST (markers of hepatocellular injury) 
and lactate dehydrogenase (LDH) (a marker of cell injury).   
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3.2.5 Cytokine analysis  
 
Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex Pro Mouse 
Chemokine 31-Plex panel assay (Bio-Rad, Kabelsketal, Germany) as previously described in 
chapter 2. The cytokines IL-1ß, −2, −4, −6, −10, −16, CCL1, −2, −3, −4, −5, −7, −11, −12, 
−17, −19, −20, −22, −24, −27, IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1, −2, −5, 
−10, −11, −12, −13, −16 and the growth factor GM-CSF were measured according to the 
manufacturer's instructions. 
 
3.2.6 Quantification of immune cells in the peritoneum  
 
As previously described in chapter 2, the peritoneal lavage exudate was collected by injecting 
5 ml of 2 mM of EDTA in PBS into the peritoneal cavity. After gentle massaging, 
approximately 4 ml of exudate was removed with an 18-G needle. Cells were washed in FACS 
buffer (0.05 % BSA, 2 mM EDTA in PBS pH 7.4) and then blocked using anti-CD16/32 
(Biolegend) for 10 min at 4oC. Peritoneal cells were analysed using anti-CD45 (clone 30-F11; 
BioLegend), anti-CD11b (clone M1/70; BioLegend), anti-F4/80 (clone BM8; BioLegend), 
anti-Ly6G (clone 1A8; BioLegend), anti-CD206 (clone C068C2; BioLegend), anti-MHCII 
(clone. M5/114.15.2; BioLegend), anti-CD3 (clone 145–2C11; BioLegend), and anti-B220 
(clone. RA-3–6B2; BioLegend) antibodies. Absolute cell count was calculated by the addition 
of counting beads (BioLegend). Data were acquired using BD LSR II Fortessa (Becton 
Dickinson) and analysed using FlowJo analysis software (version 10.6, Treestar Inc.). Gating 
strategy as seen below in Figure 3.2. 
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Figure 3.2 Representative flowcytometry gating strategy. Illustrating peritoneal lavage fluid being 
subgated to the level of B cells, T cells, neutrophils, macrophages: M1 phenotype and M2 phenotype.  
 
3.2.7 Quantification of bacteria 
 
Accurate evaluation of the number of bacteria in peritoneal lavage fluid and blood samples was 
performed by flow cytometry using the SYTO BC bacteria counting kit (Thermo Fischer 
Scientific) as previously described in chapter 2.  
 
3.2.8 Phagocytic ability  
 
Peritoneal lavage exudate containing neutrophils and macrophages were obtained 24 h after 
CLP as described above. pHrodoTM red E.Coli bioparticlesTM (Thermo Fischer Scientific) were 
resuspended in live-cell imagining solution (BioLegend) at 10 mg/ml and 10 µL of bioparticles 
were opsonised with 20 µL of fresh serum for 1 h at 37oC under gentle agitation, after which 
they were washed and resuspended in 10 µL of live cell imagining solution. 1 × 106 cells of 
peritoneal exudate were collected by centrifugation (300 g x 5 min) and resuspended in 890 
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µL of live cell imaging solution, after which 100 µl of fresh serum and 10 µL of optimised 
bioparticles were added and incubated for 45 min at 37oC under gentle agitation. Cells were 
washed and then blocked using anti-CD16/32 (Biolegend) for 10 min at 4oC followed by 
staining with surface markers anti-CD11b (clone M1/70; BioLegend), anti-Ly6G (clone 1A8; 
BioLegend) and anti-F4/80 (clone BM8; BioLegend) for 30 min at 4oC. Neutrophils were 
identified as (CD11b+, Ly6G+, F4/80-) and macrophages were identified as (CD11b+, Ly6G-, 
F4/80+). 10,000 CD11b+ cells were collected by Amnis® ImageStream®X Mk II Imaging Flow 
Cytometer (Luminex) at a magnification of x40 and analysed by IDEAS software for each 
experimental sample.  
 
3.2.8.1 Imagestream acquisition 
 
The flow rate was set to slow speed for high-resolution imaging at magnification x40. Firstly, 
multi-fluorophore labelled samples to determine optimal laser power settings based on Raw 
Max Pixel (RMP) intensity values of the channel corresponding to each fluorophore used to 
prevent saturated events. Lasers and power settings were set according to Table 3.2.  
 
Table 3.2 Laser wavelengths and power settings for phagocytosis analysis. 
Excitation Laser 
(nm) 
Power Setting (mW) Fluorophore Ab Emission Channel 
  Bright Field 1 & 9 
488 150 CD11b 2 
488 150 pHrodo Red Bioparticles 3 
488 2 SSC (Side scatter) 6 
405 80 Ly6G 8 
633 100 F4/80 11 
 
3.2.8.2 Data acquisition 
 
1,000 events were collected for each single fluorophore labelled sample with the brightfield 
and SSC turned off during acquisition to create the compensation matrix. For each 
experimental sample 10,000 events in the CD11b acquisition gate were collected. 
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3.2.8.3 Data analysis with IDEAS software 
 
The compensation matrix file was created and applied to the raw dataset for each experimental 
sample. 
Gating strategy (Figure 3.3): 
1. Gate single cells (Aspect ratio M01 vs. Area M01).  
2. Gate cells in focus (Normalized frequency vs. Gradient RMS). 
3. Gate CD11b positive cells (normalized frequency vs. intensity channel 2). 
4. Gate macrophages (F4/80+/Ly6G-) and neutrophils (Ly6G+/F4/80-) (intensity channel 
11 (F4/80) vs. intensity channel 8 (Ly6G)). 
5. Gate macrophages and neutrophils positive with bacteria. (normalized frequency vs. 
intensity of channel 3 (pHrodo red E. coli)).  Events with a value greater than 1e3 were 
gated as positive signal (pHrodo+). The percent of phagocytosis was calculated based 
on the percentage of events in the pHrodo+ events and were analysed further to 
determine the spot count of pHrodo E. coli bioparticles.  
6. To quantify the phagocytic ability of macrophages and neutrophils in Xid mice I utilized 
the capabilities of the imaging flow analysis software to count the spots of intensity 
emitted by the pHrodo-E. coli bioparticles. 
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Figure 3.3 Imagestream gating strategy. 
 
3.2.9 Western blots 
 
Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative 
western blotting analysis. The antibody used were: 1:1,000 rabbit anti-Ser176/180-IKKα/β, 
1:1,000 rabbit anti-total IKKα/β, mouse anti-Ser32/36-IkBα, mouse anti-total IkBα, rabbit anti-
Tyr223-BTK, rabbit anti-total BTK, rabbit anti-Tyr1217 PLCγ, rabbit anti-total PLCγ (from Cell 
Signalling), 1:5,000 rabbit anti NLRP3 inflammasome (from Abcam), mouse anti-caspase 1 
(p20) (from Adipogen). The apex of the heart was taken and homogenized. Proteins were then 
extracted as previously described (254) and concentrations were quantified by bicinchoninic 
acid (BCA) protein assay (Thermo Fisher Scientific Rockford, IL). Proteins were separated by 
8% sodium dodecyl sulphate (SDS)-PAGE and transferred to polyvinylidene fluoride 
membranes. Membranes were blocked in 10% milk solution with TBS-Tween and then 
incubated with the primary antibody overnight at 4°C. The next day the secondary antibody 
was added for 30 min at room temperature and visualised using the ECL detection system. 
Tubulin was used as a loading control. The immunoreactive bands were analysed by the Bio-
Rad Image Lab Software™ 6.0.1 and results were normalised to the sham bands. 
All cells Singlets Focus
CD11b Macrophage Neutrophil
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3.2.10 Statistical Analysis 
 
Statistical differences were determined using a one-way ANOVA, followed by Bonferroni post 
hoc test or unpaired Student’s t-test as appropriate (GraphPad Prism 8.0; significant when P < 









3.3.1 Xid mice have 100% predicated survival after sepsis 
 
Both WT and Xid mice that underwent sham-operated surgery had a severity score at 24 h of 
0, demonstrating that they experienced no symptoms of sepsis. When compared to sham-
operated mice, WT mice subjected to CLP showed clinical signs of severe sepsis (80%; score 
>3). In contrast, all Xid mice subjected to CLP had a score of ≤3 indicating only moderate 
sepsis (Figure 3.4 A). All mice in the WT-CLP group which received ibrutinib had a score of 
≤3 indicating moderate sepsis and all mice in the Xid-CLP + ibrutinib group had a score ≤3. 
No significant differences were observed the two genotypes receiving ibrutinib (Figure 3.4 A).  
 
When compared to sham-operated mice, WT mice subjected to CLP showed a decrease in the 
mean heart rate, whereas the mean heart rates of Xid-CLP remained similar to that of sham-
operated animals (Figure 3.4 B). When compared to WT-CLP mice, the administration of 
ibrutinib 1 h after CLP attenuated the decline in heart rate (in WT-mice). Mice in the Xid-CLP 
+ ibrutinib group had a similar heart rate to mice in the Xid-CLP group. Xid-CLP mice that 
received ibrutinib had a higher heart rate than WT-CLP mice treated with ibrutinib. 
 
When compared to sham-operated mice, WT mice subjected to CLP experienced hypothermia 
(rectal temperature of <30oC) at 24 h after the onset of CLP, whereas the rectal temperature of 
Xid-CLP, WT-CLP + ibrutinib and Xid-CLP + ibrutinib remained at 37oC (Figure 3.4 C). A 
reduction in temperature to <30oC or a change of 5oC over time in each animal has been 
reported to predict death in mice with CLP (221). As mortality of animals is not an acceptable 
routine endpoint in the UK, I used the reduction in rectal temperature <30oC as a surrogate 
marker for mortality. Using this surrogate marker, I predicted the mortality of WT-CLP mice 
to be 90% (confirming that our model is a model of severe sepsis), while the predicted mortality 
of Xid-CLP mice would be 0% (e.g. 100% predicted survival; Figure 3.4 D). WT mice 
receiving ibrutinib had a predicted mortality of 15%, whereas Xid-CLP mice receiving ibrutinib 
had a predicted mortality of 0%. 
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Figure 3.4 Xid mice have 100% predicated survival after sepsis. WT and Xid mice were randomly 
selected to undergo sham-operated or CLP surgery, 1 h later ibrutinib (30 mg/kg) was administered 
intravenously. At 24 h after CLP, physiological parameters of mice and their predicted survival were 
assessed. (A) Severity Score 24 h after CLP. (B) Temperature 24 h after CLP (oC). (C) Predicted 
percentage of survival (%). (D) Heart rate 24 h after CLP (BPM). The following groups were studied 
WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8) 
and Xid-CLP + ibrutinib (n = 6). Data are expressed as mean ± SEM and analysed by one-way ANOVA 
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3.3.2 Xid mice are protected from sepsis-induced systolic cardiac dysfunction  
 
Figure 3.5 A shows representative M-mode images in the short axis in sham-operated mice, 
CLP + vehicle mice and CLP + ibrutinib mice of WT and Xid genotypes. When compared to 
sham-operated mice, WT mice subjected to CLP showed a significant reduction in EF, FS, 
FAC, CO and SV, indicating severe global, systolic cardiac dysfunction. In contrast, Xid-mice 
subjected to CLP had only a very minor cardiac dysfunction and all indices of cardiac 
performance (EF, FS, FAC, CO and SV) were significantly higher from those measured in 
WT-CLP (Figure 3.5 B-F). Thus, the degree of cardiac dysfunction caused by CLP in Xid mice 
is significantly reduced when compared to that observed in WT-mice. When compared to WT-
CLP mice (CBA background) treatment of WT-mice with ibrutinib 1 h after CLP attenuated 
the sepsis-induced cardiac dysfunction. In contrast, administration of ibrutinib to Xid-CLP 
mice did not affect cardiac function (Figure 3.5 B-F), indicating that the addition of ibrutinib 
in Xid-mice with CLP results in no beneficial or deleterious effects due to off-target actions of 
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Figure 3.5 Xid mice are protected from sepsis-induced systolic cardiac dysfunction. WT and Xid 
mice were randomly selected to undergo sham-operated or CLP surgery, 1 h later ibrutinib (30 mg/kg) 
was administered intravenously. At 24 h after CLP, cardiac function was assessed by echocardiography. 
(A) Representative M-mode echocardiograms. (B) Ejection fraction (%). (C) Fractional shortening (%). 
(D) Fractional area change (%). (E) Cardiac output (ml/min). (F) Stroke volume (µL). The following 
groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-
CLP + ibrutinib (n = 8) and Xid-CLP + ibrutinib (n = 6). Data are expressed as mean ± SEM and 





3.3.3 Xid mice are protected from sepsis-induced diastolic dysfunction  
 
There was no difference in diastolic function between WT and Xid sham-operated mice. When 
compared to sham-operated animals, WT mice subjected for 24 h to CLP demonstrated a 
significant increase in percentage MPI (Figure 3.6) indicating the development of diastolic, 
cardiac dysfunction. When compared to WT-CLP mice, Xid mice subjected to CLP were 
protected from developing diastolic dysfunction (Figure 3.6). No difference was observed with 
the administration of ibrutinib in WT-CLP and Xid-CLP they were both attenuated the 
development of diastolic dysfunction when compared to WT-CLP mice. 
 
 
Figure 3.6 Xid mice are protected from sepsis-induced diastolic dysfunction. WT and Xid mice 
were randomly selected to undergo sham-operated or CLP surgery, 1 h later ibrutinib (30 mg/kg) was 
administered intravenously. At 24 h after CLP, cardiac function was assessed by echocardiography. (A) 
Myocardial performance index (NFT). The following groups were studied WT sham (n = 5), Xid sham 
(n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8) and Xid-CLP + ibrutinib (n 
= 6). Data are expressed as mean ± SEM and analysed by one-way ANOVA with a Bonferroni post hoc 
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3.3.4 Xid mice are protected from sepsis-induced global cardiac dysfunction 
 
More recently myocardial strain analysis has been shown to be a more direct measurement of 
intrinsic myocardial contractility, as it measures the amount of deformation that occurs when 
force is applied. From the original length of the myocardium, a positive strain value describes 
elongation/thickening of the wall, whereas negative values describe shortening. During 
contraction, the myocardium shortens longitudinally and circumferential (negative strain) and 
thickens radially (positive strain). Figure 3.7 A&B depicts the speckle tracking movement of 
the endocardium, while Figure 3.7 C&D shows representative 3D images of longitudinal and 
circumferential strain in sham-operated and CLP mice of both genotypes. When compared to 
sham-operated mice, the myocardium of WT-CLP mice elongates and contracts in both the 
longitudinal and circumferential direction (contraction observed as blue peaks and elongation 
observed as red peaks), leading to a reduced negative percentage for global longitudinal strain 
and global circumferential strain. However, in Xid-CLP mice the myocardium only contracts 
longitudinally and circumferential leading to a global longitudinal strain and global 
circumferential strain values similar to that of sham-operated animals (Figure 3.7 E&F). Thus, 
CLP in WT mice leads to global cardiac dysfunction, while Xid-CLP mice are protected from 
developing cardiac dysfunction. 
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Figure 3.7 Xid mice are protected from sepsis-induced global cardiac dysfunction. WT and Xid 
mice were randomly selected to undergo sham-operated or CLP surgery, 24 h later cardiac function was 
assessed by echocardiography. (A) Representative long axis speckle tracking of the endocardium. (B) 
Representative short axis speckle tracking of the endocardium. (C) Representative 3D longitudinal 
strain. (D) Representative 3D circumferential strain. (E) Global longitudinal strain (%). (F) Global 
circumferential strain (%). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-
CLP (n = 10) and Xid-CLP (n = 10). Data are expressed as mean ± SEM and analysed by one-way 

















































































3.3.5 Xid mice are protected from sepsis-induced renal dysfunction and hepatocellular injury  
 
In sham-operated mice (WT and Xid), there was no difference/development of kidney 
dysfunction, hepatocellular injury or cell injury. When compared to sham-operated mice, WT 
mice subjected to CLP had significant renal dysfunction (rise in urea and creatinine), 
hepatocellular injury (rise in ALT and AST) and cell injury (rise in LDH). In contrast, in Xid 
mice subjected to CLP, the degree of kidney dysfunction, hepatocellular injury and cell injury 
was significantly reduced when compared to WT-CLP mice (Figure 3.8 A-E). When compared 
to WT-CLP, treatment of WT-CLP mice with ibrutinib (1 h after CLP) significantly attenuated 
the rise of plasma/serum urea, creatinine, ALT, AST and LDH. In contrast, administration of 
ibrutinib in Xid-CLP-mice had no significant effect on organ dysfunction (as this was prevented 
in Xid-mice). No significant difference was observed between WT-CLP + ibrutinib and Xid-






Figure 3.8 Xid mice are protected from sepsis induced kidney dysfunction and hepatocellular 
injury. WT and Xid mice were randomly assigned to undergo sham-operated or CLP surgery, 24 h later 
kidney and liver function parameters were assessed in serum. (A) Urea (mmol/L). (B) Creatinine 
(µmol/L). (C) ATL (U/L). (D) AST (U/L). (E) Lactate dehydrogenase (U/L). The following groups 
were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + 
ibrutinib (n = 8) and Xid-CLP (n = 6). Data are expressed as mean ± SEM and analysed by one-way 
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3.3.6 Xid mice do not present with systemic inflammation after polymicrobial sepsis 
 
Using a multiplex array, I analysed 31 cytokines and chemokines in the serum of all animals. 
When compared to sham-operated mice, WT mice subjected to CLP sepsis showed a 
significant increase in the serum levels of pro-inflammatory cytokines TNF-a, IL-6 and IL-1b, 
the anti-inflammatory cytokine IL-10, neutrophils chemoattractant chemokines (KC & ENA-
78), monocyte chemoattractant chemokines (MCP-1, MIP-1a and MIP-1b) and G-CSF. In 
contrast, the levels of these cytokines and chemokines in the serum of Xid-CLP, WT-CLP + 
ibrutinib and Xid-CLP + ibrutinib mice were significantly reduced when compared to WT-CLP 
mice (Figure 3.9 A-I). Interestingly, when compared to WT-CLP, Xid-CLP animals resulted in 
a significant increase in CCL27, IL-2 and CXCL12. The alterations of a further 19 cytokines 


























WT Xid WT Xid WT Xid















WT Xid WT Xid WT Xid




















WT Xid WT Xid WT Xid


















WT Xid WT Xid WT Xid















WT Xid WT Xid WT Xid























WT Xid WT Xid WT Xid


















WT Xid WT Xid WT Xid
















WT Xid WT Xid WT Xid





















WT Xid WT Xid WT Xid




















WT Xid WT Xid WT Xid



















WT Xid WT Xid WT Xid



















WT Xid WT Xid WT Xid







Figure 3.9 Xid mice do not present with systemic inflammation after polymicrobial sepsis. WT 
and Xid mice were randomly selected to undergo sham-operated or CLP surgery, 1 h later ibrutinib (30 
mg/kg) was administered intravenously. 24 h later cytokines and chemokines were assessed in serum. 
(A) TNF-a serum concentration (pg/mol). (B) IL-6 serum concentration (pg/mol). (C) GM-CSF serum 
concentration (pg/mol).  (D) IL-10 serum concentration (pg/mol). (E) ENA-78/CXCL5 serum 
concentration (pg/mol). (F) KC/CXCL1 serum concentration (pg/mol). (G) MCP-1/CCL2 serum 
concentration (pg/mol). (H) MIP-1a/CCL3 serum concentration (pg/mol). (I) MIP-1b/CCL4 serum 
concentration (pg/mol). (J) CTACK/CCL27 serum concentration (pg/mol). (K) IL-2 serum 
concentration (pg/mol). (L) SDF-1a/CXCL12 serum concentration (pg/mol) (M) Heatmap of 31 
cytokines and chemokines. The following groups were studied WT sham (n = 5), Xid sham (n = 5), 
WT-CLP (n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8) and Xid-CLP (n = 6). Data are 
expressed as mean ± SEM and analysed by one-way ANOVA with a Bonferroni post hoc test. *P < 

























































































































































































































3.3.7 Xid mice have fewer infiltrating innate immune cells in the peritoneum and enhanced 
polarisation to M2 macrophages in sepsis. 
 
I then evaluated the cell composition and phenotype in the peritoneal exudates of all animals 
by flow cytometry. When compared to sham-operated mice, WT mice subjected to CLP 
showed a significant increase in the number of neutrophils and macrophages in the peritoneum. 
In contrast, Xid-CLP mice exhibited a significant reduction in the number of infiltrating 
neutrophils and macrophages when compared to WT-CLP mice (Figure 3.10 A-C). Upon 
further analysis of the subsets of macrophages, I found that the macrophages obtained from 
WT-CLP mice are predominately of the pro-inflammatory M1 phenotype (60% M1 and 40% 
M2), while the macrophages of Xid-CLP are of the pro-resolving (anti-inflammatory) M2 





Figure 3.10 Xid mice have fewer infiltrating innate immune cells in the peritoneum and enhanced 
polarisation to M2 macrophages in sepsis. WT and Xid mice were randomly assigned to undergo 
sham-operated or CLP surgery, 24 h later peritoneal lavage fluid was analysed. (A) Scattergrams 
illustrating macrophage (identified as F4/80+Ly6G-) and neutrophils (identified as F4/80-Ly6G+). (B) 
Peritoneal neutrophil (F4/80-Ly6G+) cell count per ml. (C) Peritoneal macrophage (F4/80+Ly6G-) cell 
count per ml. (D) Contour plot illustrating percentage of M1 (identified as MHCII+CD206-) and M2 
macrophages (identified as MHCII+CD206+). (E) Percentage of M1 and M2 macrophages in WT mice 
and Xid mice (%). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n 
= 10) and Xid-CLP (n = 10). Data are expressed as mean ± SEM and analysed by one-way ANOVA 
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3.3.8 Xid mice have fewer infiltrating adaptive immune cells in the peritoneum 
 
When compared to sham-operated mice, WT mice subjected to CLP resulted in a significant 
increase in B cells and no significant difference was observed in infiltrating T cells. In contrast, 
Xid-CLP mice exhibited a significant reduction in the number of infiltrating B cells, but no 
significant difference in the number of infiltrating T cell levels was observed when compared 
to WT-CLP mice (Figure 3.11 A-C).  
 
 
Figure 3.11 Xid mice have fewer infiltrating adaptive immune cells in the peritoneum. WT and 
Xid mice were randomly assigned to undergo sham-operated or CLP surgery, 24 h later peritoneal 
lavage fluid was analysed. (A) Scattergrams illustrating T cells (identified as CD3+B220- and B cells 
(identified as B220+CD3-). (B) Peritoneal B cell count per ml. (C) Peritoneal T cell count per ml. The 
following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 10) and Xid-CLP (n 
= 10). Data are expressed as mean ± SEM and analysed by one-way ANOVA with a Bonferroni post 
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3.3.9 Xid mice have fewer bacteria in peritoneum and blood 
 
The survival of sepsis relies on the body’s ability to remove bacteria from the site of infection; 
thus, I analysed the levels of bacteria in the peritoneal cavity (site of infection) and whole blood 
by flow cytometry 24 h after CLP. WT and Xid mice subjected to sham operation demonstrated 
no difference in the levels of bacteria. When compared to sham-operated mice, WT mice 
subjected to CLP exhibited elevated peritoneal and blood bacteria counts (Figure 3.12 A-D). 
However, Xid-CLP mice had significantly fewer bacteria in the peritoneal cavity and blood 
than WT-CLP mice, showing that Xid-mice clear bacteria more efficiently than WT mice 






Figure 3.12 Xid mice have fewer bacteria in peritoneum and blood. WT and Xid mice were 
randomly assigned to undergo sham-operated or CLP surgery, 24 h later peritoneal lavage fluid and 
blood was analysed. (A) Representative images of bacteria in the peritoneal cavity. (B) Representative 
images of bacteria in whole blood. (C) Peritoneal bacteria cell count per ml. (D) Blood bacteria cell 
count per ml. The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP (n = 
10), Xid-CLP (n = 10), All data are expressed as mean ± SEM for n number of observations. A value 
of **P < 0.01, was considered to be statistically significant when compared to WT-CLP by one-way 












































































3.3.10 Xid macrophages and neutrophils have increased phagocytotic ability 
 
Clearance of bacteria is secondary to phagocytosis of bacteria by neutrophils and macrophages. 
Xid mice subjected to CLP presented with a reduced number of infiltrating immune cells but 
also reduced bacterial cell counts at 24 h post CLP. This raises the question as to how fewer 
infiltrating immune cells are able to clear more bacteria? To address this question, I 
investigated whether Xid neutrophils and macrophages have increased phagocytic ability in 
vivo. I found that the percentage of neutrophils and macrophages, which are phagocytosing 
bacteria, are similar in WT-CLP and Xid-CLP mice. However, neutrophils and macrophages 
of Xid-CLP mice contain more bacteria per immune cell than WT-CLP mice, showing a 100% 
increase in the phagocytic ability of both macrophages (Figure 3.13 A-D) and neutrophils 
(Figure 3.14 A-D). Collectively, this data clearly demonstrates that Xid mice with a deficiency 
in BTK show enhanced phagocytosis in vivo resulting in improved clearance of bacteria during 
a septic episode. 
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Figure 3.13 Xid macrophages have increased phagocytic ability. WT and Xid mice were randomly 
assigned to undergo sham-operated or CLP surgery, 24 h later peritoneal lavage fluid was analysed. (A) 
Representative images of WT-CLP macrophages phagocytosis on the imagestream. (B) Representative 
images of Xid-CLP macrophages phagocytosis on the imagestream. (C) Percentage of macrophages 
that phagocytose (%). (D) Average number of bacteria within macrophages. The following groups were 
studied WT-CLP (n = 8) and Xid-CLP (n = 8). Data are expressed as mean ± SEM and analysed by a 













































































Figure 3.14 Xid neutrophils have increased phagocytic ability. WT and Xid mice were randomly 
assigned to undergo sham-operated or CLP surgery, 24 h later peritoneal lavage fluid was analysed. (A) 
Representative images of WT-CLP neutrophils phagocytosis on the imagestream. (B) Representative 
images of Xid-CLP neutrophils phagocytosis on the imagestream. (C) Percentage of macrophages that 
phagocytose (%). (D) Average number of bacteria within neutrophils. The following groups were 
studied WT-CLP (n = 8) and Xid-CLP (n = 8). Data are expressed as mean ± SEM and analysed by 












































































3.3.11 Cardiac BTK is not activated in Xid mice after polymicrobial sepsis 
 
To understand the signalling mechanism(s) associated with the observed cardiac dysfunction 
in CLP-sepsis, I investigated the effect of BTK deficiency in Xid mice on the activation of key 
signalling pathways of inflammation: BTK, NF-kB and NLRP3 inflammasome activation. 
When compared to sham-operated mice, WT mice subjected to CLP showed an increase of 
BTK activation as demonstrated by significant increases in the phosphorylation of cardiac BTK 
at Tyr223 and the phosphorylation of PLCγ at Tyr1217. No activation of BTK was detected in Xid 
mice subjected to CLP and the phosphorylation of cardiac BTK at Tyr223 and the 
phosphorylation of PLCγ at Tyr1217 in Xid-CLP mice were similar to that of sham-operated 
animals (Figure 3.15 A-B).  
 
 
Figure 3.15 BTK is not activated in the heart of Xid mice after polymicrobial sepsis. WT and Xid 
mice were randomly assigned to undergo sham-operated or CLP surgery and 24 h later signalling events 
in the cardiac tissue were assessed. Densitometric analysis of the bands is expressed as relative optical 
density (O.D.) of (A) phosphorylation of BTK at Tyr223 corrected for the corresponding total BTK and 
normalized using the related sham bands. (B) Phosphorylation of PLCg at Tyr1217 corrected for the 
corresponding total PLCg and normalised using the related sham bands. The following groups were 
studied WT sham, Xid sham, WT-CLP and Xid-CLP, n = 4 per group. Data are expressed as mean ± 
SEM and analysed by one-way ANOVA with a Bonferroni post hoc test. ***P < 0.001 ****P < 0.0001 
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3.3.12 Cardiac NF-kB is not activated in Xid mice after polymicrobial sepsis 
 
NF-kB activation plays a key role in the pathophysiology of sepsis. When compared to sham-
operated mice, WT-CLP mice exhibit a significant increase in NF-kB activation as 
demonstrated by significant increases in the phosphorylation of IKKα/β at Ser176/180 and the 
phosphorylation of IkBα at Ser32/36. When compared to WT-CLP mice, Xid-CLP mice the 
phosphorylation of IKKα/β at Ser176/180 and IkBα at Ser32/36 was significantly reduced, indicating 
that the degree of activation of NF-kB caused by sepsis in the heart was significantly lower in 
Xid-mice than in WT-mice (Figure 3.16 C-D).  
 
 
Figure 3.16 Cardiac NF-kB is not activated in Xid mice after polymicrobial sepsis. WT and Xid 
mice were randomly assigned to undergo sham-operated or CLP surgery and 24 h later signalling events 
in the cardiac tissue were assessed. Densitometric analysis of the bands is expressed as relative optical 
density (O.D.) of (A) Phosphorylation of IKKa/b at Ser176/180 corrected for the corresponding total 
IKKa/b and normalised using the sham related bands. (B) Phosphorylation of IkBa at Ser32/36 corrected 
for the corresponding total IkBa and normalised using the related sham band. The following groups 
were studied WT sham, Xid sham, WT-CLP and Xid-CLP, n = 4 per group. Data are expressed as mean 
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3.3.13 The NLRP3 inflammasome is not activated in the heart of Xid mice after polymicrobial 
sepsis. 
 
When compared to sham-operated mice, WT mice subjected to CLP showed an increase in the 
activation of the NLRP3 inflammasome, demonstrated by an increase in the expression of the 
NLRP3 inflammasome and cleavage of pro-caspase-1 to caspase-1 in the heart as well as an 
increase in the production of IL-1b in serum (Figure 3.17 A-C). In contrast, Xid-CLP mice 
showed reduced activation of NLRP3 inflammasome as demonstrated by a decrease in the 
expression of the NLRP3 inflammasome, cleavage of pro-caspase-1 to caspase-1 and IL-1b, 






Figure 3.17 The NLRP3 inflammasome is not activated in the heart of Xid mice after 
polymicrobial sepsis. WT and Xid mice were randomly assigned to undergo sham-operated or CLP 
surgery and 24 h later signalling events in the cardiac tissue were assessed. Densitometric analysis of 
the bands is expressed as relative optical density (O.D.) of (A) NLRP3 activation, corrected against 
tubulin and normalized using the sham related bands. (B) Pro-caspase-1 against activated caspase-1 and 
normalized using the sham related bands. (C) Serum IL-1b (pg/ml). The following groups were studied 
WT sham, Xid sham, WT-CLP and Xid-CLP, n = 4 per group. Data are expressed as mean ± SEM and 
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Sepsis is the overwhelming host response to infection (bacterial, fungal or viral) leading to 
shock and multiple organ dysfunction. I have previously reported that BTK inhibitors 
(ibrutinib, acalabrutinib) significantly attenuate sepsis-induced cardiac dysfunction, but BTK 
inhibitors have many off-target effects (255). In the present chapter, I investigated whether the 
beneficial effects are exclusively due to inhibition of BTK and whether a reduction in systemic 
inflammation due to BTK inhibition effects bacterial clearance. I addressed these questions by 
conducting a model of polymicrobial sepsis in Xid mice (which have a missense mutation in 
the BTK gene, resulting in BTK to be functionally impaired). I report here for the first time 
that Xid mice are protected from sepsis-induced multiple organ dysfunction (cardiac, renal and 
hepatocellular) due to increased bacterial clearance and suppression of systemic inflammation 
(cytokine storm).   
 
It has been reported that a reduction in temperature <30oC or a change of temperature of 5oC 
over time predicts mortality in animals with sepsis (221). Using this more humane surrogate 
marker, I found that Xid mice with sepsis have a predicted mortality of 0% (100% survival), 
while WT-mice with sepsis would have a predicted mortality of 90% (10% survival). I found 
that ibrutinib does not affect predicted mortality in Xid-CLP mice resulting in a predicted 
mortality of 0% (100% survival) and that delayed administration of ibrutinib in WT-CLP mice 
led to a predicated mortality of 15% (85% survival). It would be useful to confirm the impact 
of impairment in BTK function in Xid-mice on outcome (mortality) in a more long-term sepsis 
model. 
 
Sepsis results in multiple organ failure including cardiac dysfunction, renal dysfunction and 
hepatocellular injury. I report here for the first time that Xid mice subjected to sepsis are 
protected from developing cardiac dysfunction, hepatocellular injury and renal dysfunction. 
Most notably, ibrutinib significantly reduced sepsis-induced multiple organ failure in WT-mice 
but had no further beneficial effect in Xid-mice subjected to CLP-indicating that the observed 
beneficial effect of ibrutinib in WT-mice can solely be explained by inhibition of BTK-activity. 
I have reported in chapter 2 that inhibition of BTK by ibrutinib or acalabrutinib attenuated 
sepsis-induced cardiac and renal dysfunction in C57Bl/6 mice (255) and additionally I have 
now shown that delayed administration of ibrutinib in WT-CLP (CBA background) also 
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attenuates sepsis-induced cardiac dysfunction, renal dysfunction and hepatocellular injury, 
confirming that BTK inhibitors work in two different genetic backgrounds of mice. 
Furthermore, in this chapter, I report that administration of ibrutinib (which inhibits a 
significant number of kinases in addition to BTK, more than acalabrutinib) in Xid-CLP mice 
does neither result in further beneficial effects nor any adverse effects on cardiac, renal or liver 
(dys)function. Inhibition of BTK has been reported to protect against sepsis-induced lung 
injury (256,257), attenuates liver damage in a model of warm ischaemia and reperfusion (258) 
and also ameliorates kidney disease in spontaneous lupus nephritis (259). Thus, I here provide 
evidence that inhibition of BTK alone is sufficient to prevent sepsis-induced multiple organ 
injury. 
 
Ejection fraction is commonly used as a marker for cardiac function and can be used to detect 
relatively large changes in cardiac function. Due to the advances in cardiac imaging (speckle 
tracking analysis) (260), one can now also detect much more subtle changes in cardiac function 
and are able to diagnose heart failure with preserved EF specifically by focusing on the global 
longitudinal strain (261). Hoffman et al. found that myocardial strain is a preferable measure 
for monitoring cardiovascular function in murine sepsis mouse models, as it detects cardiac 
dysfunction earlier and more reliably than EF (224). In WT (CBA background) mice subjected 
to CLP-sepsis, I observed (within 24 h of the onset of sepsis) a severe, global cardiac 
dysfunction with significant changes in EF and cardiac strain (longitudinal and 
circumferential). In contrast, when Xid mice were subjected to CLP-sepsis, I found no 
significant reduction in EF and also no change in the more sensitive and reliable strain analysis, 
showing conclusively that inactivation of BTK in Xid-mice prevents the development of sepsis-
induced cardiac dysfunction.  
 
I then investigated the mechanism(s) by which inactivation of BTK protects mice against 
sepsis-induced multiple organ failure. In septic patients, an essential treatment is early source 
control (removal of infection), which is associated with improved outcomes (44). I found that 
CLP in Xid mice results in a reduction of the number of bacteria in both peritoneum and blood 
(at 24 h after onset of CLP) when compared to WT-CLP mice. This may well be due to an 
increase in phagocytosis in Xid mice. Macrophages obtained from Xid-mice do, however, not 
show defects in phagocytosis (262,263) and I found that the percentage of phagocytosing cells 
are similar in both WT and Xid mice. I discovered, however, that macrophages obtained from 
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Xid-mice with sepsis had taken up a significantly larger number of bacteria. This was also true 
for neutrophils from Xid-mice. I believe that the increase in phagocytosis by macrophages and 
neutrophils from Xid-mice could explain the observed increase in the clearance of bacteria in 
peritoneum and blood. Beguem et al. found that monocytes from healthy volunteers stimulated 
with LPS and treated with evobrutinib resulted in an increased rate of phagocytosis in vitro due 
to a switch of macrophages from the pro-inflammatory M1 to the pro-resolving M2 phenotype 
and this was associated with reduced secretion of TNF-a (264). In addition, Xid mice infected 
with F. tularensis showed enhanced bacterial clearance from the lung and spleen, which 
correlated with a significant improvement of survival when compared to wild-type controls 
(265). 
 
This raises the question of the underlying mechanisms that enables or drives increased 
phagocytosis in Xid-mice? Neither inhibition of BTK activity with ibrutinib nor inactivation of 
BTK in Xid mice affects monocyte FcgR-mediated phagocytosis, but it does suppress FcgR-
mediated cytokine production. The decrease of calcium flux due to BTK inhibition also does 
not affect phagocytosis but does decrease cytokine production (262). BTK inhibition results in 
the polarisation to M2 macrophages (which have greater phagocytic ability (266)), 
demonstrated by increased expression of CD206. CD206 is involved in phagocytosis of a 
number of bacterial strains. For example, monocyte-derived macrophages that express high 
levels of CD206 phagocytosed 78% of E.coli, while monocyte-derived macrophages that 
express low levels of CD206 only phagocytosed 30% of E.coli (267). Excessive activation of 
neutrophils is known to decrease survival and enhance susceptibility to subsequent bacterial 
infections (268). One mechanism that may contribute to the pathology of sepsis is the release 
of neutrophil extracellular traps as they contain the beneficial antimicrobial nuclear proteins 
but also damaging citrullinated histones, elastase, myeloperoxidase and MMP-3 (269,270). 
The release of neutrophil extracellular traps results in ineffective phagocytosis (271). Florence 
et al. showed that BTK was increased in the lung neutrophils and inhibiting BTK protected 
mice against lethal influenza by reducing the release of neutrophil extracellular traps. The 
decrease of neutrophil extracellular traps was also observed in human peripheral blood 
neutrophils incubated with influenza and BTK inhibitor (257). However, the exact molecular 
mechanisms underlying this phenomenon are yet to be elucidated. Future studies are required 
to increase our understanding as to how Xid macrophages and neutrophils phagocytose more 




BTK plays a fundamental role in signalling and function of B cells, but BTK is also highly 
expressed in myeloid cells such as macrophages and neutrophils (155) and inactivation of BTK 
results in reduced cell-mediated inflammatory responses  (272,273). I report here that Xid-CLP 
mice have reduced infiltrating innate immune cells (macrophages and neutrophils) in the 
peritoneum (site of infection). I propose that this may lead to a reduction of the formation of 
cytokines/chemokines in the serum and, hence, will prevent the cytokines storm.   
 
Macrophages play an important role in the two phases of sepsis (early pro-inflammatory phase 
and the later anti-inflammatory phase), as they can have either pro-inflammatory or anti-
inflammatory properties. Initially, M1 macrophages (pro-inflammatory) activate inflammation 
by secreting TNF-α, IL-1β, IL-6 and IL-12 to promote the removal of the pathogen, then M2 
macrophages repair tissue and resolve inflammation by secreting cytokines including IL-10 
(274,275). If the M1 macrophage-driven pro-inflammatory response cannot be controlled, the 
resultant cytokine storm can be a key driver of the severity of sepsis leading to organ failure 
and death (276). Inhibition of BTK drives the switch from the pro-inflammatory M1 phenotype 
to pro-resolving M2 phenotype in response to LPS (243). Here I report that macrophages 
obtained from septic Xid-mice have a pro-resolving M2 phenotype, whereas macrophages 
obtained from septic WT-mice have the M1 phenotype. Most notably, macrophages of the M2 
phenotype have a greater phagocytotic function resulting in increased clearance of apoptotic 
cells and acceleration of resolution (266). Indeed, M2 macrophages protect against sepsis-
induced lung injury (277) and sepsis-induced acute kidney injury (278). Transplantation of M2 
macrophages has been suggested as a potential therapeutic approach for sepsis-induced lung 
injury (277). 
 
Xid mice have a reduced number of B cells and BTK is not expressed in T cells. I report here 
that Xid-CLP mice show a decrease in the number of B cells, but not in T cells when compared 
to WT-CLP mice. The potential contribution of B and T cells to the pathophysiology of early 
sepsis is controversial. Kelly-Scumpia et al. set out to report how suppression of the adaptive 
immune response affects the early innate immune responses. They reported that Rag-/- deficient 
mice (which have no mature B and T cells) have reduced survival in sepsis (CLP surgery). 
Additionally, they found that B-cell deficient mice, but not T-cell deficient mice had a reduced 
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survival in sepsis and that the ‘treatment’ of RAG-/- and B-cell deficient mice with B cells 
improved survival in sepsis, suggesting that B cells, but not T cells, play an important role in 
the pathophysiology of sepsis (279). Contradictory to these results, Bossman et al. found that 
the survival of Rag-/- subjected to CLP was similar to that of WT-mice (280). In addition,  
neonatal Rag-/- mice subjected to sepsis (caecal slurry) did not have higher mortality than WT 
mice (281).  T cells have been shown to be protective (282), detrimental (283,284) or do not 
contribute to the severity of sepsis (285,286). Characteristic of sepsis-induced 
immunosuppression are reductions in CD4+ T cells and a shift from TH1 to TH2 phenotype (287), 
and it has been proposed that stopping this shift increases survival in septic patients (288).  
 
BTK plays a pivotal role in the activation of TLRs and, hence, the signalling steps leading to 
the activation of NF-kB (239), which plays a key role in the pathophysiology of septic 
cardiomyopathy (289). Here I report that Xid mice subjected to polymicrobial sepsis have 
reduced activation of BTK and NF-kB (measured as phosphorylation of IKKa/b and IkBa) in 
the heart. I have previously reported that BTK inhibitors ibrutinib or acalabrutinib reduce the 
activation of cardiac BTK and NF-kB in mice subjected to sepsis (255). Furthermore, it has 
been shown that inhibition of NF-kB activation with an inhibitor of IKK also attenuates the 
cardiac dysfunction associated with polymicrobial sepsis (289). Purvis et al. showed that 
ibrutinib treatment attenuated the activation of NF-kB and gene expression of cytokines in the 
diabetic kidney and liver (273).  Thus, I propose that an impairment in the activation of BTK 
in Xid mice leads to reduced activation of NF-kB in the heart, which contributes to or accounts 
for the observed reduction in organ injury and dysfunction observed in Xid-mice with sepsis. 
 
Activation of NF-kB leads to an increase in the production of cytokines and chemokines such 
as the pro-inflammatory cytokines TNF-a, IL-6, IL-1b and the anti-inflammatory cytokine IL-
10, neutrophils chemoattractant chemokines (KC & ENA-78), monocyte chemoattractant 
chemokines (MCP-1, MIP-1a and MIP-1b) and G-CSF, all of which contribute to the systemic 
inflammation and organ dysfunction associated with sepsis (244). Out of all these cytokines, 
the ones increased most in our model of murine sepsis were IL-6, KC and MCP-1. The levels 
of IL-8 and monocyte chemoattractant protein-1 (MCP-1) are associated with early 48-h and 
28-day mortality in sepsis patients (290). Most notably, I report that in Xid-mice subjected to 
CLP-sepsis, all of these cytokines and chemokines are markedly reduced. WT-CLP treated 
with ibrutinib also reduces the production of sepsis-associated cytokines and chemokines and 
 189 
no difference is observed with the addition of ibrutinib to Xid-CLP mice. Thus, an impairment 
of BTK activation in Xid-mice prevents NF-kB-dependent, systemic inflammation (cytokine 
storm) resulting in a reduction in organ injury/dysfunction.  
 
BTK is also involved in the assembly/activation of the NLRP3 inflammasome in both mice 
and humans (166,167). The activation of the NLRP3 inflammasome also plays a role in the 
pathophysiology of sepsis and septic cardiomyopathy (291). Pharmacological inhibition of 
NLRP3 activation with MCC950 (NLRP3 inflammasome inhibitor) reduced the neurological 
and cognitive impairment in septic animals (250). It has also been reported that genetic 
deficiency of NLRP3 promotes resolution of inflammation in polymicrobial sepsis (105). I 
report here that the activation of the NLRP3 inflammasome (measured as NLRP3 activation, 
caspase-1 activation and production of IL-1b release) was largely reduced in Xid-mice 
subjected to CLP when compared to WT-mice with sepsis. I previously reported that BTK 
inhibitors (ibrutinib or acalabrutinib) inhibit the activation of the NLRP3 inflammasome in the 
heart and production of IL-1b in septic animals (255). Purvis et al. showed that ibrutinib 
treatment attenuated the activation NLRP3 inflammasome in the diabetic kidney and liver 
(273). Thus, I propose that prevention of the activation of the NLRP3 inflammasome secondary 
to reduced activation of BTK importantly contributes to the reduction in inflammation and 
organ dysfunction observed in septic Xid-mice.  
 
I have shown that Xid-mice subjected to CLP have increased bacterial clearance and reduced 
systemic inflammation (secondary to reduced activation of the NLRP3 inflammasome and NF-
kB) and cardiac (organ) dysfunction. There is good evidence that the mortality of patients with 




I report here for the first time that inactivation of BTK is responsible for conferring protection 
against multiple organ failure in a clinically relevant model of sepsis. Most importantly I have 
shown that the inactivation of BTK in Xid mice results in an increase of phagocytosis in 
macrophages and neutrophils, thus, increasing bacterial clearance in both peritoneum and 
blood. Inactivation of BTK also results in a phenotypic switch of macrophages from M1 to the 
M2 phenotype, which aids in the resolution of sepsis. The suppression of the immune system 
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by inactivated BTK also leads to reduced activation of NF-kB and the NLRP3 inflammasome, 
therefore, preventing the induction of the cytokine storm. As the administration of ibrutinib to 
Xid-CLP mice did not result in any additional (beneficial) effects on the alterations in organ 
dysfunction and cytokine/chemokines formation caused by sepsis, our data strongly suggest 
that BTK inactivation is responsible for the observed effects of ibrutinib.  Lastly, I have found 
that BTK expression in humans is increased in the blood of septic non-survivors. Thus, BTK 
inhibitors may be repurposed for the use in sepsis (or other conditions associated with excessive 
local or systemic inflammation including COVID-19) due to their ability to reduce systemic 
inflammation (cytokine storm), their ability to enhance the phagocytosis of 
neutrophils/macrophages and switch macrophages from the pro-inflammatory M1 to the anti-

















Septic research has mainly focused on PAMPs interacting with PRRs, leading to the activation 
of NF-kB and thus the production of pro-inflammatory cytokines and chemokines. However, 
DAMPs  also contribute to the pathogenesis of sepsis by activating PRRs and their subsequent 
inflammatory signalling pathways (292), for example the release of eRNA from dying cells 
binds to and activates the TLR3 signalling pathway leading to activation of NF-kB and 
production of pro-inflammatory cytokines and chemokines (Figure 4.1).  Clinically the severity 
of sepsis has been shown to correlate with increased levels of DAMPs, such as high mobility 
group box-1 protein (HMGB1) (293), cold-inducible RNA-binding protein (CIRP) (294) and 
histone (295). DAMPs are host nuclear or cytoplasmic non-microbial molecules (296)  and are 
released from tissue injury, specifically from cells through inflammasome activation or 
passively following cell death (297). However, little is known about the role of eRNA in sepsis-
induced cardiac dysfunction. eRNA is a term used to describe several types of RNA 
(microRNA, transfer RNA, small interfering RNA and long non-coding RNA), which are 
diverse in function but share a common attribute of being found in the extracellular 
environment (298).  
 
Cardiac apoptosis is a programmed cell death caused by intrinsic or extrinsic signalling 
pathway (as previously described in section 1.6.5) and contributes to the pathophysiology of 
cardiac dysfunction. It is unknown whether intrinsic factors such as eRNA play a role in the 
activation of septic cardiac apoptosis.  
 
eRNA is modulated by endogenous RNase. RNase 1 is an antimicrobial peptide which is 
expressed in all tissues and bodily fluids and contributes to the immune system by degrading 
pathogenic RNA and eRNA (released from tissue injury and necrosis) (Figure 4.1) (193). 
RNase 1 is regulated by RNH1 (which is induced by oxidative stress (299)), thus increased 
levels of RNH1 negatively affects the antimicrobial ability of RNase. Here I hypothesis that 
administration of RNase may attenuate sepsis-induced organ dysfunction in a model of 





The roles of RNase, RNH1 and eRNA in the pathophysiology of sepsis still require further 
research. In this chapter I set out to investigate whether: 
1) RNase 1 administration attenuates sepsis-induced multiple organ failure (cardiac, renal 
and liver dysfunction). 
2) The effect of RNase 1 administration in septic mice on the production of sepsis 
associated cytokines and chemokines. 
3) RNase 1 reduces the levels of bacteria in the peritoneal cavity of septic mice  
4) Cardiac apoptosis is involved in the pathophysiology of septic mice and whether RNase 
1 administration reduces the level of cardiac apoptosis. 
5) RNase 1 levels in serum of septic mice over a 24 h time course. 
6) At 24 h in septic mice measure the levels of RNase 1, eRNA and RNH1 in serum. 
 
 
Figure 4.1 Schematic diagram of RNase activity.  RNase is released from the endothelial cells and 
eRNA is released from dying/necrotic cells. eRNA binds to TLR3 resulting in the production of pro-
inflammatory cytokines such as TNF-a, which activates the pro-apoptotic response. RNase degrades 




4.2.1 Animals  
 
This study was carried out on forty-one 10-week-old, male C57BL/6 mice (Charles River 
Laboratories UK Ltd., Kent, UK), weighing 25–30 g and kept under standard laboratory 
conditions. The animals were allowed to acclimatise to laboratory conditions for at least one 
week before undergoing experiments. Six mice were housed together (in each cage) with access 
to a chow diet and water ad libitum. They were subjected to a 12-h light and dark cycle with a 
temperature maintained at 19–23°C. The cages were cleaned regularly approximately every 
three days, with water being changed daily. Research staff inspected the animals each day for 
any signs of illness or abnormal behaviour. 
 
4.2.2 Caecal ligation and puncture (CLP) surgery 
 
Caecal ligation and puncture (CLP) surgery was performed in 10-week-old male C57Bl/6 mice 
(Table 4.1) as previously described in chapter 2. The mice were randomly assigned to under 
CLP or sham-operated surgery. Briefly, mice were anaesthetised with isoflurane (2% delivered 
in O2) and the caecum was fully ligated below the ileocaecal valve. A double puncture was 
made with an 18-G needle into the caecum and a small amount of faeces was squeezed out 
after which the caecum was returned to its anatomical position, then the laparotomy was closed. 
All animals received fluids (5 ml/kg saline into the abdomen before closure and 10 ml/kg saline 
s.c., immediately after surgery). At 6 and 18 h after surgery all animals received antibiotics 
(Imipenem/Cilastatin; 20 mg/kg dissolved in 7.5 ml/kg of saline s.c.), and analgesics 
(buprenorphine; 0.05 mg/kg i.p.). Sham-operated mice underwent the same procedure, but 
without CLP. RNase 1 or its vehicle was administrated before sepsis induction (50 μg/kg 
RNase 1 or 0.9% NaCl, i.v.), directly after surgery (200 μg/100 μL RNase 1 or 100 μL 0.9% 
NaCl, s.c.), and again 4 h after surgery (500 μg/100 μL RNase 1 or 100 μL 0.9% NaCl, s.c.). 
The surgeon was blinded to which group received the treatment or the vehicle. At the end of 
the study, mice were sacrificed, peritoneal lavage fluid and organs were collected under sterile 
conditions, and blood was withdrawn by cardiac puncture. 
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A clinical score for monitoring the health of experimental mice was used to evaluate the 
symptoms consistent with murine sepsis. The maximum score of 6 comprised the presence of 
the following signs: lethargy, piloerection, tremors, periorbital exudates, respiratory distress, 
and diarrhoea. Mice with a clinical score >3 were defined as exhibiting severe sepsis, against 
a moderate sepsis score of ≤3. Animals were culled at 24 h after the onset of sepsis (CLP).   
Table 4.1 Experimental groups used to investigate the treatment of RNase 1 in CLP-induced 
cardiac dysfunction. 




Sham + vehicle 12 
Sham + RNase 5 
CLP + vehicle 12 
CLP + RNase  12 
 
4.2.3 Assessment of cardiac function in vivo 
 
At 24 h post CLP, mice were anaesthetised (0.5 - 2% isoflurane in O2); body temperature was 
maintained at 37oC and heart rate was maintained at 450 bpm. Then, cardiac function was 
assessed by M-mode and B-mode echocardiography using the VisualSonics Vevo 3100 
echocardiographic system and an MX550D transducer as previously described in section 2.2.9. 
The following parameters were measured: left ventricular EF, FS, FAC, CO, SV, ESV and 
EDV.  
 
4.2.4 Quantification of renal dysfunction, hepatocellular injury and cell injury 
 
After 24 h, mice were sacrificed by terminal cardiac puncture, where terminal blood samples 
were immediately decanted into 1.3 ml serum gel tubes (Sarstedt, Nürnbrecht, Germany). 
Blood was left to coagulate for at least 10 min at room temperature, then samples were 
centrifuged at 9000 rpm for 3 min to separate the serum.  Then 100 µl of serum was snap-
frozen in liquid nitrogen and sent to an independent veterinary testing laboratory (MRC 
Harwell Institute, Oxford, UK) to evaluate the following biomarkers in a blinded fashion: Urea 
and creatinine (as markers of renal dysfunction), alanine aminotransferase (ALT) and aspartate 
transaminase (AST) (markers of hepatocellular injury).  
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4.2.5 Cytokine analysis  
 
Cytokines, chemokines and a growth factor were determined in serum by Bio-Plex Pro Mouse 
Chemokine 33-Plex panel assay (Bio-Rad, Kabelsketal, Germany) as previously described in 
chapter 2. The cytokines IL-1ß, −2, −4, −6, −10, −16, CCL1, −2, −3, −4, −5, −7, −11, −12, 
−17, −19, −20, −22, −24, −27, IFN-γ, TNF-α and the chemokines CX3CL1, CXCL1, −2, −5, 
−10, −11, −12, −13, −16 and the growth factor GM-CSF. 
 
4.2.6 Peritoneal lavage 
 
Mice were euthanised by an overdose of isoflurane inhalation. Once confirmed dead peritoneal 
cells were obtained by injecting 5 ml of 2mM EDTA + PBS -/- using a 25-G needle. Cells 
attached were dislodged by gentle massage of the peritoneum and collected by using an 18-G 
needle. Approximately 4 ml of the peritoneal fluid was obtained and decanted into 15 ml falcon 
tubes on ice.  
 
4.2.7 Bacteria quantification 
 
Accurate evaluation of the number of bacteria in peritoneal lavage fluid was performed by flow 
cytometry using the SYTO BC bacteria counting kit (Thermo Fischer Scientific) as previously 
described in chapter 2.  
 
4.2.8 Western blots 
 
Immunoblot analyses of cardiac tissue samples were carried out using a semi-quantitative 
western blotting analysis. The antibody used were caspase-9 (C9) mouse (catalog 9508), Bcl-
2 (D17C4) rabbit (catalog 3498), caspase-3 rabbit (catalog 9662), and Bax (D3R2M) rabbit 
(catalog 14796) all from cell signalling. The apex of the heart was taken and homogenized in 
homogenisation buffer 20 mM HEPES, pH 7.9, 1 mM MgCl2, 0.5 mM EDTA, 1% Nonidet P-
40, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 μL/mL PIC). Proteins were then extracted as 
previously described above and concentrations were quantified by bicinchoninic acid (BCA) 
protein assay (Thermo Fisher Scientific Rockford, IL). Proteins were separated by 8% sodium 
dodecyl sulphate (SDS)-PAGE and transferred to polyvinylidene fluoride membranes. 
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Membranes were blocked for 1 h in blocking buffer (10% BSA in TBS containing 0.1% 
Tween) and then incubated with the primary antibody diluted in 5% BSA in TBS containing 
0.1% Tween overnight at 4°C. The next day the membrane was washed 3 times and the 
membrane was incubated for 30 min with the HRP-conjugated secondary antibody at room 
temperature. Protein bands were detected with enhanced chemiluminescent (ECL) detection 
system. The immunoreactive bands were visualized by autoradiography and the densitometric 
analysis was performed using Gel Pro Analyzer 4.5, 2000 software (Media Cybernetics). 
Results were normalized by using Tubulin as an endogenous control. 
 
4.2.9 TUNEL assay 
 
Hearts were washed with saline and placed in formalin for 24 h after which they were 
transferred to 70% ethanol and embedded in paraffin. Tissue sections were cut at 5 µm. Paraffin 
was dewaxed by a series of alcohol: Xylene (2 x 5 min), 100% ethanol (5 min), 95% ethanol 
(5 min), 90% ethanol (5 min), 80% ethanol (5 min), 70% ethanol (5 min) and PBS ( 2 x 5 min). 
Slides were then incubated with 0.1 M citrate buffer (pH 6.0) for 5 min at 350W. Slides were 
allowed to cool for at least 1 h. Slides were washed twice with PBS and the area around the 
sample was dried. After which 50 µL of TUNEL reaction mixture was added to each sample 
(In Situ Cell Death Detection Kit TMR red (Roche)) and incubated for 1 h at 37oC in the dark. 
Slides were then rinsed three times with PBS and covered with ProLong Gold. An LSM 710 





The levels of the RNH1 and RNase 1 in mice serum were determined using a commercial 
ELISA kit (LifeSpan BioSciences). The ELISAs do not distinguish between bound RNase 1 
and unbound RNase 1 with RNH1. Then 100 µL of standard, blank and sample were 
administered into the 96 plate well in duplicate and incubated for 1 h at 37oC. Excess liquid 
was aspirated and 100 µL of detection reagent A was added to each well and incubated for 1 h 
at 37oC. Excess liquid was aspirated and washed 3 times by adding 350 µL of 1 x wash buffer 
to each well. 100 µL of detection reagent B was added to each well and incubated for 30 min 
at 37oC. After 30 min excess liquid was aspirated off and washed 5 times. 90 µL of TMB 
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substrate was added to each well and incubated for 15 min at 37oC in the dark. 50 µL of stop 
solution was then added. Optical density was immediately evaluated by a microplate reader set 
at 450 nm.  
 
4.2.11 Statistical analysis 
 
Statistical differences were determined using a one-way ANOVA, followed by Bonferroni post 
hoc test or unpaired Student’s t-test as appropriate (GraphPad Prism 8.0; significant when P < 












4.3.1 Physiological measurements of mice 24 h after surgery 
 
Mice that underwent sham-operated surgery and treated with either vehicle or RNase resulted 
in a severity score at 24 h of 0, demonstrating that they experienced no symptoms of sepsis. 
When compared to sham-operated mice, WT mice which underwent CLP demonstrated clinical 
signs of sepsis. When compared to CLP mice treated with vehicle, CLP mice that received 
RNase 1 all had a severity score of < 3 indicating moderate sepsis. (Figure 4.2 A). When 
compared to sham-operated mice, mice subjected to CLP and treated with vehicle showed a 
decrease in heart rate, whereas the heart rate of CLP mice which received RNase 1 remained 
similar to that of sham-operated animals (Figure 4.2 B). There was no difference in body 
temperature between sham-operated mice which received vehicle or RNase 1, as the 
temperature remained at the normal physiological range of 37oC. When compared to sham-
operated animals, mice subjected for 24 h to CLP and treated with vehicle demonstrated a 
significant decrease in temperature < 30oC, indicating the development of sepsis-induced 
hypothermia. When compared to CLP mice treated with vehicle, CLP mice that received 
RNase 1 were protected from developing hypothermia (Figure 4.2 C). Using the mortality 
surrogate marker of a reduction in temperature <30oC or a change of 5oC over time I find that 
both sham-operated mice had a predicted mortality of 0%. In contrast, the predicted mortality 
of CLP mice is 67%, confirming that this is a severe model of sepsis. Mice subjected to CLP 





Figure 4.2 Physiological measurements of mice 24 h after surgery. Mice were randomly selected to 
undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 24 h after 
CLP, physiological measurements of the mice were assessed. (A) Severity Score 24 h after CLP. (B) 
Heart rate 24 h after CLP (bmp). (C) Temperature 24 h after CLP (oC). (D) Predicted percentage of 
survival (%). The following groups were studied sham + vehicle (n = 12), sham + RNase (n = 5), CLP 
+ vehicle (n = 12), CLP + RNase (n = 12). All data are expressed as mean ± SEM for n number of 
observations. A value of ****P < 0.0001, *** P < 0.001 and **P < 0.01 was considered to be 
statistically significant when compared to CLP + vehicle by one-way ANOVA followed by a 
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4.3.2 RNase 1 attenuates sepsis-induced cardiac dysfunction 
 
When compared to sham-operated animals, mice subjected for 24 h to CLP and treated with 
vehicle demonstrated a significant reduction in percentage EF, FS, FAC, SV, CO (Figure 4.3 
A-F) and an increase in ESV, indicating the development of systolic, cardiac dysfunction. 
When compared to CLP-mice treated with vehicle, administration of RNase 1 in CLP-mice 
significantly attenuated the decline in EF, FS, FAC, SV, CO and the increase in ESV caused 
by CLP (Figure 4.3 A-F). No significant differences in EDV were observed between all groups. 













































































































































Figure 4.3 RNase 1 attenuates sepsis-induced cardiac dysfunction. Mice were randomly selected to 
undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 24 h after 
CLP, cardiac function was assessed by echocardiography. (A) Representative M-mode 
echocardiograms. (B) Ejection fraction (%). (C) Fractional shortening (%). (D) Fractional area change 
(%). (E) Stroke volume (µL). (F) Cardiac output (ml/min). (G) End-systolic volume (µL). (H) End-
diastolic volume (µL). The following groups were studied sham + vehicle (n = 12), sham + RNase (n = 
5), CLP + vehicle (n = 12), CLP + RNase (n = 12). All data are expressed as mean ± SEM for n number 
of observations. A value of ****P < 0.0001, *** P < 0.001, **P < 0.01, *P < 0.05 was considered to 
be statistically significant when compared to CLP + vehicle by one-way ANOVA followed by a 
Bonferroni’s post hoc test. 
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4.3.3 RNase reduces sepsis-induced kidney dysfunction 
 
When compared to sham-operated mice, mice subjected to CLP for 24 h and treated with 
vehicle developed renal dysfunction (rise in urea and creatinine). When compared to CLP-mice 
treated with vehicle, CLP-mice treated with RNase 1 showed significant decreases in serum 
urea and creatinine, demonstrating that RNase 1 reduced the sepsis-induced renal dysfunction. 
There were no significant differences between sham-operated mice receiving vehicle or RNase 




Figure 4.4 RNase 1 reduces sepsis-induced renal dysfunction. Mice were randomly selected to 
undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 24 h after 
CLP, renal function was assessed in serum. (A) Urea (mmol/L).  (B) Creatinine (µmol/L). The following 
groups were studied sham + vehicle (n = 12), sham + RNase (n = 5), CLP + vehicle (n = 12), CLP + 
RNase (n = 12). All data are expressed as mean ± SEM for n number of observations. A value of *** P 
< 0.001, **P < 0.01, *P < 0.05 was considered to be statistically significant when compared to CLP + 








































4.3.4 RNase 1 does not reduce sepsis-induced hepatocellular injury 
 
When compared to sham-operated mice, mice subjected to CLP for 24 h and treated with 
vehicle developed hepatocellular injury (rise in ALT and AST). When compared to CLP-
animals treated with vehicle, CLP-animals treated with RNase 1 resulted in no significant 
decreases in serum AST and ALT. There were no significant differences between sham-
operated mice receiving vehicle or RNase 1 (Figure 4.5 A&B). 
 
 
Figure 4.5 RNase 1 does not reduce sepsis-induced hepatocellular injury. Mice were randomly 
selected to undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 
24 h after CLP, hepatocellular injury was assessed in serum. (A) ALT (U/L). (B) AST (U/L). The 
following groups were studied sham + vehicle (n = 12), sham + RNase (n = 5), CLP + vehicle (n = 12), 
CLP + RNase (n = 12). All data are expressed as mean ± SEM for n number of observations. A value 
of **** P < 0.0001 and ***P < 0.001 was considered to be statistically significant when compared to 






























4.3.5 Effect of RNase 1 on the number of bacteria in the peritoneum 
 
When compared to sham-operated mice, mice subjected to CLP for 24 h and treated with 
vehicle developed a significant increase in peritoneal bacteria. When compared to CLP-animals 
treated with vehicle, CLP-animals treated with RNase 1 did not significantly decrease the 
number of bacteria in the peritoneum. There were no significant differences between sham-




Figure 4.6 Effect of RNase 1 on the number of bacteria in the peritoneum. Mice were randomly 
selected to undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 
24 h after CLP, bacteria were assessed in the peritoneal cavity. (A) Scattergraphs illustrating peritoneal 
bacteria (B) Bacteria cell count per ml. The following groups were studied, sham + vehicle, sham + 
RNase, CLP + vehicle and CLP + RNase.  All data are expressed as mean ± SEM for n = 5 per group. 
A value of **P < 0.01 was considered to be statistically significant when compared to CLP + vehicle 
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4.3.6 Effect of RNase on the systemic inflammation 
 
When compared to sham-operated mice there were increases in 33 cytokines and chemokines 
in the serum of mice subjected to CLP for 24 h. When compared to CLP mice, mice which 
underwent CLP and were treated with RNase 1 resulted in a decrease of cytokines and 
chemokines, specifically TNF-a (Figure 4.7).   
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Figure 4.7 Effect of RNase on the systemic inflammation. Mice were randomly selected to undergo 
sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 24 h after CLP, 
cytokines and chemokines were assessed in serum. (A) Heat map of cytokines and chemokines in 
serum. The following groups were studied sham + vehicle, CLP + vehicle and CLP + RNase. All data 











































































































































4.3.7 RNase 1 decreases cardiac apoptosis in septic mice 
 
To gain a better understanding of the underlying signalling events involved in the observed 
beneficial effects of RNase 1 on sepsis-associated cardiomyopathy, I investigated the relevant 
apoptosis pathways in cardiac tissue at 24 hours after onset of sepsis. When compared to sham-
operated mice, mice subjected to CLP for 24 h and treated with vehicle developed a significant 
increase in the activation of the intrinsic apoptosis pathway as demonstrated by increases in 
the levels of Bax, cleavage of pro-caspase 9 to caspase 9 and cleavage of pro-caspase 3 to 
caspase 3 and decease in Bcl-2 in the cardiac tissue. When compared to CLP-animals treated 
with vehicle, CLP-animals treated with RNase 1 showed a significant decrease in the levels of 
Bax, caspase 9 and caspase 3 and an increase in Bcl-2 in the cardiac tissue (Figure 4.8 A&B), 




Figure 4.8 RNase 1 decreases cardiac apoptosis in septic mice. Mice were randomly selected to 
undergo sham-operated or CLP surgery and received either RNase 1 or vehicle (saline). At 24 h after 
CLP, hearts were analysed by Western blot to analysis the apoptosis signalling pathway. The activation 
of the following was investigated: (A) Bax (B) Bcl-2 (C) Caspase 9 (D) Caspase 3. The following 
groups were studied sham + vehicle (n = 4), sham + RNase (n = 4), CLP + vehicle (n = 5) and CLP + 
RNase (n = 5). All data are expressed as mean ± SEM for n number of observations. A value of *** P 
< 0.001, **P < 0.01 and *P < 0.05 was considered to be statistically significant when compared to CLP 


























































































































4.3.8 Effect of RNase on cardiac TUNEL fluorescence in septic mice 
 
When compared to sham-operated mice, mice subjected to CLP for 24 h and treated with 
vehicle resulted in no significant increase of cardiac TUNEL fluorescence. When compared to 
CLP-animals treated with vehicle, CLP-animals treated with RNase 1 showed no significant 
decrease in cardiac TUNEL fluorescence. There were no significant differences between sham-




Figure 4.9 Effect of RNase on cardiac TUNEL fluorescence in septic mice. Mice were randomly 
selected to undergo sham-operated or CLP surgery and receive either RNase 1 or vehicle (saline). At 
24 h after CLP, hearts were analysed by TUNEL assay to analysis cardiac apoptosis. (A) Apoptotic 
cells were labelled with TUNEL (red) and nuclei or cardiomyocytes were stained with DAPI (blue) 
scale bar 100  µm. (B) Quantification of TUNEL fluorescence. The following groups were studied, 
sham + vehicle, sham + RNase, CLP + vehicle and CLP + RNase. All data is expressed as mean ± SEM 
for n = 5 for all groups. A value of *P < 0.05 was considered to be statistically significant when 
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4.3.9 Time course of RNase levels in the serum of sham-operated and septic mice  
 
At 1 h after CLP surgery RNase 1 levels were significantly reduced when compared to sham-
operated mice. At 3 h after surgery both sham-operated and CLP mice resulted in a decrease 
in RNase levels. CLP RNase levels were significantly lower than sham-operated mice. At 6 h 
after surgery sham-operated mice experienced a slight increase in RNase 1 and CLP RNase 
levels remained similar to CLP RNase levels at 3 h. There was a significant difference between 
sham-operated and CLP RNase levels at 6 h. At 12 h sham-operated RNase levels increased 
from 6 h and CLP RNase levels remained similar to levels at 6 h. A significant difference is 
observed between sham-operated and CLP mice at 12 h. Finally, at 24 h after surgery sham-
operated RNase levels dropped to levels that were similar at 3 h after sham-operated mice. CLP 
mice resulted in a slight increase in RNase levels from 12 h. A significant difference was 
observed between sham-operated and CLP mice in RNase levels at 24 h (Figure 4.10).  
 
 
Figure 4.10 Time course of RNase levels in serum of sham-operated and septic mice. Mice were 
randomly selected to undergo sham-operated or CLP surgery. At 1, 3, 6, 12 and 24 h mice were 
sacrificed, and serum was collected for RNase 1 analysis. All data are expressed as mean ± SEM for 
sham (n = 3) and CLP (n = 4). A value of ****P < 0.0001 and *** P < 0.001 was considered to be 
statistically significant when compared to CLP by an unpaired t-test. 
  
























4.3.10 Concentration of RNase, RNH1 and eRNA in the serum of septic mice at 24 h  
 
When compared to sham-operated mice, mice subjected to CLP exhibited a decrease in RNase 
1 levels at 24 h after CLP surgery and this was associated with an increase in ribonuclease 1 
inhibitor. No difference was observed in eRNA levels in serum between sham-operated and 
CLP-operated mice. When compared to CLP mice treated with vehicle, mice which underwent 
CLP and were treated with RNase 1 showed an increase in RNase 1 levels and a small, but not 
significant, decrease in ribonuclease 1 inhibitor in serum. No difference in eRNA levels was 




Figure 4.11 Concentration of RNase, RNH1 and eRNA in the serum of septic mice at 24 h. Mice 
were randomly selected to undergo sham-operated or CLP surgery and receive either RNase 1 or vehicle 
(saline). At 24 h after CLP, mice were sacrificed, and serum was collected for further analysis by 
ELISA. (A) Concentration of RNase 1 (ng/ml). (B) Concentration of ribonuclease 1 inhibitor (ng/ml). 
(C) Extracellular RNA (ng/ml). The following groups were studied sham + vehicle (n = 5), sham + 
RNase (n = 5), CLP + vehicle (n = 8) and CLP + RNase (n = 9). All data are expressed as mean ± SEM 
for n number of observations. A value of **** P < 0.0001 and *P < 0.05 was considered to be 
statistically significant when compared to CLP + vehicle by one-way ANOVA followed by a 























































Sepsis leads to cell damage and tissue injury which results in the release of eRNA promoting 
systemic inflammation. RNase A counteracts the inflammatory properties of eRNA and has 
been found to be elevated in septic patients. The aim of this study was to investigate whether 
administration of RNase 1 would attenuate sepsis-induced cardiac dysfunction and the 
potential role of RNase 1 in cardiac apoptosis.  
 
The administration of RNase in the polymicrobial murine sepsis model resulted in attenuation 
of sepsis-induced cardiac dysfunction. Additionally, Stieger et al. found that administration of 
RNase 1 in their mouse model of myocardial infarction resulted in persevered left ventricular 
function 24 h after myocardial infarction, as demonstrated by an increase of FS when compared 
to the controls (300). Also, in a rat model of heart transplantation, rats treated with RNase 1 
had a longer graft survival and flow cytometry analysis of the heart revealed reduced leukocyte 
infiltration, oedema, and thrombus formation when compared to controls (301). All these 
studies confirm that RNase has a protective role in the heart. 
 
The administration of RNase to CLP mice resulted in a reduction of kidney dysfunction 
(measured as urea and creatinine) when compared to the CLP + vehicle, demonstrating that 
RNase 1 protects the kidney from sepsis-induced kidney dysfunction. RNase 4 and 7 are 
expressed by epithelial cells in the urinary tract, with the collecting duct being the main site of 
production (302,303).  It has previously been shown that RNase 7 in urine is 1.5-fold lower in 
females who have UTI than those who are healthy, and RNase 7 humanized mice are protected 
against infections with uropathogenic E.coli. These findings show that RNase 7 plays a role in 
the host defence of kidney and bladder against uropathogenic E.coli (304).  
 
An increase in cytokine production results in the decrease of circulating RNase 1 via epigenetic 
modifications, which increases eRNA induced inflammation and contributes to the disruption 
of the vascular homeostasis (198). I report in this chapter that administration of RNase 1 
attenuates the increase in cytokines and chemokines caused by CLP-sepsis. There is evidence 
that the clearance of eRNA by RNase 1 might be responsible for the observed decrease of 
inflammation (200,213). Ma et al. found that administration of RNase 1 attenuates hepatic 
ischaemia reperfusion injury in aged mice through the inhibition of cytokine production (212).  
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RNases are antimicrobial peptides and have characteristics that allow them to interact with 
pathogens e.g. having a net positive charge allowing for RNases to bind to microbial 
membranes and forming amphipathic structures in hydrophobic environments allowing for 
them to penetrate the bacterial phospholipid bilayer. However, RNase 1 is not recognised as a 
robust antimicrobial but is considered to be an anti-viral (305). In this chapter I found that 
administration of RNase 1 did not result in a significant decrease in the number of bacteria in 
the peritoneal cavity. Lu et al. screened the 7 human RNases in vitro for their antimicrobial 
potency. They found that only RNase 3, 6 and 7 could completely inhibit the growth of M. 
aurum cultures, whereas the other RNases did not reduce the mycobacteria concentration. 
Longer exposure times to RNase 3, 6 and 7 lead to increased mycobacteria clearance (306). 
My results contradict Lu study, but they only focused on the clearance of one type of bacteria 
whereas my in vivo model is polymicrobial. Administration of RNase 1 has been shown to have 
antiviral activity against HIV-1 (307) and also leads to the activation of dendritic cells (201). 
Administration of Ear1 (similar to human RNase 1) in the rat lead to reduced growth of E.coli 
showing the potential role of RNase 1 in animal models (308). 
 
It has been shown ex vivo that inhibition of caspase activation in the apoptosis pathway reduces 
depression of cardiac function (309). However, post-mortem examination of patients with 
sepsis and healthy controls revealed that < 0.2% of the cells had undergone apoptosis and there 
were no differences between the two groups (126). Here I report that CLP results in an increase 
of cardiac apoptosis (demonstrated as a rise of Bax levels, activation of caspase 9 and 3 and a 
decrease of Bcl-2) as well as an increase in TUNEL staining. Administration of RNase 1 to 
mice subjected to sepsis results in a significant decrease in the activation of the apoptosis 
signalling pathway and a decrease in TUNEL staining. Additionally, other studies have 
investigated reducing apoptosis as a therapeutic intervention by caspase inhibition in 
cardiomyopathy induced ischemia-reperfusion and rapid ventricular pacing (310,311). In a 
model of myocardial ischemia-reperfusion administration of RNase 1 reduced the infarct size 
and reduced necrotic cell death in ischemic hearts (213).  As mentioned previously Stieger et 
al. not only found RNase 1 preserved left ventricular function but also resulted in a reduction 
of apoptosis 24 hours after ligation of the left anterior descending artery (LAD) in mice (300). 
 
 219 
In serum of septic patients, the levels of RNase 1, eRNA and RNH1 are elevated when 
compared to healthy participants (206,298). However, in my mouse model of polymicrobial 
sepsis, I found that that levels of RNase 1 decrease to low levels in septic mice even 1 h after 
CLP surgery.  RNH1 level was significantly increased in CLP mice but, no significant 
difference was observed in eRNA levels between sham-operated and CLP mice. The 
discrepancies between human septic serum and mouse septic serum could be due to the time 
of the measurement. The levels of eRNA in septic patients were measured 3 days after 
diagnosis, whereas the concentration of eRNA was measured only at 24 h after CLP surgery. 
Stieger et al. showed that eRNA levels were elevated within 30 min after ligation of LAD and 
at 2 h hour reaching a maximum eRNA concentration in serum. However, at 4 h after LAD 
eRNA levels returned to baseline (300).  
 
4.4.1 Limitations of RNase experiments  
 
A limitation of these experiments is that administration of RNase 1 was given as a pre-treatment 
just before CLP surgery, and I have yet to investigate whether the delayed administration of 
RNase 1 would affect cardiac, renal and hepatocellular function after CLP surgery. I have seen 
in chapter 2 that cardiac function is affected 1 h after CLP as demonstrated by a decrease in 
cardiac output and stroke volume. It would be useful to confirm my hypothesis that eRNA is 
elevated in earlier time points after CLP surgery, by measuring eRNA levels in mice 2 h after 
CLP surgery like Stieger et al. in the LAD model. I only measured eRNA 24 h after CLP 
surgery, where I expect eRNA had returned to baseline levels.   
 
4.4.2 Conclusion  
 
In conclusion administration of RNase 1 attenuates sepsis-induced cardiac dysfunction due to 
reduced cardiac apoptosis by the intrinsic pathway and a reduction in sepsis-associated 
cytokines/chemokines. Whether it can be translated as a therapeutic treatment for septic 
patients still remains to be answered, but it is clear that RNase 1 plays a role in the 













Research into sepsis has increased our understanding of the pathophysiology and resulted in 
changes to the guidelines for managing sepsis. But despite these efforts, sepsis is still a 
common life-threatening, heterogenic condition, globally affecting 50 million people and 
resulting in the death of 11 million every year. Sepsis represents 20% of all deaths worldwide 
(13) and is a major public health problem. Despite intensive, supportive care and current 
treatments (antibiotic therapy and fluid resuscitation), no targeted therapies have proven 
effective at reducing mortality (312,313). Therefore, research into new therapeutics for sepsis-
induced organ dysfunction is of great importance (220). 
 
5.1 The differences between murine sepsis models and human responses  
 
Laws and regulatory agencies worldwide require new drugs to first be tested on animals before 
entering clinical trials in humans. However, finding a model that reflects the complexity of 
sepsis (both hyper and hypoinflammatory phases) is challenging. Murine models are most 
commonly used as they have multiple advantages (Table 5.1).  
 
Table 5.1 Advantages of murine models 
Advantages of murine models Description 
High fecundity  ü Reach sexual maturity at 6-8 weeks 
ü 8 pups per litter 
Accelerated life cycle ü Accelerated life cycle (life expectancy is 24 months) 
Low maintenance and cheap ü Docile 
ü Minimal husbandry routine 
Necessity for preclinical 
animal model 
ü Regulatory agencies require preclinical animal models, before moving 
to clinical studies 
Inbred, outbred and 
transgenic strain 
ü Inbred animals allow for little variability 
ü Using genetically modified mice helps to understand the importance 
of a particular gene in the pathophysiology of sepsis. 
Widespread availability of 
mice and reagents 
ü Often availability of immunological reagents for mice exceeds that of 
humans 
Evolving humanized mice ü Humanized mice via method dictated by leads to a complement of 
mature human T and B cells that are not rejected by the mouse  
 
Murine sepsis models are classified into three categories based on their mechanism: 
administration of an exogenous toxin, administration of a viable pathogen and disruption of 
the animal protective barrier resulting in bacterial invasion (Table 5.2).  
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Table 5.2 Murine models of sepsis 
Type of murine 
 model 






ü Simple and reproducible  
ü Acute response 




ü Highly controlled and standardised 
model 
û Does not reflect all complex physiological 
human responses 
û High, rapid and transient increase in cytokines, 
which differ from human sepsis 
û Variability in dose, toxin and route of 
administration 
û Each bottle of LPS maybe stronger or weaker 
than the previous, concentrations change 
Exogenous 
administration 
of a viable 
pathogen 
Inoculation of live 
bacteria 
 
ü Presence of a bacterium allows 
insights into mechanisms of host 
response to pathogens 
û Growth and quantification of bacteria is 
needed before administration 
û Single bacterium model does not reflect the 
diversity of bacterium in human sepsis 
û Humans do not normally have a large quantity 
of bacteria introduced, but more of a focus that 
persistently challenges the body with bacteria 
û High doses of bacteria will result in an 
endotoxemia response due to the lysis of 
bacteria giving off LPS 
û Variability in bacterial load, route of 






ü Fibrin delays systemic absorption of 
trapped bacteria, promoting 
development of a local septic focus 
ü Reduces early mortality 
û Involves single bacteria strain, whereas human 
intra-abdominal sepsis if often polymicrobial  
Cecal slurry ü Induces polymicrobial sepsis 
ü Favours innate immune response 
ü Preferable in neonatal mice given their 
small size and technical ease to 
perform  
û No component of tissue necrosis 
û Inflammation does not persist as long as CLP 










ü Simple procedure 
ü Infectious focus 
ü Polymicrobial sepsis model 
ü Using the complete spectrum of host 
enteric bacteria 
ü Recreates human sepsis progression 
with similar hemodynamic and 
metabolic phases and the presence of 
both hyper and hypoinflammaotry 
phases 
ü Prolonged and lower elevation of 
cytokine release similar to humans  
û Variable disruption of the endogenous 
protective barrier ability in severity due to 
difference in experimental procedure, e.g. the 
size of the needle  




ü Produces polymicrobial sepsis and 
diffuse peritonitis 
ü Causes resulting bacteraemia 
ü Operator able to alter sepsis severity 
û No component of tissue necrosis 
û Technically more challenging than CLP 
û Less characterised hemodynamic response 
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In chapter 2, I have established an endotoxaemia model (LPS/PepG administration) and a 
clinically relevant model of sepsis (CLP surgery), which is classed as the “gold standard 
model” (314). Administration of bacterial wall fragments such as LPS and PepG leads to 
systemic inflammation and organ dysfunction in the absence of infection (see below), while 
CLP is a disruption of the endogenous protective barrier leading to microbial flora from the 
animal itself being leaked into the peritoneum causing infection, which then triggers systemic 
inflammation and organ dysfunction.  
 
The endotoxaemia model results in an acute hyperinflammatory response, caused by the 
activation of the TLR4 (found e.g. on the surface of macrophages and monocytes) and TLR2 
signalling pathways. Excessive activation of these pathways and the associated excessive 
systemic inflammatory response leads to impaired myocardial contractility, lactic acidosis, 
arterial hypotension, an early transient increase in TNF, prolonged elevation of IL-6 and a 
delayed increase in HMGB-1. All of these aspects of experimental ‘sepsis’ are also found in 
human sepsis, but the magnitude of the changes is significantly different between rodents and 
man. Firstly, humans are more 1000 times more sensitive to LPS than mice, with mice having 
an LD50 of LPS between 5-15 mg/kg (315). Injection of LPS (in mice) does not result in the 
hyperdynamic cardiovascular state observed in human sepsis (316).  Another shortcoming of 
the LPS/PepG model is that humans are rarely exposed to a single large bolus of an endotoxin. 
The ‘source’ of the sepsis response in man is often polymicrobial resulting in a slow release of 
bacteria and their wall-fragments (and/or toxins) from a septic insult. As a result of this, humans 
experience a more delayed increase in cytokines and chemokines, which may eventually 
culminate in a cytokine storm, whereas LPS/PepG injection results in an earlier and shorter 
duration of proinflammatory cytokine/chemokine release than that triggered by sepsis in 
humans, reaching a maximum concentration 2 h after LPS/PepG injection and begin to decline 
after 8 h (224,317). Overall, LPS/PepG is useful for studying hyperinflammation, but not of 
general sepsis, as it fails to replicate infection with live bacteria as the driver of systemic 
inflammation and organ failure (318). Thus, interventions which kill bacteria (e.g. antibiotics) 
would, for example, not be effective in models of toxaemia. 
 
The majority of infections (which ultimately lead to the development of sepsis) start in either 
the lung or the peritoneal cavity (319) and, hence, most investigators use either a model of 
peritonitis (CLP) or pneumonia as models of sepsis. Indeed, the CLP model is currently 
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considered to be the “gold standard” as it reproduces a number of factors/responses found in 
human sepsis including polymicrobial infection, systemic inflammation and multiple organ 
injury/dysfunction (314,320), although one may argue that the pneumonia model is a better 
model of sepsis caused by community-acquired pneumonia and/or COVID-19. CLP is 
associated with three different insults: trauma to the abdominal tissue secondary to laparotomy, 
caecum ligation resulting in necrosis and the puncture of the caecum resulting in faecal 
peritonitis, which ultimately leads to translocation of bacteria into the bloodstream leading 
(when uncontrolled) to septic shock (321). CLP mice experience a more delayed release of 
cytokines and chemokines similar to that seen in humans (224,317). Even though the use of 
the CLP model of sepsis has helped to gain a better insight into the pathophysiology of human 
sepsis, even this experimental animal model does not recapitulate the entire spectrum of the 
events occurring in human sepsis. Furthermore, the variation in the CLP model results in 
different rates of mortality potentially contributing to conflicting datasets (322). The severity 
of CLP is affected by the following factors: length of the caecum that is ligated (323), number 
of punctures, size of the needle used for punctures and whether antibiotics are administered 
(321). The intestinal flora is not uniform between animals or species and it has been reported 
that the type of bacteria in the caecum can influence the severity of CLP and mortality. Wilmore 
et al. showed that phylum proteobacteria in the caecum resulted in protection against CLP-
induced sepsis (324).  
During a septic insult mice and humans respond differently (Table 5.3). During sepsis, mice 
develop bradypnea and bradycardia in comparison to septic humans who develop tachypnoea 
and tachycardia (325,326). At room temperature a septic mouse will become hypothermic with 
their temperature decreasing accordingly to the severity of the disease, whereas a septic human 
will develop a fever (327). The “leakiness” of the gut is often considered the key regulator in 
the development of multiple organ failure, but the surface area between different species varies, 
for example the mouse’s surface area ratio of the small intestine to colon is 22-fold lower than 
humans (328). 
There are also known differences between the innate and adaptive immunity of mouse and 
humans (Table 5.3). In the human innate immunity the neutrophil is the most predominant 
leukocyte in the blood (50-70%) whereas, in the mouse lymphocytes are most common (70-
90%) (329). Human neutrophils are a source of defensins (a type of antimicrobial peptide, 
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involved in the host defence against an infection), but neutrophils in mice do not express 
defensins (330). The number of platelets is ten times higher in mice than humans.  Stimulation 
of macrophages with LPS and IFN-γ result in mouse macrophages to express iNOS, whereas 
human macrophages do not express iNOS upon stimulation with LPS and IFN-gamma (331). 
Regarding the adaptive immunity, humans and mice present with differences in antibody class 
switching and B cell development (332), as well as the developments and regulation of T cells 
(333). Even within strains of mice there is a difference in expression of TH1, TH2 and TH17. 
 
Table 5.3 Example of some of the differences between mice and men that may affect the 
development of sepsis. Table adapted from (313). 
 Mice Humans 







Standardised chow diet 
Decreases after sepsis 
Decreases after sepsis 
Decreases after sepsis 
Diurnal 
Varied 
Increases after sepsis 
Increases after sepsis 
Increases after sepsis 
Immune system   
Predominant white blood cells 
Enzymatic content in neutrophils 
a-defensin production by neutrophils 
Expression of CXCR1 on neutrophils 
NETosis after sepsis 
Missing genes 
 






IL-8, IL-32, IL37, LFA-3 









Caspase 4 and 5 
 
 
5.2 Why does translational research sometimes fail? 
 
For over 30 years researchers have shown effective treatments, antibodies or genetically 
engineered mice having beneficial improvements to a septic insult.  However, despite the 
advances in research made through murine models the translation of a drug from animal models 
to humans often fail in sepsis, due to a multitude of disadvantages that murine models pose 










û Human genome is larger than the mouse by 14% (315,334). 
û Differences in the innate and adaptive immune system of mice and humans.  
û Predominant leukocyte in humans is the neutrophil accounting for 50-70% of 
the total leukocyte population. However, in mice the lymphocyte accounts for 
75-90% of the total leukocyte population. 
Differences between 
strains 
û Each strain of mice has a different genetic makeup. 
û Inbreed strains are well known whereas outbred are not and not used for sepsis 
studies. 
û Adaptive immunity varies within strains e.g. C57BL/6 mice TH1 predominant 
response favouring macrophages and cell mediated immunity where as 
BALB/c A/J and DBA/2 exhibit a TH2 predominant response = antibody 
production and eosinophil activation (335). 
Effect of the 
environment 
û Mice are kept in pathogen free facilities and as a result have an immature 
immune system (336). 
Age û Mice are often 10 weeks old when used which is the equivalent to young adults, 
however sepsis is a disease of the extreme ages as well. 
û Age mice cost more and have a limited availability. 
Gender û Males represent majority of the studies. 
û Hormonal differences affect the survival in sepsis. 
Mouse homogeneity û Sepsis is a heterogenic condition using inbred mice does not represent the vast 
differences within the human population. 
Comorbid disease û In the elderly community there is a prevalence of comorbid diseases, which is 
often not reflected in animal models. 
Ability to provide 
supportive care 
û Unable to administer mechanical ventilation, vasopressors, renal replacement 
therapy and delivery of nutrition. 
Variability within 
murine models 
û The inflammatory response varies between the different models of sepsis. 
 
Most sepsis models use young and healthy animals (usually of male gender), while most 
patients with sepsis are older and have significant co-morbidities including diabetes and 
chronic kidney disease. These co-morbidities amplify the cytokine storm associated with sepsis 
and increase organ dysfunction and mortality. For most interventions shown to be effective in 
sepsis, it is unknown whether they would also be effective in older animals with co-morbidities. 
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Furthermore, numerous studies have been conducted in the endotoxin model (337–340), which 
is known to poorly mimic septic cardiomyopathy. However, even in more clinically relevant 
models few studies incorporate adequate fluid resuscitation, the use of antibiotics and most 
studies administer the treatment very early < 4 h after septic insult or as a pre-treatment. These 
factors favour a beneficial outcome and can lead to false positives and suggest limited 
predictive value of preclinical models (341). In contrast patients are diagnosed and receive 
treatment much later on where often organ dysfunction has already developed, this delay in 
receiving treatment severely effects a patient’s outcome and contributes to the shortcomings of 
translating new treatments from mice to men. 
Seok et al. researched gene expression in human and murine leukocytes following 
burn/trauma/endotoxaemia, from their data they stated “genomic responses in mouse models 
poorly mimic human inflammatory diseases” thus concluding that mouse models are unsuitable 
for studying human inflammatory conditions (342). This paper was picked up by the lay press 
calling to eliminate animal studies altogether, due to the multiple flaws and lack of 
translatability into human and ethical issues. A classic example of the failings of transability 
from mouse to man is the use of TNF-a antibodies. Mice treated with anti-TNF were protected
from a lethal dose of LPS (343). Yet the use of anti-TNF in septic patients failed to reduce 
mortality (344,345). When conducted in a clinically relevant mouse model (CLP) treatment 
with anti-TNF also failed to show any protective benefits in CLP mice (346,347) showing that 
inappropriate mouse models are to blame for the failings of the septic human anti-TNF trials.  
Even though murine models have disadvantages, there is also variability between different 
laboratories in the models of sepsis, making it difficult to compare results. For example, the 
length of the ligation, number of punctures, size of needle and whether antibiotics or fluid 
resuscitation is used effect the severity of the CLP model. Ideally, investigators need to 
standardise murine models to make data comparable. Overall, there is no perfect animal model 
of sepsis, but they are the only option to examine a fully intact biological system which is 
essential in furthering our understanding of the pathophysiology of the disease (348).  
5.3 Bruton’s tyrosine kinase 
I have shown in both models (endotoxaemia and CLP) that the BTK inhibitors ibrutinib or 
acalabrutinib attenuate LPS and CLP-induced cardiac dysfunction. Interestingly, the degree of 
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cardiac dysfunction correlates with the degree of BTK activation. BTK is involved in the 
activation of TLR’s which recognise bacteria and stimulate the immune response by leading to 
the activation of NF-kB and NLRP3 inflammasome and subsequently the production of
cytokines and chemokines in serum. The BTK inhibitors ibrutinib or acalabrutinib inhibit the 
activation of BTK and, hence, reduce the activation of NF-kB and NLRP3 inflammasome and
subsequently a decrease in the production of cytokines/chemokines in serum (Chapter 2).  
The discovery that BTK inhibitors attenuate sepsis-induced cardiac dysfunction, raised the 
question whether the observed effects of these compounds were solely due to BTK inhibition 
or due to (at least in part) an off-target effect? Ibrutinib inhibits a lot of other kinases, whereas 
acalabrutinib is more selective and both BTK inhibitors strongly inhibit 5 kinases BTK, RIPK2, 
Tec, Bmx and Erbb4 (see kinome array, chapter 3.1). To confirm whether BTK inhibition is 
responsible for the observed effects, I replicated the model of polymicrobial sepsis in Xid mice, 
which have a missense mutation within the BTK gene (arginine to cysteine at position 28 
(R28C)) in the N-terminally located pleckstrin homology domain, resulting in expression of a 
BTK protein that is functionally inactive (183,184). 
In chapter 3, I report that genetic deficiency of the BTK gene alone in Xid mice confers 
protection against cardiac, renal and liver injury in polymicrobial sepsis and reduces 
hyperimmune stimulation (‘cytokine storm’) induced by an overwhelming bacterial infection. 
These beneficial effects are (at least in part) due to enhanced bacterial phagocytosis in vivo and 
decreased activation of NF-kB and the NLRP3 inflammasome. The inactivation of BTK leads
to reduced innate immune cell recruitment and a phenotypic switch from M1 to M2 
macrophages, aiding the resolution of sepsis. By reanalysing the microarray dataset generated 
by Parnell et al. from the blood of patients with sepsis, I have shown (in chapter 3) that BTK 
expression is increased in the blood of septic non-survivors, while lower expression is 
associated with survival from sepsis, indicating that the activation of BTK plays a role in sepsis. 
Importantly, no further reduction in organ damage is seen in Xid mice treated with the BTK 
inhibitor ibrutinib, demonstrating that the protective effects of BTK inhibitors in polymicrobial 
sepsis are mediated solely by inhibition of BTK and not by off-target effects of this class of 
drugs. 
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The FDA has approved the use of the irreversible BTK inhibitors ibrutinib (first generation) in 
chronic lymphatic leukaemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, and 
graft vs. host disease (169) and acalabrutinib (more selective, second-generation) in mantle cell 
lymphoma (170). Ibrutinib is also approved by the EMA for the treatment of chronic lymphatic 
leukaemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia (171), whereas 
acalabrutinib has received an orphan designation for chronic lymphatic leukaemia, mantle cell 
lymphoma, and lymphoplasmacytic lymphoma (172–174). I have proposed in this thesis the 
potential for repurposing BTK inhibitors for the use in sepsis or other acute inflammatory 
conditions. Currently, BTK inhibitors are in clinical trials for multiple sclerosis (349), 
rheumatoid arthritis (350) and COVID-19 (351). The recent COVID-19 pandemic has driven 
the search for drugs that can be repurposed to either reduce virus load and/or the cytokine storm 
in patients with severe COVID-19 infections. COVID-19 has resulted in the development of 
cardiovascular complications such as heart failure, arrhythmia, myocarditis, cardiogenic shock 
and thromboembolic events in patients without any history of cardiovascular disease (352). It 
has been found that myocardial injury (measured by elevated TnT levels) due to COVID-19 is 
associated with high mortality rates. COVID-19 patients which did not have any pre-existing 
cardiovascular disease, but presented with myocardial injury, resulted in a mortality of 37.5%. 
The percentage of mortality increased to 69.44% in patients who had pre-existing 
cardiovascular disease and also presented with myocardial injury. If there was no myocardial 
injury from COVID-19, the mortality was 7.62% (without pre-existing cardiovascular disease) 
and 13.33% (with pre-existing cardiovascular disease) (353). AstraZeneca is currently in 
clinical trials testing acalabrutinib in patients with severe COVID-19 (Acalabrutinib: 
NCT04346199) and have found that BTK activation and IL-6 production is increased in the 
blood of COVID-19 patients (351). Roschewski et al. showed that severe COVID-19 patients 
receiving acalabrutinib had improved oxygenation and reduced CRP and plasma IL-6, 
suggesting that BTK inhibitors may be useful in the treatment of COVID-19. BTK inhibitor 
zanubrutinib is also in clinical trials for COVID-19 at BeiGene (Zanubrutinib: NCT04382586). 
Zanubrutinib is a second generation irreversible BTK inhibitor, which in November 2019 was 
granted accelerated approval for mantle cell lymphoma by the FDA (354). Interestingly, 
ibrutinib protects mice from lethal influenza-induced lung injury (257). Infection with seasonal 
influenza A virus (IAV) leads to lung inflammation and respiratory failure, similar symptoms 
to that of COVID-19.  Re-purposing BTK inhibitors for non-chronic diseases e.g. in acute 
excessive inflammation maybe an attractive avenue for BTK inhibitors, as the long-term use 
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of ibrutinib in cancer therapy has resulted in adverse effects such as bleeding complications 
(355) and increased rates of atrial fibrillations (356). Further studies would need to be carried
out in an acute setting to determine both efficacy and potential any adverse effects of BTK 
inhibitors in disease associated with acute inflammation.  
5.4 RNase 
In chapter 4, I report that administration of the antimicrobial peptide RNase 1 also results in 
attenuation of sepsis-induced cardiac dysfunction. I discovered that RNase 1 levels are 
decreased in the serum of septic mice and there is no significant difference between eRNA and 
RNH1 levels in serum of septic and treated mice, even though eRNA and RNH1 are elevated 
in humans with sepsis (298). The discrepancies between human septic serum and mouse septic 
serum could be due to the time of the measurement. eRNA levels were shown to be elevated 
between 30 min to 2 h, but at 4 h eRNA levels and returned to baseline in mice (300). In septic 
humans eRNA was measured 3 days after diagnosis, indicating a potential later increase in the 
release of eRNA (298). The cardiac dysfunction of septic mice was associated with an increase 
in cardiac apoptosis as demonstrated by TUNEL staining and the apoptosis intrinsic signalling 
pathways via western blots measured by increased activation of Bax, caspase-3, caspase-9 and 
a decrease in the activation of Bcl-2. Most notably, the administration of RNase 1 resulted in a 
decrease in both cardiac apoptosis and cardiac dysfunction. 
In the context of SARS-CoV-2, the role of RNase A has yet to be evaluated. However, in 
SARS-CoV (which is genetically similar to SARS-CoV-2 (357)) the crystallographic study of 
coronavirus revealed that the active site of endoribonuclease is structurally similar to that of 
RNase A (358). The effects of RNase A inhibitors on coronavirus resulted in a decrease of 
coronavirus replication in cell culture (359), indicating that they have the potential to modulate 
viral replication. Further studies are required to understand the role of RNase in SARS-Cov-2. 
5.5 Limitations of the studies 
One of the major limitations of all of the studies that I have done in this thesis is the inability 
to perform survival studies. There are strict regulations governing such experiments due to the 
inevitable pain and suffering these animals would have to endure. The lack of survival 
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(mortality data) is a major shortcoming of the preclinical efficacy studies reported here and 
may cast doubt when over my conclusion that e.g. BTK-inhibitors may be useful for the 
treatment of patients with sepsis. I have shown that delayed administration of ibrutinib or 
acalabrutinib protects mice against the consequences of sepsis for 24 h, but it is not clear 
whether these early beneficial effects can be sustained in a prolonged sepsis model. I have used 
the reduction in body temperature < 30oC as a surrogate marker to predict survival, but ideally 
survival studies may need to be conducted. Even in clinical trials, long term studies are not 
carried out, as normally a 28-day or 30-day mortality study is conducted and many patients 
have significant morbidity and even mortality after day 28/30 (360). Within the hospital setting, 
we have seen an improvement in 28-day mortality, however, there is an increase with 
associated-sepsis mortality that escalates yearly. Historically early deaths are associated with 
inadequate resuscitation and cardiac failure between 0 – 10 days, with a spike in late deaths 
occurring between 20 - 30 days due to persistent organ injury/failure (361,362). Nowadays this 
has been evaluated and is determined that two early peaks occur between 0 – 30 days with 
mortality being much lower than the past. However, late deaths occur after 60 days and 
continue to rise over time (362) (Figure 5.1).   
Figure 5.1 Historical and current sepsis mortality distribution. (A) Historic mortality. (B) Modern 
mortality over time. The figure is taken from (362). 
I have performed all these experiments on young healthy male mice. However, sepsis is not 
exclusive in healthy males, as it is a disease effecting everyone from neonatal to the elderly 
(where sepsis is most prominent) and of course both sexes. The majority of our ageing 
population present with co-morbidities, which impact on the septic response: for instance, type 
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1 and 2 diabetes have been shown to exacerbate sepsis and result in a higher mortality (242). 
In humans, comorbidities like type 1 and 2 diabetes are common among the population along 
with hypertension, cancer, atherosclerosis and renal disease. In CLP-sepsis, the degree of organ 
injury/dysfunction caused by CLP is age-dependent, with older mice experiencing more severe 
organ failure (363–366). I choose to perform these experiments exclusively in young healthy 
males for a number of reasons. Firstly, the three Rs. It has been shown that females have a 
natural protection against sepsis due to higher levels of circulating oestrogen or their precursors  
(367,368). High levels of oestrogen and/or oestradiol results in an increase in the activation of 
Akt, eNOS and a decrease in the activation of NF-kB and production of pro-inflammatory
cytokines, resulting in protection of cardiac dysfunction caused by sepsis, endotoxaemia (368), 
ischemia-reperfusion injury (369), or trauma-haemorrhage (370). Thus, if I included males and 
females into the study, I would have to increase the numbers of my mice. To my knowledge, 
there is no evidence that interventions work in males, but not in females. By trying to reduce 
the number of mice used I choose to exclusively perform these experiments on male mice. 
Secondly, the cost of aged mice or mice with co-morbidities increases drastically, making it 
unfeasible to routinely perform experiments in these animals. As Xid mice are X-linked 
dependent, it is also more difficult to obtain Xid females than Xid male mice. 
5.6 Future investigations 
I choose to administer BTK inhibitors 1 h after CLP surgery due to measurable septic 
parameters being visible within 1 h (decrease in CO and SV). However, in a clinical setting no 
patient receives a treatment within 1 h of an infection. It would be interesting to determine how 
late after onset of septic insult can BTK inhibitors be administered and still observe a positive 
effect. My time course data in chapter 2 suggests that the mouse is able to control the infection 
up to 12 h, indicating that there is a 12 h therapeutic window. Future studies could test out my 
hypothesis of administering BTK inhibitors at 3, 6 and 12 h after CLP surgery. Ideally if 
survival studies could be carried out this would also improve the model and translatability of 
the findings. 
I found that Xid mice subjected to CLP have the same percentage of macrophages and 
neutrophils phagocytosing bacteria, but Xid-mice with CLP phagocytose more bacteria per 
immune cell when compared to WT-mice. This raises the question of the underlying 
mechanisms that enables or drives increased phagocytosis in Xid-mice? However, the exact 
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molecular mechanisms underlying this phenomenon are yet to be elucidated. Future studies are 
required to increase our understanding as to how Xid macrophages and neutrophils phagocytose 
more bacteria per immune cell. 
By reanalysing Parnell et al. dataset I revealed that BTK expression was significantly increased 
in septic non-survivors and that BTK expression was similar in septic survivors and healthy 
patients. This indicates that increased BTK expression in septic patients correlates with 
mortality. This is an interesting finding, but it was conducted on a small cohort.  It would be 
beneficial to confirm Parnell et al. findings of increased expression of BTK in septic non-
survivors by analysing BTK activation and pro-inflammatory cytokines in the blood of septic 
patients in a larger cohort. 
Considering sepsis results in multiple organ failure and one of the main causes of infection is 
pneumonia, I have not looked at lung inflammation in my model of sepsis. It would have been 
useful to measure bacteria and infiltrating immune cells in bronchoalveolar lavage fluid. De 
Porto et al. showed that treatment with ibrutinib 3 h before and 9 h after intranasal LTA 
instillation (a model of pneumonia) reduced the infiltration and activation of macrophages and 
neutrophils, resulting in decreased release of cytokines and plasma leakage into the lungs (272). 
However, research has shown that in severe CLP (mice predicted to die) CLP-septic mice do 
not result in significant levels of lung injury as demonstrated by normal levels of arterial 
oxygen saturation, no increase in pro- or anti- inflammatory cytokines in bronchoalveolar fluid, 
no increase in recruitment of neutrophils in the lung and no histological evidence of damage to 
the lung (325). 
The number of sepsis cases is rising and globally it is the number one cause of death. However, 
for those who do recover from sepsis face a future battle, cognitive impairment and functional 
disability (371). Unfortunately, there is little research on the long-term effects of sepsis on 
cognitive and functional limitations, despite the fact these issues put a major financial burden 
on the healthcare system as well as families/caregivers of the affected (372). It is suspected 
that many patients are discharged with cognitive and functional impairments (373) and the 
onset of disability is associated with increased mortality (374). Future research is required to 
look into these issues which maybe partially preventable. It would be interesting to investigate 
the effect of BTK inhibitors on cognitive function in septic mice.  
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5.7 Conclusion 
In conclusion in this thesis, I have shown that BTK-inhibitors ibrutinib or acalabrutinib 
attenuate sepsis-induced cardiac dysfunction by reducing the production of 
cytokines/chemokines in serum and reducing the activation of cardiac BTK, NF-kB and the
NLRP3 inflammasome. I have also shown that these effects are exclusively due to BTK 
inhibition by showing that Xid mice (which have a deficiency in the activation of BTK) are 
protected from developing sepsis-induced multiple organ failure (cardiac, renal and 
hepatocellular injury) and excessive systemic inflammation (cytokine storm). I find that the 
administration of ibrutinib (a non-specific BTK inhibitor) results in no further benefit or 
adverse effect on septic Xid mice. In the Xid mice, they present with a reduced number of 
infiltrating macrophages and neutrophils, which show enhanced phagocytosis ability resulting 
in fewer bacteria in the peritoneal cavity. The Xid macrophages polarise to an M2 anti-
inflammatory state aiding in the resolution of sepsis. I propose that BTK inhibitors could be 
repurposed for sepsis. Finally, I have shown that the administration of the antimicrobial peptide 
RNase 1 attenuates sepsis-induced cardiac dysfunction and cardiac apoptosis.  
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Appendix 1: Surviving sepsis campaign international guidelines for management of sepsis and 
septic shock. The Grading of Recommendations Assessment Development and Evaluation (GRADE) 
system was used to assess the quality of evidence from high to low and determine the strength of the 
recommendation as strong, weak or best practice. 93 statements are provided with 32 strong 
recommendations, 39 weak recommendations, 18 best practice and no recommendations for four. Table 
taken from Rhodes et al. 2017. 
  
Table S2. Average concentration of cytokines in serum. Mice underwent sham or CLP surgery, 24 h later 31 cytokines and chemokines were 
assessed in serum. Data are expressed as mean ± SEM (pg/ml). The following groups were studied WT sham (n = 5), Xid sham (n = 5), WT-CLP 
(n = 10), Xid-CLP (n = 10), WT-CLP + ibrutinib (n = 8), Xid-CLP + ibrutinib (n = 6). 
WT Sham Xid Sham WT CLP Xid CLP WT CLP + ibrutinib Xid CLP + ibrutinib 
Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- Mean SEM +/- 
BCA-1/CXCL13 7034.2 3097.9 8937.8 2330.0 83810.3 4310.6 77435.3 2269.3 85285.5 3220.6 80840.9 1375.5 
CTACK/CCL27 1872.3 202.1 2327.4 398.1 3886.4 339.4 8395.2 1781.0 7661.8 1191.3 7369.2 1032.9 
ENA-78/CXCL5 1980.0 772.6 2831.5 987.5 45770.7 5248.7 8462.4 969.7 11727.6 2524.8 7210.7 982.8 
Eotaxin/CCL11 420.6 151.2 733.3 171.2 6869.6 356.5 1952.5 224.5 2690.1 465.2 1907.8 179.3 
Eotaxin-2/CCL24 13102.7 4999.2 18708.2 3000.5 56736.3 5714.4 25735.7 2079.7 11983.1 1876.6 29652.0 3562.5 
Fractalkine/CXCL1 264.5 9.1 279.7 17.5 1181.9 109.7 322.8 12.2 457.7 47.5 352.9 20.4 
GM-CSF 5.4 0.8 5.4 0.7 346.2 58.6 7.5 1.1 14.7 3.2 7.7 0.7 
I-309/CCL1 45.6 4.9 58.4 14.0 198.7 66.5 799.7 190.5 80.1 15.6 11691.8 9593.7 
IFN-γ 133.8 11.1 155.5 17.5 134.0 16.2 102.3 15.1 98.1 28.8 191.6 14.4 
IL-1β 680.0 57.0 706.3 72.6 1536.3 184.7 674.6 31.4 611.0 43.8 768.9 28.0 
IL-2 11.7 2.6 15.9 4.0 38.3 7.8 102.6 25.8 72.8 15.4 57.4 18.7 
IL-6 45.5 4.8 52.6 6.7 524272.8 43243.2 6380.9 1557.2 29367.0 18095.0 4296.7 1827.7 
IL-4 74.7 3.6 87.5 8.0 65.2 3.9 76.0 8.0 52.3 9.2 92.0 3.5 
IL-10 1296.5 84.4 1677.4 159.6 23882.5 2465.0 2077.0 370.9 3485.3 947.8 2252.3 362.6 
IL-16 978.4 68.9 1048.3 87.4 2836.1 207.4 1313.4 86.9 1814.6 200.3 1462.5 95.6 
IP-10/CXClL10 4561.3 205.3 4994.1 536.0 4837.9 327.2 4547.3 583.3 4036.2 420.8 5182.1 157.5 
I-TAC/CXCL11 4666.7 272.0 5570.1 490.2 3217.0 291.5 3372.9 340.1 2991.7 826.7 5569.5 376.0 
KC/CXCL1 298.0 24.0 337.9 24.5 158693.9 35967.2 9014.0 1570.5 16952.6 6344.1 8912.3 2432.5 
MCP-1/CCL2 515.8 36.3 601.9 59.7 262035.2 117148.0 9660.5 3217.7 10558.8 3887.3 3100.1 531.8 
MCP-5/CCL12 24.0 4.9 31.6 4.5 5348.5 785.1 935.7 129.2 1020.6 157.1 758.3 70.1 
MDC/CCL22 190.9 41.0 210.3 35.3 1869.7 235.7 494.0 48.3 515.9 36.1 717.8 69.6 
MIP-1α/CCL3 27.5 2.1 34.0 3.7 4994.4 1664.0 175.4 56.9 81.7 24.5 56.1 2.2 
MIP1-β/CCL4 123.9 6.9 141.1 12.9 51791.1 19413.9 1445.3 372.8 2859.4 1022.9 509.2 68.5 
MIP-3α/CCL20 38.8 3.4 41.7 4.4 893.8 117.3 691.2 157.2 549.9 176.4 1134.8 163.6 
MIP-3β/CCL19 2285.8 104.5 2520.6 204.6 3622.2 350.3 3830.6 351.0 2933.2 242.3 4925.1 465.9 
Rantes/CCL5 28.8 5.4 33.4 5.9 2647.5 421.4 80.0 10.3 487.9 148.7 110.0 24.3 
SCYB16/CXCL16 601.1 133.4 748.4 91.0 4588.5 467.1 2250.7 317.4 2440.4 447.1 1851.1 266.6 
SDF-1α/CXCL12 929.5 197.3 1263.0 218.9 447.7 63.0 1612.0 177.7 1113.3 341.6 2304.9 389.7 
TARC/CCL17 115.6 16.7 146.8 21.6 3293.6 376.2 2269.2 441.2 755.4 114.8 5268.3 1862.4 
TNF-α 311.2 16.7 310.6 28.0 471.7 42.9 205.1 16.5 208.5 38.7 330.8 27.1 
